

## CURRICULUM VITAE

**Name:** Mien-Chie Hung, Ph.D.

### **Title and Affiliation:**

#### **1. Primary Appointment:**

Professor and Chair  
Department of Molecular and Cellular Oncology  
The University of Texas M. D. Anderson Cancer Center  
Houston, Texas 77030

#### **2. Joint Appointments:**

Professor, Department of Surgical Oncology-Research, UTMDACC, Houston, TX 77030.

Professor, Graduate School of Biomedical Science, UT Health Science Center, Houston TX 77030.

**Citizenship:** US

**Home Address:** 5762 Birdwood Rd., Houston, TX 77096. **Tel:** (713) 777-9249

**Office Address:** Department of Molecular and Cellular Oncology, Box 108 **Tel:** (713) 792-3668  
The University of Texas M. D. Anderson Cancer Center **Fax:** (713) 794-3270  
1515 Holcombe Blvd., Houston, TX 77030  
E-mail: *mhung@mdanderson.org*

### **Education:**

National Taiwan University, B.S., Taipei, Taiwan, 1973, Chemistry.

National Taiwan University, M.S., Taipei, Taiwan, 1977, Biochemistry.

Brandeis University, Waltham, Massachusetts, Ph.D., 1983, Biochemistry.

### **Postgraduate Training:**

Postdoctoral Fellow, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts. Supervisor: Robert A. Weinberg, Ph.D., 1984-1986.

*Revised 5/9/09*

**Continuing Education:**

Executive Excellence Program, UT-Austin Graduate School of Business Administration, July 29, 2000 – February 25, 2001.

Faculty Leadership Academy, UTMDACC, February 2003 to April 2004.

**Experience/Service**

**Academic Appointments:**

Graduate Student, Department of Biochemical Science, National Taiwan University, Taipei, Taiwan, R.O.C. Graduate Scholarship from Department of Education, 1975-1977.

Assistant Research Fellow, Institute of Biological Chemistry, Academic Sinica, Taipei, Taiean, R.O.C., 1977-1978.

Predocotrual Fellow, Department of Biochemistry, Brandeis University, Waltham, Massachusetts, Gillette Graduate Teaching Fellowship, 1978-1983.

Postdoctoral Fellow, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, Postdoctoral Fellowship from Cancer Research Institute, 1984-1986.

Assistant Professor, Graduate School of Biomedical Science, The University of Texas Health Science Center, Houston, TX, 1986-1991.

Assistant Professor, Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1986-1991.

Associate Professor, Graduate School of Biomedical Science, The University of Texas Health Science Center, Houston, TX, 1991-09/1994.

Associate Professor, Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1991-09/1994.

Professor, Graduate School of Biomedical Science, The University of Texas Health Science Center, Houston, TX, 09/1994-present.

Professor, Tumor Biology Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 09/1994-08/1998.

Hubert L. and Olive Stringer Professorship, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 02/1996-04/1999.

Professor, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 09/1996-present.

Professor and Chief, Section of Molecular Cell Biology, Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 09/1998-12/1999.

Hubert L. and Olive Stringer Distinguished Professorship in Cancer Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 05/1999-02/2000.

Ruth Legett Jones Chair, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 03/2000-12/2002.

**Ruth Legett Jones Distinguished Chair, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 01/2003 – present.**

Visiting Professor, University of Puerto Rico Cancer Center, Puerto Rico.

**Distinguished Teaching Professor, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 03/2007.**

#### **Academic Administrative Appointments/Responsibilities**

Deputy Chairman (*Ad interim*), Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 02/1996-08/1998.

**Director, Breast Cancer Basic Research Program, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 02/1996-present.**

Professor, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 09/1996-present.

Professor and Chief, Section of Molecular Cell Biology, Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 09/1998-12/1999.

Chair (*Ad interim*), Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 12/1999-03/2000.

**Chair, Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 03/2000 - present.**

**Administrative Director, Bates Freeman, Basic Research and Anderson Center Building, July 2007 – present.**

**Director, Center for Biological Pathways, September 2008 - present.**

#### **Committee Activities:**

**a. National and International Committee Activities**

Member, Director Search Committee for the Division of Molecular and Genomic Medicine, National Health Research Institutes (NHRI), Taipei, Taiwan, 1999.

Member, American Association for Cancer Research Career Development Awards Committee, Philadelphia, PA, Fall 2001-2002.

Member, Search Committee for the Director of Institute of Molecular Biology, the Academia Sinica, Taipei, Taiwan. March 2002-2003.

Member, American Association for Cancer Research (AACR), Career Development Awards Committee, 2002.

Coordinating Reviewer, Cancer Apoptosis Section, American Society of Gene Therapy, 2002-2003.

Chairman, Selection Committee of 2003 National Science Council Outstanding Research Award (Medical Sciences-basic and clinical sciences), Taiwan, July 2003.

Member, Selection Committee of Research Award for Junior Researchers, Academia Sinica, Taiwan, 2003, 2004 & 2005.

Member, AACR Research Funding Awards Selection Committee for Breast Cancer Research, American Association for Cancer Research, February-March 2004.

Member, Era of Hope, The Department of Defense Breast Cancer Research Program for reviewing and selecting Abstracts, January 2005.

Member, AACR's 2005 Grants Committee: Cancer Research on the HER Family Pathway, Select recipients for AACR's funding for junior faculty and postdoctoral/clinical fellows, November 2004-April 2005 & January 2006 - February 2006.

Member, Review and Evaluation of the National Chair Award\* and the Academic Award\*, Ministry of Education, Taiwan, May - June 2005, May - June 2006 and May-June, 2007. \* The Awards are the highest rank of honor in Taiwan for scholars with distinguished academic achievements.

Member, Search Committee, Director of the Institute of Biological Chemistry, Academia Sinica, 2006.

**Member, Roundtable Meeting of Translational Research Working Group, NCI, Phoenix, Arizona, February 23-24, 2006**

Member, Selection Committee, Young Investigator Award, Academia Sinica, June 2007 - September 2007.

Member, Independent Review Committee, TRANSBIG (Breast International Group)-MINDACT (Microarray for Node Negative Disease may Avoid ChemoTherapy), Belgium, June 2007 to present.

**Member, International Affairs Committee, American Association for Cancer Research, June 2007 to April 2010.**

**Chair, 2008 AACR Basic Research Grants Committee, American Association for Cancer Research.**

**Member, 2009 AACR Education Committee, American Association for Cancer Research.**

**b. Institutional Committee Activities and Internal Advisory Board**

Member of the Recombinant DNA Subcommittee, 1986-1991.

Participation in the External Advisory Committee's Review for Breast Cancer Research in M.D. Anderson Cancer Center, May 2, 1991.

Participation in the External Review for Clinical Research Program in Breast Cancer in M.D. Anderson Cancer Center, September 11-12, 1991.

Participation in the President's Cancer Panel Visit in M.D. Anderson Cancer Center, December 9, 1991.

Alternative member of the Research Committee, 1988-1991.

Co-Chairman of the Recombinant DNA Subcommittee at MDACC, 1989-1993.

Member of Admission Committee for Graduate School for Biomedical Sciences, U.T. H.S.C. in Houston, 1988-1991.

Faculty Senate, 1991-1995.

Chairman, M.D./Ph.D. Program Report Committee, 1991-1993.

M.D./Ph.D. Program Committee, 1991-1994.

Search Committee for new faculty member of the Department of Tumor Biology, 1992-1994.

Committee Member for DNA Sequencing Core Facility, 1993-present.

Executive Committee of the Faculty Senate, 1993-1995.

Chairman, Subcommittee of the Faculty Achievement Award in Education, 1993-1994.

Academic Planning Committee of the Faculty Senate, 1993-1994.

Election Committee of the Faculty Senate, 1993-1994.

Education Committee of the Faculty Senate, 1993-1994.

Alternative member of the Executive Committee of the Science Faculty, 1993-1994.

Search Committee for Division Head of Laboratory Medicine, 1993-1994.

Steering Committee Member for "Interdisciplinary Studies in Cancer Biology", Training Program, 1993-1996.

Mid-tenure track review for Junior Faculty members inside institution including the Dept. of Tumor Biology, Molecular Pathology, Surgical Oncology, Neuro-Oncology, Molecular Oncology, and Experimental Pediatrics, 1994-present.

Chairman, Faculty Senate Election Committee, 1994-1995.

Committee Member for the Confocal Microscope Core Facility, 1995-1997.

*Ad hoc* Committee for the issue regarding funding from tobacco industry, 1994.

Participation in the External Advisory Committee's Review for Lung Cancer Spore Project, April 28, 1995.

Participation in the External Advisory Committee's Review for Gene Therapy Program, May 17, 1996.

Member of the UT-Houston Health Science Center-U.T. M.D. Anderson MD./Ph.D. Board, 1995-1996.

Alternate Member, Institutional Biosafety Committee (IBC), The University of Texas M. D. Anderson Cancer Center, 1995 – present.

Member of Search Committee for Chairman, Department of Human Cancer Genetics, 1996 – 1997.

Member of Program Committee for MDACC Annual Basic Science Research Symposium, 1996-1997.

Member of the Research Small Working Group, UTMDACC, 1996.

**Steering Committee Member for “Breast Cancer Research Program”, 1996 – present.**

Steering Committee Member for “Cancer Therapeutics Discovery Initiative”, 1996 – present.

Alternative Member of the Executive Committee of Science Faculty, 1996 – 1998.

Member of the Faculty Classification Committee (Promotion Committee), UTMDACC, 1996 – 1998.

Member of the Multidisciplinary Research Program Steering Committee, 1997 – 1998.

Member of Search Committee for Chief Academic Officer, President Advisory Committee, 1997.

Member of Search Committee for Division Head, Division of Surgery, 1997.

Member of Search Committee for Division Head, Pathology and Laboratory Medicine, 1997- 1998.

Member of the Institutional Centralized Tissue Banking Facility, UTMDACC, 1997.

Institutional Review for faculty promotion requested by Vice President for Academic Affairs, 1998-present.

Member of the UT-Houston Health Science Center-U.T. M.D. Anderson M.D./Ph.D. Board, 1998 – 1999.

Member of the Search Committee for Chair, Department of Gynecology, UTMDACC, 1998 – 1999.

Member of the Search Committee for Faculty Member in the Department of Molecular Pathology, UTMDACC, 1998 – present.

Member of the Search Committee for Faculty Member in Breast Pathology, UTMDACC, 1998 – present.

Member of the Search Committee for Faculty Member in the Division of Medicine, UTMDACC, 1998 – 1999.

Member of the Promotion Tenure Committee, UTMDACC, 1998 – 1999.

Member of the Faculty Peer and Grievance Review, UTMDACC, 1998 – 1999.

Member of Internal Scientific Advisory Committee for the Cancer Metastasis Research Center (CMRC), 1998- present.

Faculty Achievement Award Parent Committee, UTMDACC, 1998, 1999.

Member, Technology Development Board, The University of Texas M. D. Anderson Cancer Center, 1999 – present.

Patent Steering Sub-Committee, The University of Texas M. D. Anderson Cancer Center, 1999 – present.

Member, Vector Core Advisory Committee, Gene Therapy and Prevention Program 1999 – present.

Member, Program Committee, Human Cancer Gene Prevention and Therapy Program/The Baylor College of Medicine Center for Cell and Gene Therapy Symposium, September 27, 1999.

Member of the Postdoctoral Programs Advisory Committee, The University of Texas M. D. Anderson Cancer Center, 1999 – present.

Chairman, Subcommittee of Faculty Achievement Award on Basic Research, 1999.

Member, Advisory Committee of Center for Breast Cancer (Marketing, Advertising, Philanthropy), MDACC, 1999-present.

Member, Graduate Medical Education Core Curriculum Committee (Tumor Cell Biology), Core Curriculum, 1999-2000.

Member, Advisory Committee, Training Grant in Academic Hematology/Oncology, 1999-present.

**Member, Research Council, The University of Texas M. D. Anderson Cancer Center, 2000-present.**

Member, Program Internal Advisory Committee, U54 Puerto Rico Cancer Center (PRCC)/MDACC, Partners in Excellence for Cancer Research, 2000-present.

Member, Faculty Achievement Award Evaluation Subcommittee on Education, The University of Texas M. D. Anderson Cancer Center, 2000.

Member, Division of Medicine, Head Search Committee, The University of Texas M. D. Anderson Cancer Center, 2000.

**Member, Executive Council Science Faculty, The University of Texas M. D. Anderson Cancer Center, 2000-present.**

Alternate Member, Institutional Biosafety Committee, The University of Texas M. D. Anderson Cancer Center, 2000.



Participation in the University of Cancer Foundation Board of Visitors Annual Meeting, November 2, 2000.

Member, Graduate Medical Education Core Curriculum Committee, The University of Texas M. D. Anderson Cancer Center, 2000-2001.

**Member, Oversight Committee for the Cancer Therapeutics Discovery Program and the Pharmaceutical Development Center, The University of Texas M. D. Anderson Cancer Center, 2000–present.**

**Member, Intellectual Property Oversight Committee, The University of Texas M. D. Anderson Cancer Center, 2000-present.**

**Member of Human Resources Subcommittee, MDACC, January 2002-present.**

Member, Organizing Committee, the 44<sup>th</sup> Clinical Conference "The Biology and Therapy of Cancer Metastasis" The University of Texas M. D. Anderson Cancer Center, March 18-20, 2002.

Faculty Search Committee, the Departments of Immunology; and Endocrine, Neoplasia, and Hormonal Disorders; and Surgical Oncology, MDACC, March 2002-present.

Research Fellows Search Committee, the Department of Gynecology Oncology, MDACC, May 2002- present.

Member, Breast Cancer Serum/DNA Bank Oversight Committee, MDACC, May 2002-present.

Member, Search Committee for Chair of Experimental Radiation Oncology Department, MDACC, May 2002.

Faculty Search Committee, the Departments of Molecular Therapeutics; and Neuro-Oncology, MDACC, June 2002.

Member, Technology Review Committee for Institutional Grant Proposals, MDACC, July 2002- November 2006.

Member, Funding Initiatives and Faculty Contacts for the Developmental Chemotherapy and Biotherapy Program, MDACC, September 1, 2002- present.

Member of Internal Advisory Board, Therapeutic Lung PO1 entitled "Vascular Targeted Therapy of Primary and Metastatic Lung Cancer" (P.I. Roy S. Herbst, M.D., Ph.D. Co-PIs: Isaiah J. Fidler, DVM, PH.D. and Waun Ki Hong, Ph.D.), October 2002-present.

Member of Internal Advisory Board, Brain SPORE (P.I. Dr. Alfred W. K. Yung), April 2003-present.

Member of Internal Advisory Board, H&N SPORE (P.I. Dr. Waun Ki Hong), 2003-present.

Member of the Internal Advisory Board, PO1 entitled "Novel Approaches to Cancer Gene Therapy." (P.I. Jack Roth, Ph.D.) This PO1 is being submitted by investigators in the W. M. Keck Center for Cancer Gene Therapy, February 2003-present.

Member, the Translational Research Faculty Development Committee, 2003-present.

**Chair, Experimental Therapeutics Advisory Committee, February 2003- July 2003.**

Consultants, R21 Traditional Chinese Medicine Center Grant (MDACC in collaboration with Cancer Hospital, Fudan University, Shanghai, China).

Member of the Internal Advisory Committee, MRP application titled "Esophageal Cancer: Molecular Mechanisms of Progression and Response to Therapy" (P.I Jaffer Ajani), May 2003.

Member, Division of Cancer Medicine Executive Council, 2003 – present.

Member, Extramural Program of MDACC Steering Committee, Samsung Medical Center of S. Korea, February 2004 – present.

Consultant, R13 grant application for “The Annual SINO-US Seminar Series on Clinical Oncology - East Meets West” (MDACC in collaboration with three Cancer Centers in China), July 2004-present.

Faculty Search Committee, Department of Breast Medical Oncology, and Department of Molecular Pathology, 2004 – present.

Member, Scientific Environment and Mentoring Committee, 2004 – present.

Member, GI Cancer Programs and Breast Cancer Programs, Clinical Strategies Advisory Committee, 2004 – present.

Member, Internal Advisory Board, PO1 “Integrative Biology of Ovarian Cancer” PI: Gordon Mills, February 2005- present.

Member, User’s Committee for the CCSG (P30) Genomics Core, 2005- present.

Member, Shared Resources Core Matching Committee, Partnership for Excellence in Cancer Research between M.D. Anderson Cancer Center and University of Puerto Rico, 2005- present.

Member, Search committee for the Deputy Division Chair for Research in the Division of Anesthesiology/Pain Medicine and Critical Care Medicine, 2005.

Member, Steering Committee for the Extramural Programs to review the scientific and academic collaborations on the Sister Institute Agreement -- Institute Gustave Roussy (IGR) of France, March 23, 2005.

**Member, Research Strategies Advisory Committee, May 2005 – present.**

Member, China Steering Committee, Extramural Programs, 2005.

**Member, Promotion and Tenure Committee, August 2005- July 2008.**

**Member, President's Committee on Patents and Intellectual Property, August 2005 – .**

Member, Faculty Search Committee for the Department of Neurosurgery, December 2005.

**Participation in Research Strategies Retreats, June 9, August 4 and September 29, 2006.**

**Participation in The Washington Advisory Group meetings on Research Strategies, June 27, 2006 (via Teleconference); and November 8, 2006.**

**Participation in The McKinsey Consultant Group workshop on International Activities, May 1; and brainstorm on July 10, 2006.**

Member, Search Committee for Chair, Department of Molecular Genetics, May 2006.

Member, Faculty *ad hoc* Subcommittee of the Institutional Animal Care and Use Committee (IACUC), June 2006.

Member, Search Committee for Division Head - Cancer Prevention and Population Sciences, June 2006.

**Member, Management Committee, September 2006 – August 2008.**

**Member, University Cancer Foundation Administrative Board, September 2006 – August 2008.**

Member, Nominating Committee of Dr. Tom Matney Endowed Professorship in Genetics, GSBS, July 2006.

Member, Internal Advisory Board, Department of Experimental Therapeutics, July 2006.

Member, Search Committee for the Associate Vice President for Women Faculty Programs, September 2006.

Member. Executive Committee of the M. D. Anderson Prostate Cancer Research

Program (PCRP), January 1, 2007 to December 31, 2009.

Member, Internal Advisory Board, Lymphoma SPORE (in preparation), January 2007 to present.

Member, the Women's Faculty Advisory Committee, February 2007 – August 2008.

Member, \*Small Advisory Group to assist Drs. Mendelsohn and DuBois in identifying a Chair for the Department of Molecular Genetics, July 2007 - present.\*A three-member group: Drs. Mien-Chie Hung, Jean-Pierre Issa and William Klein.

**Member representing the Basic Science Chairs, Center for Global Oncology Executive Committee, February 2008-**

Member, Search Committee, Department Chair of Clinical Cancer Prevention Chair, April 2008-

Member, Search Committee for Faculty of Breast Medical Oncology, August 2008 to present

Member, Search Committee for Faculty of Molecular/Developmental Biology, October 2008 to present.

Member, Search Committee for Faculty of Molecular Pathology, October 2008 to present.

Co-Chair, Search Committee for Faculty of Infectious Diseases, October 2008 to present.

**c. Evaluation of the Faculty Members for the other Institutes:**

Outside review member for faculty promotion at the University of California, Los Angeles, Wayne State University, the Univ. of Wisconsin, and the University of Pittsburgh, 1994-1997.

Division of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan.

Division of Cancer Research, National Health Research Institutes, Taiwan.

Institute of Biological Chemistry, Academia Sinica, Taiwan.

Institute of Biomedical Sciences, Academia Sinica, Taiwan.

Institute of Molecular Biology, Academia Sinica, Taiwan.

Genomic Research Center, Academia Sinica, Taiwan.

Associate Director at the Genomics Center and Distinguished Research Fellow, Academia Sinica, Taiwan.

Division of Hematology and Oncology, University of Michigan, MI.

Department of Internal Medicine, UT Health Center at Houston, TX.

Sealy Center for Cancer Cell Biology, UT Medical Branch at Galveston, TX.

Department of Pathology, Wayne State University School of Medicine, MI.

Department of Biochemistry, New York Medical College, NY.

Division of Pharmaceutics, College of Pharmacy, Ohio State University, OH.

Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, IN.

Department of Biochemistry and Biophysics, School of Medicine, the University of North Carolina at Chapel Hill, NC.

Outside Reviewer for Intramural Scientists, NIH, Bethesda, MD.

Department of Biological Chemistry, College of Medicine, University of California at Irvine, CA.

Center for Tissue Regeneration and Repair, Orthopaedic Surgery Department, University of California-Davis, Sacramento, CA.

Center for Aging and Developmental Biology, University of Rochester, Rochester, NY.

Department of Gene and Cell Medicine, Mount Sinai School of Medicine, NY.

School of Pharmacy, Pittsburgh University, PA.

Cancer Biology Program, Harvard Medical School, MA.

Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, UN.

Department of Oncology and Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington DC.

**d. Consultant/ Member of External Scientific Advisory Board:**

National Taiwan University Hospital, Cancer Research Group, 1992-1995.

The Israel Science Foundation, Grant Review Committee, 1993-1994.

Advisory Board, Institut für Klinische Chemie und Laboratoriumsmedizin-Zentrallaboratorium, Germany, 1993 – 1995.

Member of The External Advisory Committee - Program Project on "Study on the Genetic Alterations and Tumor Associated mRNA in Cancers in Taiwan" - National Taiwan University, 1993.

Member, Grant Review Panel for Clinical Research Centers, Institute of Biomedical Sciences, Academia Sinica, Taiwan, R.O.C. 1994-1995.

R Gene Therapeutics, Inc. Consultant, 1994-1996.

Development Center for Biotechnology, Consultant, Taipei, Taiwan, 1994-1995.

Member, Grant Review Panel for California Breast Cancer Research Foundation, 1995-1996.

Member of the Scientific Advisory Board, Targeted Genetics Corporation, 1996-2001.

Member of the Post-doctoral Fellowship Review Panel for the Susan Komen Breast Cancer Foundation, 1997.

**National Health Research Institute, Member of the Scientific Advisory Board, Taiwan, 1997 – present.**

Member of the Scientific Advisory Board, Division of Molecular & Genomic Medicine and Division of Cancer Biology, National Health Research Institute, Taiwan, 1997 – present.

Member, Promotion Committee, Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan, 1998-present.

Scientific Review Committee (SRC) on Medical Science of the National Health Research Institutes (NHRI), Taiwan, 1998.

Member, Grants Review Panel for Frontier Program on Medical Gene Research, National Science Council, Republic of China, Taiwan, 1998 - present.

Member of the External/Internal Advisory Committee, Program Project on “Studies on Treatment and Biology of Common Cancers in Taiwan” – National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan, 1998 – present.

Member of Scientific Advisory Board, Biocyte Therapeutics, Inc., 1999-2001.

Member, Research Grants Review Council, University Grants Committee, Hong Kong, China, 1999-2000.

**Member, Advisory Committee, National Science and Technology Program in Pharmaceuticals and Biotechnology, National Science Council, Taipei, Taiwan, 1999-2002, 2005-2007 and 2007-2009.**

Member, Advisory Board, Research Excellence Program Project National Chen-Kung University, Tainan, Taiwan, 2001-present.

Member of Advisory Board, The Laboratory for Integrated DNA Microarray Analysis (LIDMA), Chen-Kung University, Taipei, Taiwan, 2001 – present.

Member of Advisory Board for Ovarian Spore Grant at Fox Chase Cancer Center, Philadelphia, PA, 2001-2006.

Member, External Scientific Advisory Board, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, 2002 – present.

Member of Advisory Board, the Sino-America Hi-Tech, May 12, 2002.

Member of External Advisory Board, Baylor Breast Cancer SPORE grant (P.I. Kent Osborne, M.D.), Baylor College of Medicine, Houston, TX. June 2002 – present.

Board Member of Alchemgen Therapeutics Inc. (ATI), Houston, TX, April 16, 2002-April 15, 2004.

Member, Scientific Advisory Board, Genomic Research Center, Academia Sinica, Taipei, Taiwan, 2002 – present.

Member, Advisory Committee, National Science and Technology Program for Genomic Medicine, Academia Sinica, Taiwan. January 12, 2003 to January 11, 2006.

Member, Technical Advisory Committee, Biomedical Engineering Center (BMEC), Industrial Technology Research Institute (ITRI), Hsinchu, Taiwan, February 2003-present.

Consultant, Biotechnology Oversight Program, Ministry of Science and Technology of China, May 2003.

Member, External Advisory Board, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, 2003 – present.

Member, External Advisory Board, Division of Biotechnology and Pharmaceutical Research, National Health Research Institute, Taiwan, 2003 – present.

Scientific Advisory Board Member, ADImmune Corporation, Taiwan, June 2003 – present.

Member, Advisory Committee, Project “Genomic Studies and Clinical Applications of Lung Cancer in Taiwan-Emphasizing on Female Adenocarcinoma”, National Health Research Institute, Taiwan, August 2003 – present.

Member, External Advisory Board, Center of Excellence in Biomedical Research (COBRE) application entitled "Mentoring Cancer Research in Oklahoma", University of Oklahoma Health Science Center, November 2004 – present.

Scientific Advisory Board Member, InterPath Pharmaceuticals, Delaware, October 2005 – present.

Member of External Advisory Board, Breast SPORE Northwestern University Feinberg School of Medicine, December 2005.

Member of External Advisory Board, Breast SPORE University of Texas Southwestern Medical Center, January 2006.

Member of Scientific Advisory Board, Asian Fund for Cancer Research (AFCR)-National Foundation for Cancer Research, Bethesda, MD, 2006 - present.

Member, Advisory Board, The Breast Cancer Society of Taiwan, 2006 - present.

Member, Scientific Advisory Board, the First Key Opinion Leader Advisory of Monogram Biosciences, June 3, 2006, Atlanta, GA.

Member, Advisory Committee, Angiogenesis Center, National Taiwan University, May 20, 2006 to May 19, 2009.

Member, Review Committee, Excellence Research Project, National Taiwan University, June 2006 to May 2007.

Member. President’s Committee, Kaohsiung Medical University, Kaohsiung, Taiwan, November 1, 2006 to June 30, 2009.

**e. Military or Government Service:**

Military Service in Taiwan, Republic of China, 1973 – 1975.

**Honors and Awards:**

Post-doctoral Fellowship Award, Cancer Research Institution, Inc., 1984-1986.

Basil O'Connor Starter Award, March of Dimes Foundation, 1987-1989.



Dean's Teaching Excellence List, Graduate School of Biomedical Sciences, The University of Texas Health Science Center in Houston, 1987-present.

**John P. McGovern Outstanding Teacher Award, The University Texas Health Science Center in Houston, 1989-1990 (one awardee each year is elected out of 400 faculty members by entire student body of the Graduate School of Biomedical Science in Houston; the awardee receives a certificate and \$1000 cash).**

Service Award in the area of education, Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, 1990.

**John P. McGovern Outstanding Teacher Award, The University of Texas Health Science Center in Houston, 1992-1993 (The first faculty member to receive this award twice in the Graduate School of Biomedical Sciences).**

**Faculty Achievement Award in Education, The University of Texas M.D. Anderson Cancer Center, 1993 (nominated by Faculty Senate, evaluated by two separate committees and outside reviewers; each awardee receives a certificate, a medal, and \$35,000).**

International Directory of Distinguished Leadership, American Biographical Institute, Inc., Raleigh, North Carolina, Fifth Edition, 1994.

International Leaders in Achievement, Third Edition, International Biographical Centre, Cambridge, England, 1994.

Most Admired Man of the Decade, American Biographical Institute, Inc., Raleigh, North Carolina, 1994.

Who's Who in Science and Engineering, 3rd Edition of Marquis Who's Who in Science and Engineering, New Providence, New Jersey, 1996-97.

Who's Who in America, 51st Edition of Marquis Who's Who, New Providence, New Jersey, 1997.

Who's Who in America, 2nd Edition of Marquis Who's Who in Medicine and Healthcare, New Providence, New Jersey, 1997.

Who's Who in America, 4th Edition of Who's Who in Science and Engineering, New Providence, New Jersey, 1997 – 1998.

**American Association of Chinese Professionals (AACP), Outstanding Achievement Award, Houston, Texas, May 1997. (This society gives one award per year to recognize one Chinese American for his/her outstanding achievement).**

**Faculty Achievement Award in Basic Research, The University of Texas M.D. Anderson Cancer Center, 1998 (nominated by Faculty Senate, evaluated by two separate committees and some outside reviewers; each awardee receives a certificate, a medal, and \$35,000).**

2000 Outstanding Scientists of the 20th Century, International Biographical Centre, Cambridge, England, 1998.

**John P. McGovern Outstanding Teacher Award, The University of Texas Health Science Center in Houston, 1998-1999 (The only faculty member to receive this award three times in the Graduate School of Biomedical Sciences. After receiving this award three times, Dr. Hung has decided not to be considered for this award again, in order to recognize outstanding teachers from other faculty members).**

Who's Who in America, 17<sup>th</sup> Edition of Who's Who in the World, Marquis Who's Who, New Providence, New Jersey, 1999.

Who's Who in America, 5<sup>th</sup> Edition in Who's Who in Science and Engineering, Marquis Who's Who, New Providence, New Jersey, 1999.

Who's Who in America, 2000, 54<sup>th</sup> Edition – Classic, Marquis Who's Who, New Providence, New Jersey, 1999.

Education Spotlight, Educator of the Month for November 2000, The University of Texas M. D. Anderson Cancer Center, 2000.

**Academician of the Academia Sinica, Taiwan, 2002.**

**Honorary Professor, Peking Union Medical College, Chinese Academy of Medical Sciences, China, 2004.**

**President's Circle Leadership Council, American Association for Cancer Research Foundation, 2004.**

Reappointed with the Highest Commendation by the Membership Committee, GSBS (less than 2% GSBS faculty reappointed with the highest commendation), June 2005.

**Member, Advisory Committee of Bio Taiwan, Industrial Technology & Strategy Review Board of Executive Yuan of Taiwan, June 6, 2005 – June 6, 2007.**

**Invited Speaker, "Assessing Progress, Advancing Change: Challenges in Translational Research", President's Cancer Panel, Washington, D.C., October 24, 2005.**

Education Spotlight, Educator of the Month for January 2006, The University of Texas M. D. Anderson Cancer Center, 2006.

**Member, Roundtable Meeting of Translational Research Working Group, NCI, Phoenix, Arizona, February 22-24, 2006**

**Member, The University of Texas Academy of Health Science Education, October 5, 2006.**

**MDACC second annual “Best Boss Award”, July 2007.** Dr. Hung is one of 10 employees received awards in the second annual Best Boss Award Program competition. Sixteen finalists also were named, out of a slate of more than 80 candidates.

## **Research**

### **Extramural Grant and Contract Support: Total Direct Costs/(ADC)**

#### **Active - Serving as a Principal Investigator or a Project Leader:**

1. National Institutes of Health, National Cancer Institute PO1 CA099031, “Growth Factor Receptor Signaling in Breast Cancer Progression”, Program Principal Investigator, \$4,942,615 (TDC), Project 1 Project Leader, “Functionality of ErbB2/Akt Signaling in Breast Cancer”, \$148,896 (ADC) and Director, Administrative Core, \$69,568 (ADC), 04/01/2003 - 03/31/2008. \*renewal application submitted on October 9, 2008.
2. National Institutes of Health, National Cancer Institute RO1 CA109311, Principle Investigator, “HER2/neu in tumor progression of breast cancer”, \$201,518 (ADC), 07/01/2004 - 06/30/2009.
3. National Cancer Institute, UT MDACC Pancreatic SPORE, P20 CA101936, Co-Principal Investigator, (P.I.: James Abbruzzese, M.D.) \$4,272,315 (TDC), Project 1 Project Leader, M.-C. Hung, Ph.D., “Development of Novel Gene Therapy for Pancreatic Cancer” \$180,454 (ADC), 07/01/2003 - 06/30/2008.
4. Michael Kadoorie Funded Research into Cancer Genetics, Kadoorie Charitable Foundation, Principle Investigator, “Genetic Factors in Hepatocellular Carcinoma”, \$214,704 (ADC), 10/01/2004-09/30/2007; competing renewal funded 2008-2011.
5. UT MDACC Breast SPORE, 1P50 CA116199, Co-Principal Investigator, Mien-Chie Hung, Ph.D. (P.I. Gabriel N. Hortobagyi M.D.) \$7,741,905 (TDC), Project 5 Project Leader, Mien-Chie Hung, Ph.D., “Targeting Breast Cancer-Specific Gene Therapy” \$225,956 (ADC), 09/01/2005-08/31/2010.
6. National Institutes of Health, National Cancer Institute P50 CA83639, UT MDACC Ovarian SPORE, (P.I.: Robert Bast, M.D.) Project 3 Project Leader, M.-C. Hung, Ph.D., “E1A Gene Therapy in Ovarian Cancer,” \$237,389 (ADC), 09/01/2005-08/31/2010.

7. Department of Defense Breast Cancer Research Program, Synergistic Idea Award, Principal Investigator, “Dissect Protein Complexes Dynamic Interaction in Breast Cancer by Photon-Burst Spectroscopy”, \$250,000 (ADC), 09/01/2008-08/31/2010.

**Active- MDACC Cancer Center Supporting Grant (CA16672, P.I.: John Medelsohn, M.D.) as Program Leader:** Cell Biology and Signaling Transduction Program, Program Leader (Co-leaders: Drs. Edward Yeh and Dihua Yu), July 2008- Sept 2012.

**Philanthropic Funds:**

1. President’s Excellence Fund, September 2005 – August 2010, \$200,000 (ADC).
2. The National Breast Cancer Foundation, Inc. \$300,000 on August 2008.
3. Patel Memorial Breast Cancer Research Fund, 10/2003 - present
4. Henry & Carol Zarrow Ovarian Cancer Fund, “Development of a Novel E1A/Liposome Gene Therapy for Ovarian Cancer Patients”, \$250,000 (ADC), 04/01/2003-03/31/2005. (MDACC contact- Dr. Robert C. Bast, Jr.).
5. The National Breast Cancer Foundation, Inc. \$20,000 on 6/17/03 (MDACC Contact: Jennifer F. Covington and Aimee Clark).
6. The National Breast Cancer Foundation, Inc. \$100,000 on 12/27/04.
7. Topfer Fund for pancreatic cancer.
8. The National Breast Cancer Foundation, Inc. \$100,000 on June 2006.

**Active - Serve as a Co-Investigator/Subcontractor:**

1. Breast Cancer Research Foundation “Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein”, (P.I.-G. N. Hortobagyi, M.D.) Co-P.I. M.-C. Hung, \$250,000(ADC)-one year, 10/01/2008 – 09/30/2009.
2. Department of Defense Center of Excellence (W81WXH-06-2-0033) “Studies directed toward the eradication of brain metastasis of breast cancer”, (P.I.-P. Steeg, Ph.D.), P.I., Subcontract: M-C. Hung, \$89,261 (ADC), 06/01/2006-05/31/2011.

**Pending- Serve as a Principal Investigator or a Project Leader**

**Pending-Serve as a Co-Investigator/Subcontractor**

**Inactive - Serving as a Principal Investigator or a Project Leader:**

1. Marcus Foundation, Principle Investigator, “E1A-Liposome Gene Therapy for Metastatic Ovarian Cancer”, \$491,765 (ADC), 10/01/2006-09/30/2008.
2. Susan G. Komen Breast Cancer Foundation, BCTR76906, Principal Investigator, “Role of IFIX in breast cancer metastasis”, \$250,000 (ADC), 05/01/2006 – 04/30/2008.
3. Department of Defense Breast Cancer Research Program (BCRP), CDMRP/DOD, Center of Excellence BC13020, DAMD 17-02-1-0694, “Development of targeted strategies for breast cancer”, (P.I.:G.N. Hortobagyi, M.D.), Task 3 Leader, M.-C. Hung, Ph.D., “Development of Bik/Bok Gene Therapies using Liposome-mediated Systemic Gene Transfer”, \$213,140 (ADC), 09/01/2002-08/31/2006\*. \*One year no-cost extension to 08/2007.
4. Alchemgen Therapeutics Inc. “Chemo-Preventive Activity of Emodin and other Tyrosine Kinase Inhibitors, Growth Inhibition of p21 and Pro-apoptotic Proteins; Tumor-Specific Expression and Drugs Screening Systems Targeting Growth Factor Receptors; Gene Delivery System for Gene Therapy”, LSA01-304, 11/2001 - 10/2006, \$5,000,000.
5. National Institutes of Health, National Cancer Institute 2R01 CA58880, “E1A Gene Therapy in Breast Cancer,” P.I., 08/1997 - 01/2005, \$1,317,358/\$ 261,000 (ADC).
6. National Institutes of Health, National Cancer Institute 1P50 CA83639 (PP3)-1, UT MDACC Ovarian SPORE, Project 3 Leader, “E1A Gene Therapy in Ovarian Cancer,” M.-C. Hung, Project Leader, 09/1999 - 08/2004, \$1,096,945/\$237,389 (ADC) (P.I.: Robert Bast, M.D.).
7. Department of Defense U.S. Army Medical Research and Materiel Command, DAMD17-01-1-0071, “The p202 Gene as a Tumor Suppressor in Prostate Cancer Cells,” P.I., 06/2001-05/2004\*, \$562,500/\$101,141 (ADC) (\*one year one time no cost extension to 05/2005.)
8. Department of Defense U.S. Army Medical Research and Materiel Command, DAMD17-00-1-0312, “p202 as a Potential Therapeutic Gene for Breast Cancer”, 04/2000-03/2003\*, \$225,000/\$75,000 (ADC) (\*one year one time no cost extension to 03/2004.)
9. U.S. Army Training Programs in Breast Cancer Research at the UTMDACC, U.S. Army Medical Research, Grant No. DAMD17-99-1-9264, M.-C. Hung, P.I., 09/1999-08/2003\*, \$781,359/\$185,185 (ADC) (\*one year one time no cost extension to 08/2004.)
10. Susan G. Komen Breast Cancer Foundation, “Development of a Targeted Gene Therapy Method for Breast Cancer”, 10/2001-09/2003\*, \$250,000/\$100,000 (ADC) (\*one year one time no cost extension to 09/2004.)
11. Enchira Biotechnology Corporation, “Laboratory Study Agreement LS00-333-1 “Directed Evolution of Growth Factors and Receptors,” P.I., 11/2000-10/2002, \$300,000.
12. National Cancer Institute, Grant No. 2 R01 CA58880, “The c-erbB2 Oncogene and E1A Suppressor in Breast Cancer,” P.I., 10/1997 - 01/2001, \$539,880.

13. National Cancer Institute, Grant No. NIH R01 CA77858, "PEA3 in HER-2/*neu*-overexpressing Ovarian Cancer," P.I., 04/1998 - 03/2002, \$540,000.
14. Tanox, Inc., "Development of BOK Gene Therapy for Ovarian Cancer," SR99-163-1, P.I., 5/19/2000-5/31/2001, \$125,000.
15. Target Genetics Corp. "E1A Cancer Gene Therapy in Animal Models", CS97-003-02, 08/2001-07/2002, \$187,500.
16. Targeted Genetics Corporation, "Product Development for E1A-Liposome as an Anti-cancer Agent," P.I., 02/1997 - 02/2001, \$1,025,866.
17. Biocyte Therapeutics Incorporation, "Product Development for PEA3 as a Tumor Suppressor in Breast Cancer,"SR97-00, P.I., 06/1997 - 06/2001, \$1,061,616.
18. National Institutes of Health, National Cancer Institute, Grant No. R01 CA 60856, "The HER2/*neu* and Heregulin in Human Ovarian Cancer," P.I., 07/1993-06/1998, \$454,080.
19. U.S. Army Medical Research and Development Command, Log. No. B4335017, "Multiple Genetic Alterations in Breast Cancer," P.I., 08/1994-98/1998, \$795,560.
20. U.S. Army Medical Research and Development Command, #RP951651, "Targeting HER-2/*neu* overexpressing by suicide ribozyme in breast cancer," P.I., 08/1996-07/1998. \$150,000.
21. National Institutes of Health, National Cancer Institute, Grant No. R01 CA 58880, "The *neu* Oncogene in Breast Cancer," P.I., 02/1993-01/1997, \$330,891.
22. R. Gene Therapeutics, Inc., "HER2/*neu* Targeting Cancer Therapy," P.I., 05/1994-10/1996, \$500,000.
23. RGene Therapeutics, Inc., "Optimization of E1A-Liposome Therapeutic Efficacy," P.I. 11/1995-10/1996, \$40,000.
24. National Research Institute of Chinese Medicine, "A Rapid Strategy for Identification of Potential Anti-Cancer Drugs from Herbal Medicine," P.I., 04/1992-present, \$40,000.
25. Schering-Plough Research, "Identification of the HER2/*neu* ligand," P.I., 04/1991-present, \$40,000.
26. RGene Therapeutics, Inc., "Supplement of the E1A-Liposome Phase I Clinical Trial," P.I., 03/1996-03/1997, \$65,000.
27. Carrington Laboratories, Inc., "Effects of acemannan on transformation of the *neu*-transformed cells," P.I., 01/1990-present, \$13,500.

28. Smokeless Tobacco Research Council, Inc. Grant No. 0287, "The *neu* Proto-oncogene in Lung Cancer," P.I., 07/1991-06/1994, \$230,000.
29. Council for Tobacco Research, Grant No. 2527, "Isolation of the Ligand and Cloning of its cDNA for the *neu* Encoded Receptor," P.I., 0719/89-06/1993, \$220,000.
30. National Institutes of Health, National Cancer Institute, Grant No. R01 CA 45265, "Regulation of the *neu* Oncogene," P.I., 04/1988-11/1992, \$307,709.
31. American Cancer Society, Grant. No. CD-360, "Transcription Mechanisms of the *neu* Oncogenes," P.I., 01/1988-06/1990, \$180,000.
32. The Robert A. Welch Foundation, Grant No. G1134, "Ligand Isolation and cloning of its cDNA for the *c-erbB-2* Receptor," P.I., 04/1988-03/1991, \$75,000.
33. March of Dimes Birth Defects Foundation, Grant No. 5-621, "Cloning of a Regulatory Factor Gene Required for Expression of the *neu* and EGF Receptor Genes," P.I., 09/1987-06/1990, \$70,000.
34. March of Dimes, Birth Defects Foundation, Grant No. 1-1211, P.I., 07/1990-6/1992, \$60,000.
35. Biomedical Research Support Grant, Grant. No. RR5511-25, "Identification and Cloning of a Gene Required for Expression of the *neu* Gene," P.I., 08/1987-02/1989, \$20,000.

#### **Inactive - Serving as a Co-Investigator**

1. Breast Cancer Research Foundation "Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein", (P.I.-G. N. Hortobagyi, M.D.) Co-P.I. M.-C. Hung, \$250,000(ADC)-one year, 10/2005 – 9/2006 and 10/2006-9/2007.
2. U54 PRCC/MDACC Partnership for Excellence in Cancer Research, A National Institutes of Health Partnership between The University of Puerto Rico Cancer Center and The University of Texas M. D. Anderson Cancer Center, "Inhibiting Angiogenesis in Breast Tumors by Inducing *Unfolded Protein Response* (UPR): Testing a New Paradigm", (P.I.-G. K. Banerjee, Ph.D., University of Puerto Rico School of Medicine, San Juan, Puerto Rico), Collaborator: M.-C. Hung, 10/01/2004 - 09/30/2007, \$25,000 (ADC).
3. Breast Cancer Research Foundation "AIM2 as a therapeutic agent for breast cancer", (P.I.-G. N. Hortobagyi, M.D.) Co-P.I. M.-C. Hung, \$250,000(ADC)-one year, 10/2004 - 09/2005.
4. Breast Cancer Research Foundation "A Novel Apoptotic Molecule Mtd for the Treatment of Breast Cancer", (P.I.-G. N. Hortobagyi, M.D.) Co-P.I. M.-C. Hung, \$250,000(ADC), 10/2003-09/2004.
5. National Institutes of Health, National Cancer Institute, Phase I Clinical Studies of Chemopreventive Agents, NO1-CN-05023-39, "Breast Epithelial Cell Culture,

- Chemopreventive Agent Treatment, RNA Preparation, from 9 Initial Cultures Pre and Post-Treatment with 3-5 Chemopreventive Agents," Subcontract (NO1 P.I.-Louise Strong), 02/2001-02/2004, \$84,000.
6. Breast Cancer Research Foundation "The p202 Gene Therapy in Breast Cancer", (P.I.-Dr. Gabriel N. Hortobagyi) Co-P.I. M.-C. Hung \$250,000 (ADC), 10/01/2001-09/30/2002.
  7. PEA3 as a Potential Therapeutic Agent for Breast Cancer, Breast Cancer Research Foundation (P.I.-Dr. Gabriel N. Hortobagyi), 10/01/2000-09/30/2002, \$250,000.
  8. Nonviral Gene Delivery System Using Novel Polymers and Tumor Targeting Agents. RSNA Research and Education Fund, (P. I.-Dr. Carolyn Aitken Nichol), 03/1997 - 09/1997, \$19,990.
  9. Characterization of Epitopes Recognized by T Cells on Ovarian Cancer, NCI/NIH, CA57293, (P.I.-Dr. Constantin G. Ionnides), 07/1992-06/1994, \$272,536.
  10. Breast Spore Feasibility Award, NCI/NIH CA58136, (PI-Dr. Gabriel N. Hortobagyi) 12/1992-11/1994, \$70,000.
  11. The Council for Tobacco Research-USA, Inc., Grant No. 2264M, Co-Investigator, (P.I.-Dr. James C. Chan) "Molecular Studies of a New Transforming Growth Factor 'TAP'", 01/1989-12/1991, \$187,237.
  12. Characterization of Transmembrane TNF. American Cancer Society. Grant No. IM-571, Co-Principal Investigator, 07/1989-06/1992, \$160,000 (P.I.-Dr. Jim Klostergaard).
  13. Development and Evaluation of Human Tumor Necrosis Factor Variants. Advanced Technology Program from Texas Higher Education, 000015-002 Coordinating Board, Co-Principal Investigator, 01/1990-12/1991, \$191,176 (P.I.-Dr. Jim Klostergaard).
  14. Tumor Targeting of Recombinant Human Tumor Necrosis Factors. Grant No. Texas Higher Education Coordinating Board, Advanced Technology Program, Co-Principal Investigator, 01/1991-12/1993, \$190,000 (P.I.-Dr. Jim Klostergaard).
  15. Autocrine Growth Regulation in Human Glioma, NIH, R01 CA-51148, Co-Investigator, 12/1989-11/1994, \$510,388 (P.I.-Dr. Alfred Yung).
  16. *Neu* Oncogene and Metastasis. NIH, R03 CA-54989, Co-Investigator, 08/1991-07/1993, \$80,000 (P.I.-Dr. Dihua Yu).
  17. Surgical Stress Impairment of Human NK Cell Cytotoxicity. NIH, R01 CA51512, Co-Investigator, 12/1989-11/1994, \$350,000 (P.I.-Dr. Raphael E. Pollock).

**Serving as a Mentor/Sponsor**



1. Role of Nuclear Tyrosine Kinase in Breast Cancer: National Institutes of Health Mentored Clinician Investigator Award 1K08-CA91895, (P.I.-Dr. Funda Meric) (Mentor- Dr. Mien-Chie Hung), 08/2001-07/2006, \$630,000.
2. Role of Nuclear Tyrosine Kinase in Breast Cancer. US Army Breast Cancer Research Program Career Development Award (P.I.-Dr. Funda Meric), (Mentor – Dr. Mien-Chie Hung), (returned due to scientific overlap with K08), 2001.
3. Tumor Suppression and Sensitization to Taxol Induced apoptosis of E1A in Breast Cancer Cells. US Army Breast Cancer Research Program Postdoctoral Fellowship Award (P.I.-Dr. Yong Liao), (Mentor – Dr. Mien-Chie Hung), 06/01/2001-05/31/2004, \$150,000.
4. Development of DNA Binding Domain of PEA3 as a Potential Gene Therapy Agent for Breast Cancer. US Army Breast Cancer Research Training Grant Award (Predoctoral Fellowship), P.I.- Zhenming Yu,. (Mentor – Dr. Mien-Chie Hung), 09/1999 - 2001.
5. p202 as Potential Therapeutic Gene for Breast Cancer. US Army Breast Cancer Research Training Grant Award (Predoctoral Fellowship), P.I.-Yong Wen, (Mentor – Dr. Mien-Chie Hung), 09/1999 - 2001.
6. Identification and Characterization of a Taxol Induced Gene; a Novel Therapeutic Approach Under the Control of Taxol Induced Gene Promoter. US Army Breast Cancer Research Training Grant Award (Postdoctoral Fellowship), P.I.-Dr. Keishi Makino, (Mentor – Dr. Mien-Chie Hung), 09/1999 – 2001.
7. Roles of Serine-Threonine Kinase Akt in Breast Cancer and its Potential Therapeutic Application. US Army Breast Cancer Research Training Grant Award (Postdoctoral Fellowship), P.I.-Dr. Binhua Peter Zhou, (Mentor – Dr. Mien-Chie Hung), 09/1999 – 2001.
8. (T32) Training Program in Molecular Pathology of Cancer. P.I.-Ryan Von Lindern (Predoctoral Award), NIH CA67759, (Mentor – Dr. Mien-Chie Hung), 05/1998 – 04/2003.
9. Adenovirus E1A as a Therapeutic Agent in Breast Cancer. KO-8, Mentored Clinical Scientist Development Award. (P.I.-Dr. Naoto Ueno), (Mentor - Dr. Mien-Chie Hung), 09/1998-08/2003, \$400,000.
10. BC971438 “Adenovirus E1A Gene Therapy Combined with Chemotherapy or the p53 Gene in Human Breast Cancer” (P.I.-Dr. Naoto Ueno), (Mentor – Dr. Mien-Chie Hung), this award was returned to the U.S. Army Medical Research due to overlap with the KO8 NIH funding).
11. Mitosis-Specific Negative Regulation of EGF-Receptor in Breast Cancer: Molecular Mechanisms, Biological Significance and Therapeutic Application. U.S. Army Medical Research and Development Command, Predoctoral Award to Mr. Shiaw-Yih Lin (replaced by Stephanie Miller from 03/00-04/01), (Mentor-Dr. Mien-Chie Hung), 05/1998-04/2001, \$64,500.

12. Roles of the CDK Inhibitors p27<sup>Kip1</sup> and p57<sup>Kip2</sup> in the Development of Breast Cancer. U.S. Army Medical Research and Development Command, Postdoctoral Award. (P.I.-Dr. Heng-Yin Yang), (Mentor- Dr. Mien-Chie Hung), 05/1998-04/2001, \$120,000.
13. Induction of apoptosis in human breast cancer by adenoviral mediated gene transfer of the transcriptional factor E2F1. U.S. Army Medical Research and Development Command, Research Carrier Development Award. (P.I.-Dr. Kelly Hunt), (Mentor-Dr. Mien-Chie Hung), 09/1997 - 08/2001, \$198,720.
14. Development of PEA3 as a potential gene therapy against breast cancer. U.S. Army Medical Research and Development Command, TR950023, Predoctoral Award to Ms. Xiangming Xing (replaced by Zhenming Yu from 10/98 – 9/99), (Mentor-Dr. Mien-Chie Hung) 08/1996-07/1999, \$80,000.
15. A novel apoptotic molecule Bok for treatment of breast cancer. U.S. Army Medical Research and Development Command, Postdoctoral Award. (P.I.-Dr. Geoffrey Bartholomeusz), (Mentor-Dr. Mien-Chie Hung), 03/01/02-02/28/05.
16. Targeting breast cancer by cancer-specific recombinase-mediated transgene expression. U.S. Army Medical Research and Development Command, Predoctoral Award, (P.I.-Yan Li), (Mentor-Dr. Mien-Chie Hung), 04/01/02-03/31/05.
17. Novel Transcriptional Function of Nuclear EGF Receptor, National Research Service Award, T32 CA09299-24 to Department of Molecular Genetics, (PI-Dr. Hui-Wen Lo), (Mentor-Dr. Mien-Chie Hung), National Institute of Health, 11/01/2002-12/31/2004.
18. “The molecular mechanisms of E1A-mediated tumor suppression”, Odyssey Scholar Award, (P.I.-Dr. Jen-Liang Su), (Mentor- Dr. Mien-Chie Hung), the Cockrell Foundation Award for Scientific Achievement, June 1, 2006-May 31, 2007.
19. “Inhibition of Mad1 by Akt Promotes HER-2/neu Oncogenic Signaling” (PI-Dung-Fang Lee), (Mentor- Dr. Mien-Chie Hung), Predoctoral Traineeship Award, Department of Defense Breast Cancer Research Program, February 2005- January 2008.
20. Role of Nuclear EGF Receptor in Human Cancers Postdoctoral Research Fellowship, PF TBE-109873 (PI-Dr. Hui-Wen Lo), (Mentor-Dr. Mien-Chie Hung), American Cancer Society, 07/01/2005-06/30/2007.
21. “Identifying Protein-Protein Interactions and Dynamics in Breast Cancer by Nanochannel Device” (PI-Chao-Kai Chou), (Mentor- Dr. Mien-Chie Hung), Predoctoral Traineeship Award, Department of Defense Breast Cancer Research Program, August 2006- July 2009.
22. Dung-Fang Lee, T. C. Hsu Endowed Memorial Scholarship, Graduate School of Biomedical Science, (Mentor- Dr. Mien-Chie Hung), September 2006.
23. Dung-Fang Lee, Andrew Sowell-Wade Huggins Scholarship, Graduate School of Biomedical Science, (Mentor- Dr. Mien-Chie Hung), 2006-2007.

24. “VISA to cancer therapy”, (PI-Hui Song), (Mentor- Dr. Mien-Chie Hung), Predoctoral Traineeship Award, U T Health Center, Center for Clinical and Translational Science (CCTS) T32 training program of NIH, April 1, 2007 – March 31, 2008.
25. “Suppression of cell proliferation and induction of autophagy by ARD1”, (PI-Hsu-Ping Kuo), (Mentor- Dr. Mien-Chie Hung), Predoctoral Traineeship Award, Department of Defense Breast Cancer Research Program, January 2008- December 2011.
26. Hsu-Ping Kuo, Andrew Sowell-Wade Huggins Scholarship, Graduate School of Biomedical Science, (Mentor- Dr. Mien-Chie Hung), 2007-2008.
27. Dung-Fang Lee, Alfred Knudson Jr. Outstanding Dissertation Award, 2008.
28. Hsu-Ping Kuo, Trainee Excellence Award, October 2008.
29. Jer-Yen Yang, Andrew Sowell-Wade Huggins Scholarship, Graduate School of Biomedical Science, (Mentor- Dr. Mien-Chie Hung), 2009-2010.

#### **Patents Granted and Pending:**

1. Klostergaard, J., Utsumi, T., **Hung, M.-C.** Preparation and Characterization of Liposomal Formulations of Lipophilic Human Tumor Necrosis Factor (UT MDACC 208, 440).
2. **Hung, M.-C.**, Yu, D., Chang, Y., Matin, A. Methods and Compositions for the Suppression of *Neu*-Mediated Transformations (UT MDACC 256, 364, 416, 468). The Royalty and the license right of this patent have resulted in multiple million dollars into our institution.
3. **Hung, M.-C.**, Zhang, L. Sensitization of HER-2/*neu*-overexpressing cancer cells to chemotherapeutic agents by tyrosine kinase inhibitors (UTMDACC: 471).
4. **Hung, M.-C.**, Ueno, N.T. Sensitization of *HER-2/neu* overexpressing cancer cells to chemotherapy (MDA96-012). Patent No: US 6,395,712 B1/Date of Patent: May 28, 2002
5. **Hung, M.-C.**, Xing, X-M. PEA3 is a Tumor Suppressor (UTMDACC 500).
6. **Hung, M.-C.**, Chen, H., Yu, D. Suppression of NEU Overexpression Using a Mini-E1A Gene (US 6,326,356 B1).
7. Tari, A., Lopez-Berestein, G., **Hung, M.-C.** Growth Inhibition of Her2/Neu Positive Breast Cancer Cells by Liposomal Grb2 Antisense Oligos (UTMDACC:511).
8. **Hung, M.-C.** Wang, S-C. Specific Gene Targeting Using Fusion DNA-Binding Domains from Multiple Trans-Regulators, (IDR98:030).
9. **Hung, M.-C.**, Li, K. Shc Deletion Mutant Suppresses Transformation by HER-2/*neu* (IDR98:039).

10. **Hung, M.C.**, Chen, H., Yu, D., Maxwell, B. (Patent Coordinator, Targeted Genetics Corporation), et al. Mini-E1A Genes and Gene Products (UTMDACC 556).
11. **Hung, M.C.**, Xing, X-M. Human PEA3 is a Tumor Suppressor for Cancer Cells (UTMDACC:582).
12. **Hung, M.-C.**, Yan, D-H., Wen, Y., Spohn, W.H. The p202 Gene is a Novel Tumor Suppressor Gene (IDR99-005).
13. **Hung, M.-C.**, Xia, W., Lau, Y-K. Predicting survival of patients with squamous cell carcinoma (US 6,852,483, February 8, 2005 issued).
14. **Hung, M.-C.**, Liao, Y. Akt oncogene and p38 pro-apoptotic gene as targets for E1A gene therapy (MDA00-059).
15. **Hung, M.-C.**, Xia, X. Lin, S-Y.  $\beta$ catenin as a prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression (MDA01-026).
16. **Hung, M.-C.**, Lau, Y-K, Wen, Y. Emodin and other tyrosine kinase inhibitors as chemopreventive agents. (MDA01-038).
17. **Hung, M.-C.**, Zhou, B. Mutant p21Cip1/WAF1 as a potent form of growth inhibitor (MDA01-043).
18. **Hung, M.-C.**, Zou, Y., Geoffrey Bartholomeusz, Kwong, K.Y. Antitumor activity of a Bok family gene. (MDA01-080).
19. **Hung, M.-C.**, Lin, S.Y. Nuclear localization of EGF receptor and its new role as a transcription factor. (MDA01-077).
20. **Hung, M.-C.**, Kwong, K.Y., Zou, Y. T-cell factor (Tcf)-responsive CMV promoter (TOP-CMV)-TK/Gancycovir treatment selectively suppresses growth of colon cancers both *in vitro* and *in vivo*. (MDA-02-048). Invention disclosure.
21. Lachman L. B., Price, J. E., Wang, X., Rao, X.-M., Wang, J.-P. and **Hung, M.-C.** SINCP containing the Gene for Rat HER2/Neu as a Vaccine for HER2/Neu Expressing Tumors. Invention disclosure.
22. Lachman, L. B., Price, J. E., Wang, X., Wang, J.-P. and **Hung, M.-C.** Viral Particle Replicon from Venezuela Encephalitis Virus Containing the Gene for Rat HER2/Neu as a Vaccine for HER2/Neu Expressing Tumors. Invention disclosure.
23. Yu, D., Nagata, Y., Lan, K.-H. and **Hung, M.-C.** Using inhibitors of the PI3K/Akt family proteins to sensitize Herceptin-resistant ErbB2-overexpressing breast cancers to Herceptin treatment. Invention disclosure.

24. Yu, D., Yao, J., Neal, C., Yang, W., Zhou, X., Pollock, R.E., **Hung, M.-C.**, and Nguyen, N. 14-3-3zeta overexpression as a poor prognosis factor, and a therapeutic target in multiple cancer types. Invention disclosure.
25. Lachman, L. B., Zhou, H. S., Wang, X., Wang, J.-P., Price, J. E., **Hung, M.-C.** and Beaudet, A. L. The use of E1, E2a-deleted human adenovirus type 5 containing the gene for HER2/*neu* as an anti-tumor vaccine for HER2/*neu*-expressing tumors. Invention disclosure. (MDA03-054).
26. **Hung, M.-C.**, C.-P. Day and K.-M. Rau Breast cancer-specific promoter. Invention disclosure.

### **Clinical Trials Involved:**

#### **Serving as Study Co-chairman**

1. Protocol DM 94-129: Phase I Study of E1A Gene Therapy for Patients with Metastatic Breast or Epithelial Ovarian Cancer that Overexpresses HER-2/*neu*. Study Chairman: Gabriel N. Hortobagyi, M.D.
2. Protocol ID 96-117: Phase I Study of Intratumoral E1A Gene Therapy for Patients with Unresectable or Metastatic Solid Tumors that Overexpress HER-2/*neu*. Protocol Chairman: James Murray, M.D.
3. Protocol ID 99-037: Phase II Study of *E1A* Gene Therapy for Patients with HER-2/*Neu*-Overexpression Advanced Epithelial Ovarian Cancer. Study Chairman: Naoto T. Ueno, M.D., Ph.D.
4. Protocol 2004-0980: A Phase I Study of BIKDD Therapy in Advanced Breast Cancer. Study Chairman: Gabriel N. Hortobagyi, M.D., Co-Chairmen: Gabriel Lopez-Berestein, M.D. and Mien-Chie Hung, Ph.D. Changed to Protocol: 2007-0411: A Phase I Study of BikDD Therapy in Advanced Breast Cancer. Chairman: Gabriel N. Hortobagyi, M.D., Co-Chairmen: Jennifer K Litton, M.D. and Mien-Chie Hung, Ph.D.
5. Protocol 2007-0762: A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of the BikDD Nanoparticle in Patients with Advanced Pancreatic Cancer. Chairman: Milind Javle, M.D., Co-chairman: James L. Abbruzzese, M.D., and Mien-Chie Hung, Ph.D.

#### **Serving as Collaborator**

1. Protocol DM 96-188: Chemotherapy and Antibody response Evaluation (CARE): a Phase III Multinational Randomized Study of Recombinant Humanized Anti-p185<sup>HER2</sup> Monoclonal Antibody (rhuMAR<sup>HER2</sup>) Combined with Chemotherapy in Patients with <sup>HER2</sup> who have not

Received Cytotoxic Chemotherapy for metastatic Breast Cancer”. Study Chairman: James L. Murray, M.D.

2. Protocol DM 95-046: Phase II Study of High-dose Chemotherapy and Autologous Blood Progenitor Cell Rescue for Primary Breast Cancer Refractory to Preoperative Chemotherapy. Study Chairman: Richard Champlin, M.D.
3. Protocol DM 99-015: Phase II Multidose, Single Arm, Single Institution Clinical Trial of Cisplatin and Gemcitabine in Combination with Recombinant Humanized Anti-p185<sup>HER2</sup> Monoclonal Antibody (Herceptin®) in Patients Who Have Untreated Metastatic (Stage IV) Non-Small Cell Lung Cancer. Study Chairmen: Roy S. Herbst M.D., Ph.D. and Ralph Zinner, M.D.
4. Protocol: Phase II, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination with local administration of Ad5CMV-p53 (RPR/INGN 201) in Locally Advanced Breast Cancer (LABC). Study Chairman: Massimo Cristofanilli, M.D.
5. Protocol: Phase II Trial of ST1571 in Metastatic Breast Cancer. Study Chairman: Massimo Cristofanilli, M.D.
6. Protocol: Phase I/II Dose Escalation, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination with Local Administration of AD5CMV-p53 (INGN-201) in Locally Advanced Breast Cancer (LABC) with Overexpression of p53 Protein and/or Mutated p53 Gene. Chairman: Massimo Cristofanilli, M.D.
7. Protocol: DM95-046: Phase II Study of High-Dose Chemotherapy and Autologous Blood Progenitor Cell Rescue for Primary Breast Cancer Refractory to Preoperative Chemotherapy. Study Chairman: Richard Champlin, M.D.
8. Protocol ID02-321: A Phase 1/2 Randomized Study of Intraperitoneal tgDCC-E1A and Intravenous Paclitaxel in Women with Platinum-Resistant Ovarian Cancer. P.I.: Judith Wolf, M.D., Co-PI: Naoto Ueno, M.D., Ph.D.

#### **Grant Reviews and Site Visits:**

##### **a. NIH**

1. National Cancer Institute, Special Review Committee for PO-1, Los Angeles, 10/1990.
2. National Cancer Institute, Special Review Committee for PO-1, Washington, DC, 11/1990.
3. NIH CBY-2 Study Section (*Ad hoc* member), 06/1993.
4. NIH Pathology B Study Section (*Ad hoc* member), 01/1994, 02/1995, 06/1995, 10/1995, 02/1996, 06/1996.
5. NIH Medical Biochemistry Study Section (*Ad hoc* member), 07/1994.

6. **Member of NIH Pathology B Study Section, 07/1996-06/2000.**
7. NIH Pathology B Special Emphasis Review Panel (Telephone Conference), 03/1997, 07/1998, 12/1998, 04/1999.
8. NIH Experimental Therapeutics 1 Special Review Panel (Telephone Conference), 07/1998.
9. Member, Experimental Therapeutics-2 Study Section, Special Emphasis Panel (Teleconference Review), 07/1999.
10. **Member, Basic and Preclinical Subcommittee C, NCI Initial Review Group, National Cancer Institute, Bethesda, MD, 2001-2005.**
11. Member, Scientific Review on Pathology B Study Section Advisory Councils, Washington, D.C., October 3, 2001.
12. Member, Pathology B Study Section, Center for Scientific Review Special Emphasis Panel (Teleconference), November 13, 2001.
13. Member, Scientific Review on NCI Subcommittee C, Washington, D.C., December 4-7, 2001.
14. Chairperson, Site Visit, NCI Initial Review Group, Subcommittee C, Columbus, OH. February 10-12, 2002.
15. Chairperson, SEP/PTHB-Study Section, Teleconference, March 27, 2002.
16. Member, NIH Path B Study Section, Washington, D.C., April 24-27, 2002.
17. Member, NIH Path B Study Section, Washington, D.C. June 4-7, 2002.
18. Member, Pancreatic Cancer Spore of MDACC Pre-Application Meeting, Rockville, MD June 26, 2002.
19. Member, NCI 10<sup>th</sup> SPORE Investigators' Workshop, Chantilly, VA. July 13-14, 2002.
20. Member, NIH Sub-C Committee Meeting, Washington, D. C. July 30-August 2, 2002.
21. Member, NIH Sub-C Study Section, teleconference, August 15, 2002.
22. Member, Teleconference on PO-1 Review, NCI, NIH, September 13, 2002.
23. Chairperson, NIH SEP Study Section, teleconference on RO1 review, November 14, 2002.
24. Member and Session Speaker, Sponsored by the Tumor Biology and Metastasis Branch, NCI. "Proteases and Cancer: Biology and Clinical Applications Workshop", Session: Novel

- Aspects of Proteases “Nuclear translocation of ErbB GFs”, Bethesda, MD. November 20-22, 2002.
25. Member, Site Visit for the Sub-Committee C of NIH, Columbia University, NYC, January 8-10, 2003.
  26. Chairperson, Site Visit for the Sub-Committee C of NIH, Ohio State University, Columbus, Ohio, February 4-6, 2003.
  27. Member, Site Visit for the Sub-Committee C of NIH, Burnham Institute, La Jolla, CA, February 26-28, 2003.
  28. Member, Teleconference on PO-1 review, NCI, NIH, March 25, 2003.
  29. Member, Subcommittee C, NIH, April 22-24, 2003.
  30. Member, Study Section on the RFA “Molecular Interactions between Tumor Cells and Bone”, Cancer Biology Program of NCI, Bethesda, MD, April 24-25, 2003.
  31. Chairperson, Teleconference on PO-1 Review, NCI, NIH, May 12, 2003.
  32. Member, Site Visit for the Sub-Committee C of NIH, Whitehead Institute, Massachusetts Institute of Technology, MA, May 29-31, 2003.
  33. Member, Teleconference on PO-1 review, NCI, NIH, July 2, 2003.
  34. Member, Subcommittee C, NIH, July 29-31, 2003.
  35. Chair, PO1 review NIH, D.C., February 4-5, 2004.
  36. Member, SEP teleconference, NIH, March 23, 2004.
  37. Member, Subcommittee C, NIH, April 13-15, 2004.
  38. Chair, “Signal Transduction” cluster for Jan 2005 NCAB, NIH, September 9-10, 2004.
  39. Member, Grant Review for Path B section, Washington DC, October 5-6, 2004.
  40. Member, U01 Grant Review for Subcommittee C, NIH, October 2004.
  41. Member, Subcommittee C, NIH, December 8-10, 2004.
  42. Member, Subcommittee C, NIH, April 6-8, 2005.
  43. Member, PO1 Grant Review, NIH, May 22-24, 2006.
  44. Reviewer, Pancreatic Cancer SPORE, NIH, August 7, 2006.



45. Member, PO1 Grant Review, NIH, January 29-31, 2007.
- 46. Ad-hoc Member, Board of Scientific Counselors, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, April 11-12, 2007.**
- 47. Ad-hoc Member, Director's New Innovator Awards, NIH, May-June 2008.**
- 48. Ad-hoc Member, Stem Cell RFA, NIH, July 21-22, 2008.**
- 49. Ad-hoc Member, NIH Small Business Grant Review, Teleconference, March 19, 2009.**
- 50. Ad-hoc Member, NIH CCSG Site Visit, Duke Comprehensive Cancer Center, Duke Medical School, Durham, North Carolina, May 18-20, 2009.**

**b. Other Institutions**

1. Member, Review Panel, The National Science & Technology Program in Pharmaceuticals and Biotechnology, Taipei, Taiwan, June 29-30, 2000.
2. Member, Science & Technology Advisory Group, 5<sup>th</sup> Biotech SRB Meeting, Executive Yuan, Taipei, Taiwan, May 21-25, 2001.
3. Member, External Advisory Meeting, Fox Chase Cancer Center, Ovarian SPORE Meeting, Philadelphia, PA, June 27-28, 2001 and June 12-13, 2002.
4. Member, CEX-2 Committee, Breast Cancer Research Program 2001 Centers of Excellence, Tysons Corners, VA, Aug. 22-24, 2001.
5. Member, Review Panel, The National Science & Technology Program in Pharmaceuticals and Biotechnology, Taoyuan, Taiwan, November 24-27, 2001.
6. Member and Host, Review Panel of Genomic Medicine Grant Proposals, the Department of Health (DOH) of Taiwan, Houston, TX. January 12, 2002.
7. Member, Review Panel, National Research Program for Genomic Medicine (NRPGM) Grant Proposals on "Proteomics", National Science Council (NSC) of Taiwan, Pasadena, CA. March 29-31, 2002.
8. Member, PPG Workshop and CDG Review Committee, NHRI, Taipei, Taiwan, September 2-4, 2002.
9. Member, Grant Review Panel, NHRI, Taipei, Taiwan, September 5-7, 2002.
10. Member, Scientific Review Panel, Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan, December 3-4, 2002.

11. Member, Scientific Review Panel, Division of Cancer Biology, NHRI, Taiwan, January 23-25, 2003.
12. Member, Scientific Review Panel, National Chung-Kung University Medical College, Tainan, Taiwan, February 15-16, 2003.
13. Member, Grant Review of Vienna Science and Technology Fund (WWTF)--Life Science 2003 Call. **Austria**, August 2003.
14. Member, Scientific Review Committee, NHRI, Taipei, Taiwan, August 12-14, 2003.
15. Member, External Review Committee, Division of Biotechnology and Pharmaceutical Research, NHRI, Taipei, Taiwan, November 10-12, 2003.
16. **Chair**, Scientific Review Panel for the Program for Promoting Academic Excellence of University (PPAEU Phase II), National Science Council, Taiwan, May 2004.
17. Member, Grant Review for the International Program on Research Excellence in Collaborative Effort, National Science Council, Taiwan, June 2004.
18. Review coordinator, External Reviewers for the Program for Promoting Academic Excellence of University (PPAEU Phase II Preproposal), National Science Council, Taiwan, in USA June 2004.
19. Member, External Advisory Board, MGM Division, NHRI, Taipei, Taiwan, July 3-4, 2004.
20. Member, Research Grants Council, Competitive Earnmarked Research Grants (RGC CERG) 2005-2006 Exercise, Hong Kong University, **HK**, July 11-13, 2004.
21. **Chair**, Brainstorming Workshop in Cancer Session (RGC CERG), Hong Kong University, HK, July 12, 2004.
22. Site Visit, Center Development Grant, National Health Research Institute, Taipei, Taiwan, August 22-23, 2004.
23. Member, External Scientific Progress and Grant Review for the President Laboratory of National Health Research Institute, September 2004.
24. Member, Grant Review for the Genesis Oncology Trust, New Zealand Cancer Research Funding Charity, **New Zealand**, October 2004.
25. Member, Grant Review for Genomics and Proteomics Program Project (GPPP) at Genomic Research Center, Academia Sincia, Taiwan, October 2004.
26. Member, External Advisory Board, Ovarian SPORE Fox Chase Cancer Center, Philadelphia, PA., December 13, 2004.

27. Member, Site Visit of Core Facilities for Genomic Medicine, National Research Program for Genomic Medicine (NRPGM), National Science Council, Taipei, Taiwan, December 15-17, 2004.
28. Member, Scientific Advisory Board, Genomic Research Center, Academia Sinica, Taipei, Taiwan, December 17, 2004.
29. Member, Grant review for the Association for International Cancer Research, **United Kingdom**, January 2005.
30. Member, External Advisory Board Meeting, Breast SPORE Baylor College of Medicine, Houston, TX, March 4, 2005.
31. Member, Scientific Review Panel, National Chung-Kung University Medical College, Tainan, Taiwan, March 14-15, 2005.
32. Member, Scientific Review, Israel Science Foundation, **Israel**, April 2005.
33. Member, Grant Review for the Italian Association for Cancer Research, **Italy**, April 2005.
34. Member, International Scientific Review, the Catalan Agency for Health Technology Assessment and Research (CAHTA), TV3 Marató Foundation, Catalonia, **Spain**, June 2005.
35. Member, Grant Review and Site Visit for the “An RNAi Core Facility”, the National Research Program for Genomic Medicine (NRPGM), National Science Council of Taiwan, May - June 2005 (for written comment).
36. Member, Grant Review for Promoting Academic Excellence of University (PPAEU, Phase II), National Science Council of Taiwan, June 2005.
37. Member, Grant Review for the “Microarray and SNP Core Facility for Genomic Medicine”, the National Research Program for Genomic Medicine (NRPGM), National Science Council of Taiwan, July 2005.
38. Member, Grant Review for the Cancer Research Society Inc. **Canada**, July 2005.
39. Member, Grant Review for the Cancer Research **UK**, September 2005.
40. **Chair**, Scientific Advisory Committee, Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, October 5-7, 2005.
41. Member, Annual Review of President Laboratory, National Health Research Institutes, November, 2005.
42. Member, External Advisory Board, Ovarian SPORE Fox Chase Cancer Center, Philadelphia, PA., December 1, 2005.

43. **Chair**, External Reviewers, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan, December 16-17, 2005.
44. Member, Annual Review of National Research Program Genomic Medicine (NRPGM), National Science Council, January 2006.
45. Member, Grant Review for Wellcome Trust, **UK**, February 2006.
46. Member, Steering Committee of National Science & Technology Pharmaceutical Biotechnology Programs (NSTPBP-SCM), National Science Council, Taipei, Taiwan, March 4, 2006.
47. Member, Thematic Project Evaluating Committee, Academia Sinica, Taipei, Taiwan, March 9, 2006.
48. Member, Program Review on Minister of Education for Promoting Academic Excellence of Universities “Gene Regulation and Signal Transduction”, National Chang Kung University, Tainan, Taiwan, March 14, 2006.
49. Member, Grant Review for the Austrian Science Fund (RWF), **Austria**, March 2006.
50. Member, Grant Review for the Translational Research Award, Health Research Board, **Ireland**, March 2006.
51. Member, Grant Review for the **National Science Foundation, USA**, April 2006.
52. **Chair**, Brainstorming Workshop in Cancer Session (RGC CERG), Hong Kong University, **HK**, September 12, 2006.
53. **Chair**, Scientific Advisory Committee, Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, August 29-30, 2006.
54. Member, Grant Review for University of Kuwait, **Kuwait**, January 2007.
55. Member, Grant Review, **Israel Science Foundation**, Israel, February 2007.
- 56. Member**, External reviewers for the Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Taipei, Taiwan, May 2-3, 2007.
57. Member, Grant Review for the Foundation of Alliance for Cancer Gene Therapy, May 2007.
58. Reviewer, Iran National Science Council, Iran, January 2008.
59. Member, Scientific Advisory Committee, Institute of Molecular Biology, Academia Sinica, July 5-6, 2008.

60. Member, Scientific Advisory Committee, Institute of Biological Chemistry, Academia Sinica, October 14-16, 2008.
- 61. Member, 2009 Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research Scientific Review Committee, January-February 2009.**
- 62. Member, 2<sup>nd</sup> Round Reviewer, 2009 Academia Sinica Research Award for Junior Research Investigators, March 2009.**
- 63. Member, 2<sup>nd</sup> Round Reviewer and Thematic Research Program Review Committee (Division of Life Sciences), Academia Sinica, Taipei, Taiwan, March 13, 2009.**
64. Member, Joint Scientific Review Committee of Division of Molecular and Genomic Medicine and National Institute of Cancer Research, NHRI, Zhunan, Taiwan, April 10-13, 2009.
- 65. Chair, a Three-member Review Committee, Department of Cancer Biology, University of Massachusetts School of Medicine, Worcester, MA, June 29-20, 2009.**
66. Member, Biennial Scientific Advisory Board Meeting, Genomics Research Center, Academia Sinica, Taipei, Taiwan, January 2010.

## Publications

### Published and Accepted Articles in Refereed Journals:

1. Hung, M.-C., Cheng, K.L., Lai, M.Z. and Chen, Y.H. Studies on the status of met-phe-met segment and disulfide linkage in formosan cardiotoxin. *J. Chinese Biochem. Soc.* 6:27-36, 1977.
2. **Hung, M.-C.** and Chen, Y.H. Conformational stability of a snake cardiotoxin. *Int. J. Peptide Protein Res.* 10:277-285, 1977.
3. Wong, C.H., Chen, Y.H., **Hung, M.-C.**, Wang, K.T., Ho, C. L. and Lo, T.B. Renaturation of a reduced Taiwan cobra cardiotoxin. *Biochem. Biophys. Acta* 533:105-111, 1978.
4. Hsiao, S.L., **Hung, M.-C.**, Wong, C.H. and Wang, K.T. Solid phase synthesis of c-terminal disulfide loop of Taiwan cobra cardiotoxin and its immunochemical and conformational studies. *Proc. Natl. Science Council R.O.C.* 2:346-351, 1978.
5. **Hung, M.-C.**, Pan, Y.H., Cheng, K.L. and Chen, Y.H. The status of tyrosyl residues in a formosan cardiotoxin. *Biochem. Biophys. Acta* 535:178-187, 1978.
6. **Hung, M.-C.** and Wensink, P.C. The sequence of the drosophila melanogaster gene for yolk protein 1. *Nucl. Acids Res.* 9:6407-6419, 1981.
7. **Hung, M.-C.**, Barnett, T., Woolford, C. and Wensink, P.C. Transcript maps of drosophila yolk protein genes. *J. Mol. Biol.* 154:581-602, 1982.
8. Chen, Y.H., Tai, J.C., Huang, W.J., Lai, M.J., **Hung, M.-C.**, Lai, M.D. and Yang, J.T. Role of aromatic residues in the structure-function relationship of  $\alpha$ -bungarotoxin. *Biochemistry* 21:2592-2600, 1982.

9. **Hung, M.-C.** and Wensink, P.C. Sequence and structure conservation on yolk proteins and their genes. *J. Mol. Biol.* 164:481-492, 1983.
10. **Hung, M.-C.** and Wensink, P.C. Different restriction enzyme-generated sticky DNA ends can be joined *in vitro*. *Nuc. Acid Res.* 12:1863-1874, 1984.
11. Garabedian, M.J., **Hung, M.-C.** and Wensink, P.C. Independent control elements that determine yolk protein gene expression in alternative drosophila tissues. *Proc. Natl. Acad. Sci.* 82:1396-1400, 1985.
12. Schechter, A.L., **Hung, M.-C.**, Vaidyanathan, L., Weinberg, R.A., Yang-Feng, T.L., Francke, U., Ullrich, A. and Coussens, L. The *neu* gene: an *erbB* homologous gene distinct from the gene encoding the epidermal growth factor receptor. *Science* 229:976-978, 1985.
13. **Hung, M.-C.**, Schechter, A.L., Chevray, P.-Y.M., Stern, D.F. and Weinberg, R.A. Molecular cloning of the *neu* gene: absence of gross structural alteration in oncogenic alleles. *Proc. Natl. Acad. Sci.* 83:261-264, 1986.
14. Bargmann, C.I., **Hung, M.-C.** and Weinberg, R.A. The *neu* oncogene encodes an epidermal growth factor receptor-related protein. *Nature* 319:226-230, 1986.
15. Bargmann, C.I., **Hung, M.-C.** and Weinberg, R.A. Multiple independent activations of the *neu* oncogene by a point mutation altering the transmembrane domain of p185. *Cell* 45:649-657, 1986.
16. **Hung, M.-C.**, Thompson, K., Chiu, I.M. and Rosner, M. Characterization of rodent epidermal growth factor receptor transcript using a mouse genomic probe. *Biochem. Biophys. Res. Comm.* 141:1109-1115, 1986.
17. Blackshear, P.J., Stumpo, D.J., Kennington, E.A., Tuttle, J.S., Orth, D.N., Thompson, K.L., **Hung, M.-C.** and Rosner, M.R. Decreased levels of hepatic epidermal growth factor receptors in obese hyperglycemic mice. *J. Biol. Chem.* 262:12356-12364, 1987.
18. Steck, P.A., Lee, P., **Hung, M.-C.** and Yung, W.K. Expression of an altered epidermal growth factor receptor by human glioblastoma cells. *Cancer Res.* 48:5433-5439, 1988.
19. **Hung, M.-C.**, Yan, D.-H. and Xhao, X. Amplification of the proto-*neu* gene facilitates oncogenic activation by a single point mutation. *Proc. Natl. Acad. Sci.* 86:2545-2548, 1989.
20. Schneider, P.M., **Hung, M.-C.**, Chiocca, S.M., Manning, J., Zhao, X., Fang, K. and Roth, J.A. Differential expression of the *c-erbB2* gene in human small cell and non-small cell lung cancer. *Cancer Res.* 49:4968-4971, 1989.
21. Zhang, X., Silva, E., Gershenson, D. and **Hung, M.-C.** Amplification and rearrangement of *c-erb B* proto-oncogene in cancer of human genital tract. *Oncogene* 4:985-989, 1989.
22. Matin, A., Cheng, K.L., Suen, T.C. and **Hung, M.-C.** Effects of glucocorticoids on oncogene-transformed NIH3T3 cells. *Oncogene* 5:111-116, 1990.
23. Suen, T.C., Rodriguez, R.U., **Hung, M.-C.** and Klostergaard, J. Growth factor activity of TNF- $\alpha$  in *v-abl* transformed NIH 3T3 cells. *Lymphokine Res.* 9:15-26, 1990.
24. Yu, D., Suen, T.-C., Yan, D.-H., Chang, L. and **Hung, M.-C.** Repression of the HER-2/*neu* proto-oncogene by the adenovirus 5E1A gene products. *Proc. Natl. Acad. Sci.* 87:4499-4503, 1990.
25. Yung, W.K.A., Zhang, X., Steck, P.A. and **Hung, M.-C.** Differential amplification of the TGF- $\alpha$  gene in human gliomas. *Cancer Comm.* 2:201-205, 1990.
26. Saya, H., Ara, S., Lee, P., Ro, J. and **Hung, M.-C.** Direct sequencing analysis of transmembrane region of human *neu* gene by polymerase chain reaction. *Mol. Carcinogenesis* 4:198-201, 1990.

27. Schneider, P.M., **Hung, M.-C.**, Ames, R.S. and Roth, J.A. An epigenetic alteration in the epidermal growth factor receptor gene is detected in human non-small cell lung cancer. *Lung Cancer* 6:65-72, 1990.
28. Suen, T.C. and **Hung, M.-C.** Multiple cis-acting elements and trans-acting factors involved in *neu* regulation. *Mol. Cell. Biol.* 10:6306-6315, 1990.
29. Zhau, H.E., Zhang, X., von Eschenbach, A.C., Scorsone, K., Babaian, J., Ro, J.Y. and **Hung, M.-C.** Amplification and expression of the *c-erbB-2/neu* proto-oncogene in human bladder cancer. *Mol. Carcinogenesis* 3:254-257, 1990.
30. Suen, T.C. and **Hung, M.-C.** *c-myc* reverses *neu*-induced transformed morphology by transcriptional repression. *Mol. Cell. Biol.* 11:354-362, 1991.
31. Yan, D-H., Chang, L. and **Hung, M.-C.** Repressed expression of the *c-erbB-2* proto-oncogene by the adenovirus 5 E1A gene products. *Oncogene* 6:343-345, 1991.
32. Yu, D., Scorsone, K. and **Hung, M.-C.** The adenovirus-5 E1A gene products act as a transformation suppressor of *neu* oncogene. *Mol. Cell. Biol.* 11:1745-1750, 1991.
33. Yan, D-H. and **Hung, M.-C.** Identification and characterization of a novel enhancer for the *neu* promoter. *Mol. Cell. Biol.* 11:1875-1882, 1991.
34. Utsumi, T., **Hung, M.-C.** and Klostergaard, J. Preparation and characterization of liposomal-lipophilic TNF. *Cancer Res.* 51:3362-3366, 1991.
35. Klostergaard, J., Leroux, M.E. and **Hung, M.-C.** Cellular models of macrophage tumoricidal effector mechanisms *in vitro*: characterization of cytolytic responses to TNF- and nitric oxide-pathways *in vitro*. *J. Immunol.* 147:2802-2808, 1991.
36. Yu, D. and **Hung, M.-C.** Expression of activated rat *neu* oncogene is sufficient to induce experimental metastasis in NIH3T3 Cells. *Oncogene* 6:1991-1996, 1991.
37. Utsumi, T., **Hung, M.-C.** and Klostergaard, J. The role of amino functions in recombinant human tumor necrosis factor in expression of biological activity. *Mol. Immunol.* 29(1):77-81, 1992.
38. **Hung, M.-C.**, Zhang, X., Yan, D-H., Zhang, H-Z., He, G-P., Zhang, T-Q. and Shi, D. Aberrant expression of the *c-erbB-2/neu* proto-oncogene in ovarian cancer. *Cancer Lett.* 61:95-103, 1992.
39. Chan, J.C., Scanlon, M., Zhang, H-Z., Jia, L.B., Yu, D. and **Hung, M.-C.**, French, M. and Eastman, E.M. Molecular cloning and characterization of v-*mos*- activated transformation associated proteins (TAP). *J. Biol. Chem.* 267:1099-1103, 1992.
40. White, M. and **Hung, M.-C.** Cloning and characterization of the mouse *neu* promoter. *Oncogene* 7:677-683, 1992.
41. Shi, D., He, G., Cao, S., Pan, W., Zhang, H.Z., Yu, D. and **Hung, M.-C.** Overexpression of the *c-erbB-2/neu*-encoded p185 in primary lung cancer. *Mol. Carcinogenesis* 5:212-218, 1992.
42. Zhao, X.Y. and **Hung, M.-C.** Negative autoregulation of the *neu* gene is mediated by a novel enhancer. *Mol. Cell. Biol.* 12:2739-2748, 1992.
43. Yu, D., Matin, A. and **Hung, M.-C.** The retinoblastoma gene product suppresses *neu* oncogene-induced transformation via transcriptional repression of *neu*. *J. Biol. Chem.* 267:10203-10206, 1992.
44. Yan, D-H., Marin, M. and **Hung, M.-C.** Differential expression of the *neu* oncogene in mouse liver and pancreatic cell lines. *Biochem. Biophys. Res. Comm.* 186(1):363-370, 1992.
45. Yu, D., Hamada, J., Zhang, H., Nicolson, G. and **Hung, M.-C.** Mechanism of *c-erb B2/neu* oncogene induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. *Oncogene* 7:2263-2270, 1992.

46. Hou, L., Shi, D., Tu, S.M., Zhang, H-Z., **Hung, M.-C.** and Ling, D. Oral cancer progression and *c-erb B-2/neu* proto-oncogene expression. *Cancer Lett.* 65:215-220, 1992.
47. Russell, K.S. and **Hung, M.-C.** Transcriptional repression of the *neu* proto-oncogene by estrogen. *Cancer Res.* 52:6224-6629, 1992.
48. Sexton, T. and **Hung, M.-C.** Regulation of *neu* oncogene transcription by the *tax* gene product of HTLV-I involves both positive and negative *cis*-acting elements. *J. Genetics & Mol. Biol.* 3:41-46, 1992.
49. Matin, A. and **Hung, M.-C.** Repression of *neu*-induced clonogenicity by dimethylsulfoxide correlates to decreased levels of *neu* encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins. *Cancer Lett.* 68:55-60, 1993.
50. Yan, D-H. and **Hung, M.-C.** Differential activity of the RVR enhancer element is involved in the decreased expression of the *neu* oncogene in NR-6 cells compared with its parental Swiss Webster 3T3 cells. *Mol. Carcinogenesis* 7:44-49, 1993.
51. Yu, D., Wolf, J., Scanlon, M., Price, J. and **Hung, M.-C.** Enhanced *c-erbB-2/neu* expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. *Cancer Res.* 53:891-898, 1993.
52. Utsumi, T., Levitan, A., **Hung, M.-C.** and Klostergaard, J. Effects of truncation of human pro-TNF transmembrane domain on cellular targeting. *J. Biol. Chem.* 268:9511-9516, 1993.
53. Donato, N.J., Yan, D.-H., **Hung, M.-C.** and Rosenblum, M.G. EGF receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. *Cell Growth & Different.* 4:411-419, 1993.
54. Reardon, D. and **Hung, M.-C.** Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat *neu* oncogene. *J. Biol Chem.* 268:18136-18142, 1993.
55. Yu, D., Shi, D., Scanlon, M. and **Hung, M.-C.** Re-expression of *neu*-encoded oncoprotein counteracts the tumor-suppressing activity of E1A. *Cancer Res.* 53:5784-5790, 1993.
56. Matin, A. and **Hung, M.-C.** Negative regulation of the *neu* promoter by the SV40 large T antigen. *Cell Growth & Different.* 4:1051-1056, 1993.
57. Reardon, D., Xie, Y., and **Hung, M.-C.** The microfocus assay system (MFAS): a simple quantitative assay to identify inhibitory drugs targeted against specific oncogenes. *Oncol. Rep.* 1:37-41, 1994.
58. Miller, S., Suen, T.C., Sexton, T., and **Hung, M.-C.** Mechanisms of deregulated HER-2/*neu* in breast cancer cell lines. *Int. J. Oncol.* 4:599-608, 1994.
59. Yen, R.L. and **Hung, M.-C.** Complex regulation of the adenovirus E2 promoter by the viral oncoproteins E1A and E7 and tumor suppressor Rb. *Int. J. Oncol.* 4:109-115, 1994.
60. Matin, A. and **Hung, M.-C.** The retinoblastoma gene product, Rb, represses *neu* expression through two regions within the *neu* regulatory sequence. *Oncogene* 9:1333-1339, 1994.
61. Yu, D., Matin, A., Hinds, P. and **Hung, M.-C.** Transcriptional regulation of *neu* by RB and E1A in Rat-1 cells. *Cell Growth & Different.* 5:431-438, 1994.
62. Tang, P., **Hung, M.-C.** and Klostergaard, J. TNF cytotoxicity: effects of HER-2/*neu* expression and inhibitors of ADP-ribosylation. *Lympho. Cyto. Res.* 13:117-123, 1994.
63. Miller, S.J. and **Hung, M.-C.** HER-2/*neu* overexpression counteracts the growth effects of *c-myc* in breast cancer cells. *Int. J. Oncol.* 4:965-969, 1994.
64. Yu, D., Wang, S.S., Dulski, K.M., Nicolson, G.L., and **Hung, M.-C.** *C-erbB-2/neu* overexpression enhanced metastatic potential in human lung cancer cells by induction of metastasis-associated properties. *Cancer Res.* 54:3260-3266, 1994.



65. Tsai, C-M., Perng, R-P., Chen, M-H., Jan, Y-H., **Hung, M.-C.**, Ku, T-Y., and Chang, K-T. Greater enhancement of chemosensitivity by caffeine in high p185<sup>neu</sup> expressing human non-small cell lung cancer cell lines. *J. Natl. Cancer Inst.* 86:1018-1020, 1994.
66. Reardon, D. and **Hung, M.-C.** Suppressed autophosphorylation and tyrosine kinase activity in revertant cell lines expressing rat *neu* oncogene. *Oncol. Rep.* 1:895-902, 1994.
67. Xie, Y. and **Hung, M.-C.** Nuclear localization of p185<sup>neu</sup> tyrosine kinase and its association with transcriptional transactivation. *Biochem. Biophys. Res. Comm.* 203:1589-1598, 1994.
68. Tomasovic, S.P., Khodadadian, M., **Hung, M.-C.** and Klostergaard, J. Hyperthermia enhances the cytotoxicity of NIH 3T3 cells transfected with a noncleavable transmembrane pro-tumor necrosis factor deletion mutant. *J. Immunother.* 16:181-187, 1994.
69. Gee, J.E., Yen, R.L., **Hung, M.-C.** and Hogan, M.E. Triplex formation at the rat *neu* oncogene promoter. *Gene* 149:109-114, 1994.
70. Kiyokawa, N., Yan, D-H., Brown, M.E. and **Hung, M.-C.** Cell-cycle-dependent regulation of p185<sup>neu</sup>: a close relationship between disruption of this regulation and transformation. *Proc. Natl. Acad. Sci.* 92:1092-1096, 1995.
71. Tsai, C-M., Yu, D., Chang, K-T., Wu, L-H., Perng, R-P., Ibrahim, N.K. and **Hung, M.-C.** Enhanced chemoresistance by elevation of the levels of p185<sup>neu</sup> in the HER-2/*neu* transfected human lung cancer cells. *J. Natl. Cancer Inst.* 87:682-684, 1995.
72. Zhang, Y., Yu, D., Xia, W. and **Hung, M.-C.** HER-2/*neu*-targeting via adenovirus-mediated E1A delivery in an animal model. *Oncogene* 10:1947-1954, 1995.
73. Matin, A., Xie, Y. Kao, M-C. and **Hung, M.-C.** Rodent p53 suppresses the transforming activity of the activated *neu* oncogene by modulating the basal promoter activity of *neu*. *Int. J. Oncol.* 6:1087-1092, 1995.
74. Miller, S.J. and **Hung, M.-C.** Regulation of HER-2/*neu* gene expression. *Oncol. Rep.* 2:497-503, 1995.
75. Xie, Y., Li, K. and **Hung, M.-C.** Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated *neu*. *Oncogene* 10:2409-2413, 1995.
76. Beckhardt, R.N., Kiyokawa, N., Xi, L., Liu, T.J., **Hung, M.-C.**, El-Naggar, A.K., Zhang, H.Z. and Clayman, G.L. HER-2/*neu* oncogene characterization in head and neck squamous cell carcinoma. *Arch. Otolaryngology-Head and Neck Surg.* 121:1265-1270, 1995.
77. Zhang, L., Chang, C.-J., Bacus, S. and **Hung, M.-C.** Suppressed transformation and induced differentiation of HER-2/*neu*-overexpressing breast cancer cells by emodin. *Cancer Res.* 55:3890-3896, 1995.
78. Tang, P., **Hung, M.-C.** and Klostergaard, J. ADP-ribosylation inhibitors inhibit cellular RNA synthesis but do not affect expression of MnSOD and hsp70 in TNF- $\alpha$ -sensitive and TNF- $\alpha$ -resistant tumor cells. *J. Interferon Cytokine Res.* 15:791-797, 1995.
79. Utsumi, T., Kawabata, Z., Tokunaga, T., Ide, A., Akimaru, K., Levitan, A., Tang, P., **Hung, M.-C.** and Klostergaard, J. Human pro-tumor necrosis factor: molecular determinants of membrane translocation, sorting and maturation. *Mol. Cell. Biol.* 15:6398-6405, 1995.
80. Yu, D., Matin, A., Xia, W., Sorgi, F., Huang, L. and **Hung, M.-C.** Liposome-mediated E1A gene transfer as therapy for ovarian cancers that overexpress HER-2/*neu*. *Oncogene* 11:1383-1388, 1995.
81. Gum, R., Wang, S.W., Yu, D., **Hung, M.-C.** and Boyd, D. Up-regulation of urokinase-type plasminogen activator expression by the HER-2/*neu* protooncogene. *Anticancer Res.* 15:1167-1172, 1995.
82. Lee, K.F., Simon, H., Chen, H., Bates, B., **Hung, M.-C.** and Hauser, C. A requirement of *erbB2* in neural and cardiac development. *Nature* 378:394-398, 1995.

83. Xie, Y., Pendergast, A.M. and **Hung, M.-C.** Dominant-negative mutant of Grb2 induced reversal of the transformed phenotypes caused by the point-mutation activated rat *neu*. *J. Biol. Chem.* 270:30717-30724, 1995.
84. Utsumi, T., Kuranami, J., Tou, E., Ide, A., Akimaru, K., **Hung, M.-C.** and Klostergaard, J. *In vitro* synthesis of an N-myristoylated fusion protein that binds to the liposomal surface. *Arch. Biochem. Biophys.* 326:179-184, 1996
85. Xing, X., Matin, A., Yu, D., Xia, W., Sorgi, F., Huang, L. and **Hung, M.-C.** Mutant SV 40 large T antigen as gene therapy agent for ovarian cancer. *Cancer Gene Ther.* 3:168-174, 1996.
86. Zhang, L. and **Hung, M.-C.** Sensitization of the HER-2/*neu*-overexpressing non-small-cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor, emodin. *Oncogene* 12:571-576, 1996
87. Tang, P., **Hung, M.-C.** and Klostergaard, J. The length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. *Biochemistry* 35:8226-8233, 1996.
88. Tang, P., **Hung, M.-C.** and Klostergaard, J. Human pro-tumor necrosis factor is a homotrimer. *Biochemistry* 35:8216-8225, 1996.
89. Xie, Y. and **Hung, M.-C.** p66 Shc isoform down-regulated and not required for HER-2/*neu* signaling pathway in human breast cancer cell lines with HER-2/*neu* overexpression. *Biochem. Biophys. Res. Comm.* 221:140-145, 1996.
90. Russell, K.S., Lee, E.K., Kiyokawa, N., Saya, H. and **Hung, M.-C.** Effects of estrogen receptor expression on growth and transformation of cells overexpressing *neu*. *Oncol. Rep.* 3: 433-437, 1996.
91. Ueno, N.T., Kiyokawa, N. and **Hung, M.-C.** Growth suppression of low HER-2/*neu*-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. *Oncol. Rep.* 3:509-511, 1996.
92. Miller, S.J., Xing, X., Xi, L. and **Hung, M.-C.** Identification of a specific DNA region required for enhanced transcription of HER-2/*neu* in the MDA-MB453 breast cancer cell line. *DNA Cell. Biol.* 15:749-757, 1996.
93. Yu, D., Liu, B., Tan, M., Li, J., Wang, S.S. and **Hung, M.-C.** Overexpression of *c-erbB-2/neu* in breast cancer cells confers increased resistance to Taxol via *mdr-1*-independent mechanisms. *Oncogene* 13:1359-1365, 1996.
94. Chang, J.Y., Xia, W., Shao, R. and **Hung, M.-C.** Inhibition of intratracheal lung cancer development by systemic delivery of E1A. *Oncogene* 13:1405-1412, 1996.
95. Xia, W., Lau, J.Y.K., Zhang, H.Z., Liu, A.R., Li, L., Kiyokawa, N., Clayman, G., Katz, R. and **Hung, M.-C.** Strong correlation between *c-erbB-2* overexpression and overall survival of patients with oral squamous cell carcinoma. *Clin. Cancer Res.* 3:3-9, 1997.
96. Chang, J.Y., Xia, W., Shao, R., Sorgi, F., Hortobagyi, G.N., Huang, L. and **Hung, M.-C.** The tumor suppression activity of E1A in HER-2/*neu*-overexpressing breast cancer. *Oncogene* 14:561-568, 1997.
97. Xing, X. Liu, V., Xia, W., Stephens, L.C., Huang, L., Lopez-Berestein, G. and **Hung M.-C.** Safety studies of the intraperitoneal infection of E1A-liposome complex in mice. *Gene Ther.* 4:238-243, 1997.
98. Lou, W., Wood, C.G., Earley, K., **Hung, M.-C.** and Lin, S.H. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. *Oncogene* 14:1697-1704, 1997.

99. Chen, H., Yu, D., Chinnadurai, G., Karunakaran, D. and **Hung, M.-C.** Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. *Oncogene* 14:1965-1971, 1997.
100. Pollock, R.E., Lang, A., El-Naggar, A.K., Radinsky, R. and **Hung, M.-C.** Enhanced MDM2 oncoprotein expression in soft tissue sarcoma: several possible regulatory mechanisms. *Sarcoma* 1:23-29, 1997.
101. Wang, S.-C, Lin, S.H, Su, L.-K. and **Hung M.-C.** Changes of BRCA2 Expression During Progression of the Cell Cycle. *Biochem. Biophys. Res. Comm.* 234: 247-251, 1997.
102. Gershenson, D.M., Baker, V.V., Price, J.E., **Hung, M.-C.**, El-Naggar, A.K., Tortolero-Luna, G. and Silva, E.G. Molecular profile of advanced-stage transitional cell carcinoma of the ovary. *Am. J. Obstet. Gynecol.* 177:120-125, 1997.
103. Ueno, N.T., Yu, D. and **Hung, M.-C.** Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus 5 E1A. *Oncogene* 15:953-960, 1997.
104. Brader, K.R., Wolf, J.K., **Hung, M.-C.**, Yu, D., Crispens, M.A., van Golen, K.L. and Price, J.E. Adenovirus E1A expression enhance the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. *Clin. Cancer Res.* 3:2017-2024, 1997.
105. Kiyokawa, N., Karunakaran, D., Lee, E.K., Xie, Y., Yan, D-H. and **Hung M.-C.** Involvement of cdc2-mediated phosphorylation in the cell-cycle dependent regulation of p185<sup>neu</sup>. *Oncogene* 15:2633-2641, 1997.
106. Petit, A.M.V., Rak, J., **Hung, M.-C.**, Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells *in vitro* and *in vivo*: angiogenic implications for signal transduction therapy of solid tumors. *Am. J. Pathol.* 151:1523-1530, 1997.
107. Liu, B., Sun, D., Xia, W., **Hung, M.-C.** and Yu, D. Cross-reactivity of C219 anti-P170<sup>mdr-1</sup> antibody with P185<sup>c-erbB2</sup> in breast cancer cells: Cautions on evaluating P170<sup>mdr-1</sup>. *J. Natl. Cancer Inst.* 89:1524-1529, 1997\*. \*Accompanied by Editorial: Chang, H.S.L., Ling, V. Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: Diagnostic and Clinical Implications. *J. Natl. Cancer Inst.* 89:1473-1475, 1997.
108. Hunt, K.K., Deng, J., Liu, T-J., Wilson-Heiner, M., Swisher, S.G., Clayman, G., and **Hung, M.-C.** Adenovirus-Mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. *Cancer Res.* 57:4722-4726, 1997.
109. Chen, H. and **Hung, M.-C.** Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. *J. Biol. Chem.* 272:6101-6104, 1997.
110. Kiyokawa, N., Lee, E.K., Karunakaran, D., Lin, S-Y. and **Hung M.-C.** Mitosis-specific negative regulation of EGF-receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. *J. Biol. Chem.* 272:18656-18665, 1997.
111. Bourguignon, L.Y.W., Zhu, H.B., Chu, A., Zhang, L., and **Hung, M.-C.** Interaction between CD44 and p185<sup>neu</sup> promotes human ovarian tumor cell activation. *J. Biol. Chem.* 272:27913-27918, 1997.
112. Shao, R., Karunakaran, D., Zhou, B.P., Li, K., Lo, S-S., Deng, J., Chiao, P. and **Hung, M.-C.** Inhibition of NF-κB activity is required for E1A-mediated sensitization of radiation-induced apoptosis. *J. Biol. Chem.* 272:32739-32742, 1997.

113. Le, X-F, Mu, Z-M, Vallian, S., **Hung, M.-C.** and Chang, K-S. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. *Oncogene* 16:1839-1849, 1998.
114. Yu, D., Liu, B., Sun, D., Jing, T., Price, J.E., Singletary, S.E., Ibrahim, N., Hortobagyi, G.N., and **Hung, M.-C.** Overexpression of both p185<sup>c-erbB2</sup> and p170<sup>mdr-1</sup> renders breast cancer cells highly resistant to Taxol. *Oncogene* 16:2087-2094, 1998.
115. Zhang, L., Lau, J.Y.-K, Xi, L., Hong, R.L., Kim, D., Chen, C.F., Hortobagyi, G.N., Chang, C-J. and **Hung, M.-C.** Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. *Oncogene* 16:2855-2863, 1998.
116. Deng, J., Xia, W. and **Hung, M.-C.** Adenovirus 5 E1A-mediated tumor suppression with E1A-mediated apoptosis *in vivo*. *Oncogene* 17:2167-2175, 1998.
117. Kwong, K.-Y. and **Hung, M.-C.** A novel splice variant of HER2 with increased transformation activities. *Mol. Carcinogenesis* 23:62-68, 1998.
118. Su, L.K, Wang, S-C., Qi, Y., Luo, W., **Hung, M.-C.** and Lin, S.H. Characterization of BRCA2: Temperature sensitivity of detection and cell-cycle regulated expression. *Oncogene* 17:2377-2381, 1998.
119. Xing, X., Zhang, S., Chang, J.Y., Tucker, S.D., Chen, H., Huang, L. and **Hung, M.-C.** Safety study and characterization of E1A-liposome complex gene-therapy protocol in an ovarian cancer model. *Gene Ther.* 5:1538-1544, 1998.
120. Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T.J. and **Hung, M.-C.** Overexpression of erbB2 blocks Taxol-induced apoptosis by upregulation of p21<sup>cip1</sup> which inhibits p34<sup>cdc2</sup> kinase. *Mol. Cell* 2:581-591, 1998.
121. Yan, D-H., Wen, Y., Spohn, B., Choubey, D., Gutterman, J.U. and **Hung, M.-C.** Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. *Oncogene* 18: 807-811, 1999.
122. Zhang, L., Lau, J.Y.-K, Xia, W., Hortobagyi, G.N. and **Hung, M.-C.** Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. *Clin. Cancer Res.* 5: 343-353, 1999.
123. Tari, A.M., **Hung, M.-C.**, Li, K. and Lopez-Berestein, G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. *Oncogene* 18:1325-1332, 1999.
124. Ueno, N.T., Xia, W., Tucker, S.D., Zhang, S., Lopez-Berestein, G., Huang, L. and **Hung, M.-C.** Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery. *Oncol. Rep.* 6:257-262, 1999.
125. Li, K., Shao, R. and **Hung, M.-C.** Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by point mutation-activated *neu* through a MAPK-independent pathway. *Oncogene* 18:2617-2626, 1999.
126. Lo, S.S., Lo, S.H., Wang, S.-C. and **Hung, M.-C.** Inhibition of focal contacts formation is inhibited in cells transformed by p185<sup>neu</sup>. *Mol. Carcinogenesis* 25:150-154, 1999.
127. Hong, R.L, Spohn, B. and **Hung, M.-C.** Curcumin inhibits tyrosin-kinase activity of p185<sup>neu</sup> and also depletes p185<sup>neu</sup> protein after dissociating it from GRP94. *Clin. Cancer Res.* 5:1884-1891, 1999.
128. Shao, R., Hu, M.C-T., Zhou, B.P., Lin, S-Y., Chiao, P., von Lindern, R.H., Spohn, B. and **Hung, M.-C.** E1A sensitizes cells to tumor necrosis factor-induced apoptosis through

- inhibition of I $\kappa$ B kinases and nuclear factor  $\kappa$ B activities. *J. Biol. Chem.* 274:21495-21498, 1999.
129. Lee, W.P., Liao, Y. Robinson, D., Kung, H-J, Liu, E.T. and **Hung, M.-C.** Axl-Gas6 interaction counteracts by E1A-mediated cell growth suppression and proapoptotic activity. *Mol. Cell. Biol.* 19:8075-8092, 1999.
  130. Xia, W., Lau, J.Y.-K., Zhang, H-Z, Xiao, F.Y., Chen, L., Johnston, D.A., Liu, A-R, Li, L., Katz R.L. and **Hung, M.-C.** Combination of EGFR, HER-2/*neu*, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. *Clin. Cancer Res.* 5:4164-4174, 1999.
  131. Lu, Y., Lin, Y.Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S.X., Davies, M.A., Khan, H., Furui, T., Mao, M., Zinner, R., **Hung, M.-C.**, Steck, P. and Mills, G.B. The PTEN/MMC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene* 18:7034-7045, 1999.
  132. Lee, R.J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G.K. III, Siegel, P.M., **Hung, M.-C.**, Yarden, Y., Horowitz, J.M., Muller, W.J. and Pestell, R.G. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. *Mol. Cell. Biol.* 20:672-683, 2000.
  133. Wen Y., Yan, D-H., Spohn, B., Deng, J. and **Hung, M.-C.** Tumor suppression and sensitization to tumor necrosis factor  $\alpha$ -induced apoptosis by an interferon inducible protein, p202 in breast cancer cells. *Cancer Res.* 60:42-46, 2000.
  134. Xing, X., Wang, S-C., Xia, W., Zou, Y., Shao, R., Kwong, K.-Y., Yu, Z., Zhang, S., Miller, S., Huang, L. and **Hung, M.-C.** The Ets protein PEA3 suppresses HER-2/*neu* overexpression and inhibits tumorigenesis. *Nat. Med.* 6:189-195, 2000.
  135. Ueno, N.T., Bartholomeusz, C., Hermann, J.L., Estrov, Z., Shao, R., Andreeff, M., Price, J.E., Paul, R.W., Anklesaria, P., Yu, D. and **Hung, M.-C.** E1A-mediated paclitaxel sensitization in HER-2/*neu*-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway. *Clin. Cancer Res.* 6:250-259, 2000.
  136. Lin, S.-Y., Xia, W., Wang, J. C., Kwong, K-Y., Spohn, B., Wen, Y., Pestell, R.G. and **Hung, M.-C.**  $\beta$ -catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. *Proc. Natl. Acad. Sci.* 97:4262-4266, 2000.
  137. Zhou, B.P., Hu, M.C.-T., Miller, S., Yu, Z., Xia, W., Lin, S.-Y., and **Hung, M.-C.** HER-2/*neu* blocks TNF-induced apoptosis via the Akt/NK- $\kappa$ B Pathway. *J. Biol. Chem.* 275:8027-8031, 2000.
  138. Xia, W., Lau, J.Y.-K., Johnston, D.A., Sheng, S-J. and **Hung, M.-C.** High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. *Oncogene* 19:2398-2403, 2000.
  139. Shao, R., Xia, W. and **Hung, M.-C.** Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. *Cancer Res.* 60:3123-3126, 2000.
  140. Xu, F., Xia, W., Luo, R.Z., Peng, H., Zhao, S., Dai, J., Long, Y., Zhao, L., Le, W., Liu, J., Parlow, A.F., **Hung, M.-C.**, Bast, R.C. Jr., and Yu, Y. The human *ARHI* tumor suppressor gene inhibits lactation and growth in transgenic mice. *Cancer Res.* 60:4913-4920, 2000.
  141. Yin, S., **Hung, M.-C.**, and Goodrich, D.W. Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis. *Cancer Gene Ther.* 7:985-990, 2000.

142. Yang, H.-Y., Zhou, B.P., **Hung, M.-C.** and Lee, M.-H. Oncogenic signals of HER-2/*neu* in regulating the stability of the cyclin-dependent kinase inhibitor p27. *J. Biol Chem.* 275:24735-24739, 2000.
143. Meric, F. Liao, Y., Lee, W.P., Pollock, R.E. and **Hung, M.-C.** Adenovirus E1A does not induce expression of the Ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines. *Clin. Cancer Res.* 6:3832-3836, 2000.
144. Lim, S.J., Lepez-Berestein, G., **Hung, M.-C.**, Lupu, R. and Tari, A.M. GrB2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. *Oncogene* 19:6271-6276, 2000.
145. Vadlamudi, R., Adam, L., Wang, R.A., Mandal, M., Nguyen, D., Sahin, A., Chernoff, J., **Hung, M.-C.** and Kumar, R. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. *J. Biol. Chem.* 275:36238-36244, 2000.
146. Wen, Y., Hu, M.C-T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.-H. and **Hung, M.-C.** HER-2/*neu* promotes androgen-independent survival and growth of prostate cancer Akt pathway. *Cancer Res.* 60:6841-6845, 2000.
147. Newman, L., Xia, W., Yang, H-Y., Sahin, A., Bondy, M., Lukmanji, F., **Hung, M.-C.** and Lee, M.-H. Correlation of p27 protein expression with HER-2/*neu* expression in breast cancer. *Molec. Carcinogen.* 29:1-7, 2001.
148. Zou, Y., Wu, Q.P., Tansey, W., Chow, D., **Hung, M.-C.**, Charnsangavej, C., Wallalce, S. and Li, C. Effectiveness of water soluble poly(L-glutamic acid) camptothecin conjugate a lung cancer xenografted in nude mice. *Int. J. Oncol.* 18:331-336, 2001.
149. Hortobagyi, G.N., Ueno, N.T., Xia, W., Zhang, S., Wolf, J.W., Putnam, J.B., Weiden, P.L., Willey, J.S., Carey, M., Warner, D.L., Payne, J.Y., Tucker, S.D., Bartholomeusz, C., Kilbourn, R.G., De Jager, R.L., Sneige, N., Katz, R.L., Daifuku, R., Ibrahim, N.K., Murray, J.L., Theriault, R.L., Valero, V., Gershenson, D.M., Bevers, M.W., Huang, L., Lopez-Berestein, G. and **Hung, M.-C.** Cationic liposome-mediated adenovirus type 5 E1A gene transfer to human breast and ovarian cancer cells and its biological effects: A phase I clinical trial. *J. Clin. Oncol.* 19:3422-3433, 2001.
150. Yang, H-Y, Shao, R., **Hung, M.-C.** and Lee, M.-H. p27 Kip1 inhibits HER2/*neu*-mediated cell growth and tumorigenesis. *Oncogene* 20:3695-3702, 2001.
151. Makino, K., Yu, D. and **Hung, M.-C.** Transcriptional upregulation and activation of p53Cdc via p34<sup>cdc2</sup> in Taxol-induced apoptosis. *Oncogene* 20:2537-2534, 2001.
152. Wang, S.-C., Makino, K., Xia, W., Kim, J.S., Im, S.A., Peng, H., Mok, S.C., Singletary, S.E. and **Hung, M.-C.** DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. *Oncogene* 20:6960-6964, 2001.
153. Zhou, Z., Jia, S-F., **Hung, M.-C.** and Kleinerman, E.S. E1A sensitizes HER2/*neu*-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. *Cancer Res.* 61:3394-3398, 2001.
154. Wang, S.-C., Makino, K., Su, L.-K., Pao, A., Kim, J.S. and **Hung, M.-C.** Ultraviolet irradiation induces depletion of BRCA2 protein through a p53-independent proteasome-independent pathway. *Cancer Res.* 61:2838-2842, 2001.
155. Wen, Y., Yan, D.-H., Wang, B., Spohn, B., Shao, R., Zou, Y., Ding, Y., Xie, K. and **Hung, M.-C.** p202, an interferon-inducible protein, mediates multiple anti-tumor activities in human pancreatic cancer xenograft models. *Cancer Res.* 61:7142-7147, 2001\*. \*Accompanied by Abstract. Exciting anti-cancer activities associated with an interferon-inducible protein. *TherapeuticAdvances*, Dec., 2001.

156. Shao, R., Tsai, E.-M., Wei, K., von Lindern, R., Chen, Y.-H., Makino, K. and **Hung, M.-C.** E1A inhibition of radiation-induced NF- $\kappa$ B activity through suppression of IKK activity and I $\kappa$ B degradation, independent of Akt activation. *Cancer Res.* 61:7413-7416, 2001.
157. Zhou, B.P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H. and **Hung, M.-C.** Cytoplasmic localization of p21<sup>Cip1/WAF1</sup> by Akt-induced phosphorylation in *HER-2/neu*-overexpressing cells. *Nat. Cell Biol.* 3:245-252, 2001\*. \*Accompanied by *News and Views* by El-Deiry, W.S. Akt takes centre stage in cell-cycle deregulation. *Nat. Cell Biol.* 3:E71-E73, 2001.
158. Lin, S.-Y., Makino, K. Xia, W., Matin, A., Wen, Y., Kwong, K.Y., Bourguignon, L.Y.W. and **Hung, M.-C.** Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nat. Cell Biol.* 3:803-808, 2001\*. \*Accompanied by *News and Views* by Waugh, M.G., and Hsuan, J.J. EGF receptor as transcription factors: ridiculous or sublime? *Nat. Cell Biol.* 3: E209-E211, 2001. Accompanied by *Perspective: Signal Transduction* by Heldin, C.-H. and Ericsson, J. RIPPING tyrosine kinase receptors apart. *Science* 294: 2111-2112, 2001. Also accompanied by *News and Comments* by Wong, R. W. C. and Chan, S. Y. EGFR as a transcription factor. *Trends in Genetics* 17: 625-626, 2001.
159. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and **Hung, M.-C.** *HER-2/neu* induces ubiquitination via Akt-mediated MDM2 phosphorylation. *Nat. Cell Biol.* 3:973-982, 2001\*. \*Accompanied by *Research Round up* by Brooksbank, C. Oncogenes: breaking and entering. *Nature Reviews Cancer, October 1st*, 2001.
160. Yoo, G.H., **Hung, M.-C.**, Lopez-Berestein, G., LaFollete, S., Ensley, J. F., Carey, M., Baston, E., Reynolds, T.C. and Murray, J. L. Phase I of intratumoral liposome *E1A* gene therapy in patients with recurrent breast and head and neck cancer. *Clin. Cancer Res.* 7:1237-1245, 2001.
161. Tsai E.-M., Wang, S.-C., Lee, J.-N. and **Hung, M.-C.** Akt activation by estrogen in estrogen receptor-negative breast cancer cells. *Cancer Res.* 61:8390-8392, 2001.
162. Bourguignon, L.Y.W., Zhu H., Zhou, B.P. Diedrich, F., Singleton, P.A. and **Hung, M.-C.** Hyaluronan (HA) promotes CD44v3-Vav2 interaction with Grb2-p185<sup>HER2</sup> and induces Rac1 & Ras signaling during ovarian tumor cell migration and growth. *J. Biol. Chem.*, 276:48679-48692,2001.
163. Deng, J., Zhang, H., Kloosterbore, F., Liao, Y., Kloostergaard, J., Levitt, M.L. and **Hung, M.-C.** Ceramide does not act as a general second messenger for UV-induced apoptosis. *Oncogene* 21:44-52, 2002.
164. Lee, W.P., Wen, Y., Varnum, B. and **Hung, M.-C.** Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. *Oncogene* 21:329-336, 2002.
165. Zou, Y., Peng, H., Zhou, B.P., Wen, Y., Tsai, E.-M., Wang, S.-C. and **Hung, M.-C.** \*Systemic tumor suppression by the pro-apoptotic gene *bik*. *Cancer Res.* 62:8-12, 2002. \*Correction 62:4167, 2002.
166. Deng, J., Kloosterboer, F., Xia, W. and **Hung, M.-C.** The N-terminal domain and CR2 domains of adenovirus *E1A* mediate two distinct mechanisms of tumor suppression. *Cancer Res.* 62: 346-350, 2002.
167. Meric, F., Lee, W.P., Sahin, A., Zhang, H.X., Kung, H.-J. and **Hung, M.-C.** Expression profile of tyrosine kinases in breast cancer. *Clin. Cancer Res.* 8:361-367, 2002.
168. Wang, S.-C., Shao, R., Pao, A.Y., **Hung, M.-C.** and Su, L.-K. Inhibition of cancer cell growth by *BRAC2*. *Cancer Res.* 62:1311-1314, 2002.

169. Cristofanilli, M., De Gasperis, G., Zhang, L., **Hung, M.-C.**, Gascoyne, P.R.C. and Hortobagyi, G.N. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. *Clin. Cancer Res.* 8:615-619, 2002.
170. Feng, Z., Hu, W., Komissarova, E., Pao, A., **Hung, M.-C.**, Adair, G.M. and Tang, M.-S. Transcriptional-coupled DNA repair is genomic context-dependent. *J. Biol. Chem.* 277:12777-12783, 2002.
171. Villaret, D., Glisson, B., Kenady, D., Hanna, E., Carey, M., Gleich, L., Yoo, G. H., Futran, N., **Hung, M.-C.**, Anklesaria, P. and Heald, A. E. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. *Head & Neck* 24:661-669, 2002.
172. Tari, A.M., Lim, S.-J., **Hung, M.-C.**, Esteva, F.J. and Lopez-Berestein, G. Her2/neu induces all-*trans* retinoic acid (ATRA) resistance in breast cancer cells. *Oncogene* 21:5224-5232, 2002.
173. Vorburger, S., Pataer, A., Yoshida, K., Barber, G., Xia, W., Chiao, P., Ellis, L., **Hung, M.-C.**, Swisher, S. and Hunt, K.K. Role for the double-stranded RNA activated protein kinase PKR ub E2F-1-induced apoptosis. *Oncogene* 21:6278-6288, 2002.
174. Tan, M., Jing, T., Lan, K.-H., Neal, C.L., Li, P., Lee, S., Fang, E., Nagata, Y., Liu, J., Arlinghaus, R., **Hung, M.-C.** and Yu, D. Phosphorylation on tyrosine-15 of p34<sup>cdc2</sup> by ErbB2 inhibits p34<sup>cdc2</sup> activation and is involved in resistance to Taxol-induced apoptosis. *Mol. Cell* 9: 993-1004, 2002\*. \* Selected as a cover on May issue.
175. Bourguignon, L.Y.W., Lan, K.-H., Singleton, P., Lin, S.-Y., Yu, D. and **Hung, M.-C.** Localizing the EGF receptor-Reply. *Nat. Cell Biol.* 4:E22-23, 2002.
176. Zhou, B.P., Liao, Y. and **Hung, M.-C.** HER-2/neu induces ubiquitination via Akt-mediated MDM2 phosphorylation\*. \*Corrigendum – *Nat. Cell Biol.* 4:736, 2002.
177. Ding, Y., Wen Y., Spohn. B., Wang, L., Xia, W., Kwong, K. Y., Shao, R., Li, Z., Hortobagyi, G. N., **Hung, M.-C.** and Yan, D.-H. Pro-apoptotic and anti-tumor activities of adenovirus-mediated p202 gene transfer. *Clin. Cancer Res.* 8:3290-3297, 2002.
178. Asada, S., Choi, Y., Yamada, M., Wang, S.-C., **Hung, M.-C.**, Qin, J. and Uesugi, M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. *Proc. Natl. Acad. Sci. USA* 99:12747-12752, 2002.
179. Yeh, S., Tsai, M.-Y., Xu, Q., Mu, X.-M., Lardy, H., Huang, K.-E., Lin, H., Yeh, S.-D., Altuwajiri, S., Zhou, X., Xing, L., Boyce, B.F., **Hung, M.-C.**, Zhang, S. and Chang, C. Generation and characterization of androgen receptor knockout (ARKO) mice: an *in vivo* model for the study of androgen functions in selective tissues. *Proc. Natl. Acad. Sci. USA* 99: 13498-13503, 2002.
180. Lee, S., Yang, W., Lan, K.-H., Sellapan, S., Klos, K., Hortobagyi, G.N., **Hung, M.-C.** and Yu, D. Enhanced sensitization to Taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. *Cancer Res.* 62: 5703-5710, 2002.
181. Ueno, N.T., Bartholomeusz, C., Xia, W., Anklesaria, P., Bruckheimer, E. M., Mebel, E., Paul, R., Li, S., Yoo, G., Huang, L. and **Hung, M.-C.** Systemic gene therapy in a human xenograft tumor models by liposomal delivery of the E1A gene. *Cancer Res* 62:6712-6716, 2002.
182. Kwong, K.-Y., Zou, Y., Day, C.-P. and **Hung, M.-C.** The suppression of colon cancer cell growth in nude mice by targeting  $\beta$ -catenin/TCF pathway. *Oncogene* 21:8340-8346, 2002.
183. Feng, Z., Hu, W., Chen, J. X., Pao, A., Li, H., Rom, W. N., **Hung, M.-C.**, Adair, G.M. and Tang, M.-S. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. *J. Natl. Cancer Inst.* 94:1527-1536, 2002\*. \*Accompanied by



- Editorial* "Etiology of the mutational spectrum of ras gene in human carcinomas" by Kelley, M. J. and Littman, S. J. *J. Natl. Cancer Inst.* 94:1516-1517, 2002. Accompanied by BBC news embargo "Carcinogen in cigarettes causes mutation linked to lung cancer" on October 14, 2002.
184. Deng, J., Miller, S.A., Wang, H.-Y., Xia, W., Wen, Y., Zhou, B.P., Lin, S.-Y., Li, Y.M. and **Hung, M.-C.**  $\beta$ -Catenin interacts with and inhibits NF- $\kappa$ B in human colon and breast cancers. *Cancer Cell* 2:323-334, 2002.
  185. Lee, C.M., Shvartsman, H., Deavers, M.T., Wang, S.-C., Xia, W., Schmandt, R., Bodurka, D.C., Atkinson, E.N., Malpica, A., Gershenson, D.M., **Hung, M.-C.** and Lu, K.H.  $\beta$ -catenin nuclear localization is associated with grade in ovarian serous carcinoma. *Gyn. Oncol.* 88:363-368, 2003.
  186. Najafi, S.M.A., Li, Z., Makino, K., Shao, R. and **Hung, M.-C.** The adenoviral E1A induces p21<sup>WAF1/CIP1</sup> expression in cancer cells. *Biochem. Biophys. Res. Comm.* 305: 1099-1104, 2003.
  187. Wen, Y., Giri, D., Yan, D.-H., Spohn, B., Zinner, R. G., Xia, W., Thompson, T.C., Matusik, R.J. and **Hung, M.-C.** Prostate specific anti-tumor activity by probasin promoter-directed p202 expression. *Mol. Carcinogen.* 37:130-137, 2003.
  188. Liao, Y. and **Hung, M.-C.** Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. *Mol. Cell. Biol.* 23:6836-6848, 2003.
  189. Coombes, K.R., Fritsche, H. A. Jr., Clarke, C., Chen, J.-N., Baggerly, K.A., Morris, J.S., Xiao, L.-C., **Hung, M.-C.** and Kuerer, H.M. Quality control and peak finding for proteomics data collected from nipple aspirate fluid using enhanced laser desorption and ionization. *Clin. Chem.* 49:1615-1623, 2003.
  190. Lee, W.P., Tai, D.-I., Tsai, S.-L., Yeh, C.-T., Chao, Y., Lee, S.-D. and **Hung, M.-C.** Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. *Cancer Res.* 63:6229-6236, 2003.
  191. Li, Y.M., Wen, Y., Zhou, B.P., Kuo, H.-P., Ding, Q. and **Hung, M.-C.** Enhancement of Bik antitumor effect by Bik mutants. *Cancer Res.* 63:7630-7633, 2003.
  192. Hoque, A., Carter, J., Xia, W., **Hung, M.-C.**, Sahin, A.A., Sen S. and Lippman S.M. Loss of Aurora A/STK15/BTAK overexpression correlates with transition of *in situ* to invasive ductal carcinoma of the breast. *Cancer Epidemiol Biomarker Prev* 12:1518-1522, 2003.
  193. Royce, M.E., Xia, W., Sahin A.A., Katayama, H., Johnston, D.A., Hortobagyi, G.N., Sen S. and **Hung, M.-C.** STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade by not with prognosis. *Cancer* 100:12-19, 2004.
  194. Deng, J. Xia, W., Miller, S.A., Wen, Y., Wang, H. and **Hung, M.-C.** Cross-regulation of NF- $\kappa$ B by the APC/GSK-3 $\beta$ /beta-catenin pathway. *Mol. Carcino.* 39:139-146, 2004.
  195. Yan, D.-H., Wen, Y., Su, L.-K., Xia, W., Wang, S.-C., Zhang, S., Gan, L., Lee, D.-F., Frey J.A., Hortobagyi, G.N. and **Hung, M.-C.** A delayed chemically-induced tumorigenesis in *Brca2* mutant mice. *Oncogene* 23:1896-1901, 2004.
  196. Noh, W.-C., Mondesire, W.H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G.B., **Hung, M.-C.** and Meric-Bernstam, F. Determinants of rapamycin sensitivity in breast cancer cells. *Clin. Cancer Res.* 10:1013-1023, 2004.
  197. Lee C.M., Lo, H.-W., Shao, R., Wang, S.-C., Xia, W., Gershenson, D.M. and **Hung M.-C.** Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. *Cancer Res.* 64:1788-93, 2004\*. \*Selected as a Highlight article in March 2004.

198. Xia, W., Chen, J.-S., Zhou, X., Sun, P.-R., Liao, Y., Zhou, B.P. and **Hung, M.-C.** Phosphorylation/cytoplasmic localization of p21<sup>cip1/WAF1</sup> is associated with HER2/*neu* overexpression and provides a novel combination predictor for worse prognosis in breast cancer patients. *Clin. Cancer Res.* 10:3815-3824, 2004.
199. Makino, K., Day, C.-P., Wang, S.-C., Li, Y.M. and **Hung, M.-C.** Upregulation of IKK $\alpha$ /IKK $\beta$  by integrin linked kinase is required for HER2/*neu*-induced NF- $\kappa$ B anti-apoptotic pathway. *Oncogene* 23: 3883-3887 2004\*. \*Corrigenda 23:8857,2004.
200. Hu, M.C-T, Lee, D.-F., Xia, W., Golfman, L., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S, Hanada, N., Saso, H., Kobayashi R. and **Hung, M.-C.** I $\kappa$ B kinase promotes tumorigenesis through inhibition of Forkhead transcription factor FOXO3a. *Cell* 117:225-237, 2004\*. \*Accompanied by **Review**: "FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation." Accili, D. and Arden, K. C. *Cell* 117: 421-426, 2004; **Review**: "FoxO: Linking new signaling pathways." Arden, K.C. *Mol. Cell* 14:416-418, 2004; and news release from MD Anderson Cancer Center special press release, Eurekalert, Reuters Health, Medical News Today-UK and WBBM-TV (CBS) Chicago.
201. Nahta, R., **Hung, M.-C.** and Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. *Cancer Res.* 64:2343-2346, 2004.
202. Nahta, R., Takahashi, T., Ueno, N.T., **Hung, M.-C.** and Esteva, F.J. P27<sup>kip1</sup> down-regulation is associated with trastuzumab resistance in breast cancer cells. *Cancer Res.* 64:3981-3986, 2004.
203. Nagata, Y., Lan, K-H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, P., Monia, B.P., Nguyen, N.T., Hortobagyi, G.N., **Hung, M.-C.** and Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 6:117-127, 2004\*. \*Accompanied by many news release—Nature online news: www.nature.com/news; CNN news on Aug. 23, 2004; NBC Universal news on Aug. 23, 2004; MD Anderson Special News Release, Aug. 23, 2004; National Post of Canada, Aug. 24, 2004; Cancer Biology and Therapy, Aug. 24, 2004; The World Journal-- New York, Aug. 24, 2004; BCN (BreastCancer.Net) News, Aug. 24, 2004; www.reutershealth.com. ; Medical Post- Toronto; Shingtao Daily (a Chinese news paper); and Houston Chronicle.
204. Liao, Y., Zou, Y., Xia, W. and **Hung, M.-C.** Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a non-rival mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. *Cancer Gene Therapy* 11:594-602, 2004\*. \*Accompanied by BCN (BreastCancer.Net) News.
205. Liao, Y. and **Hung, M.-C.** A new role of protein phosphatase 2A in adenoviral E1A protein mediated sensitization to anti-cancer drug-induced apoptosis in human breast cancer cells. *Cancer Res.* 64:5938-5942, 2004.
206. Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and **Hung, M.-C.** Binding at and transactivation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. *Cancer Cell* 6:251-261, 2004\*. \*Accompanied by BCN (BreastCancer.Net) News; MD Anderson Special News Release, Sept 30, 2004.
207. Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gundaz, M. and **Hung, M.-C.** Dual regulation of Snail by GSK-3 $\beta$ -mediated phosphorylation in control of epithelial-mesenchymal transition. *Nat. Cell Biol.* 6:931-940, 2004\*. \*Accompanied by *News and*

- Views** “GSK-3 $\beta$  sets Snail’s pace” Schlessinger K. and Hall, A. *Nat. Cell Biol.* 6:913-915, 2004; news release: Hindustan Times (largest English Daily in India); BCN (BreastCancer.Net) News; MD Anderson Special News Release, Sept 29, 2004; “*A Snail’s Life In The Fast Lane: Looking Upstream For New Cancer Metastasis Insights*” Breindl, A. BioWorld<sup>®</sup> Today. Vol. 15 No. 212, Nov 2, 2004.
208. Mondesire, W.H., Jian, W., Zhang, H., Ensor, J., **Hung, M-C.**, Mills, G.B. and Meric-Bernstam, F. Targeting mTOR synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. *Clin. Cancer Res.* 10:7031-7047, 2004.
209. Kuerer, H.M., Coombes, K.R., Chen, J-N., Xiao, L, Clarke, C.H., Fritsche, H., Krishnamurthy, S., Marcy, S., **Hung, M-C.** and Hunt, K.K. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. *Surgery* 136:1061-1069, 2004.
210. Chen, J-S., Liu, J-C., Shen, L., Rau, K-M., Kuo, H-P., Li, Y.M., Shi, D., Lee, Y-C., Chang, K-J. and **Hung, M-C.** Cancer-specific activation of the survivin promoter and its potential use in gene therapy. *Cancer Gene Therapy* 11:740-747, 2004.
211. Li, Y.M., Pan, Y., Wei, Y., Cheng, X., Zhou, B., Tan, M., Zhou, X., Xia, W., Hortobagyi, G.N., Yu, D. and **Hung, M-C.** Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. *Cancer Cell* 6:459-469, 2004\*. \*Accompanied by **Previews**: “A new key in breast cancer metastasis” Benovic, J. L. and Marchese, A. *Cancer Cell* 6:429-430, 2004 and news release from MD Anderson Special News Release on November 15, and BCN (BreastCancer.Net) News. **Research Highlights**: “Metastasis-One step closer” McCarthy N. *Nat. Rev. Cancer* 5:4, 2005.
212. Li, Z., Day, C-P., Yang, J-Y., Tsai, W-B., Lozano, G., Shih H-M., **Hung, M-C.** Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. *Cancer Res.* 64:9080-9085, 2004\*. \*Selected as a highlight article in the "CANCER RESEARCH Highlights: Selected Articles from this Issue".
213. Lo, H-W., Xia, W., Wei, Y., Seyed-Mohamed, A., Huang, S-F. and **Hung, M-C.** Novel prognostic value of nuclear EGF receptor in breast cancer. *Cancer Res.* 65:338-348, 2005\*<sup>#</sup>. \*Selected as a highlight article in the "CANCER RESEARCH Highlights: Selected Articles from this Issue". Accompanied by BCN (BreastCancer.Net) News. <sup>#</sup> Erratum in: *Cancer Res.* Mar 1; 65:2045, 2005.
214. Pawlik, T.M., Fritsche, H., Coombes, K.R., Xiao, L., Krishnamurthy, S., Hunt, K.K., Pusztai, L., Chen, J-N., Clarke, C.H., Arun, B., **Hung, M-C.** and Kuerer, H.M. Significant differences in ductal fluid protein expression in healthy women versus those with breast cancer identified by time-of-flight mass spectrometry. *Breast Cancer Res. and Treat.* 89:149-157, 2005.
215. Dong, J., Peng, J., Zhang, H., Mondesire, W.H., Jian, W., Mills, G.B., **Hung, M-C.** and Funda Meric-Bernstam. Role of glycogen synthase kinase 3 $\beta$  rapamycin-mediated cell cycle regulation and chemosensitivity. *Cancer Res.* 65:1961-1972, 2005.
216. Cha, T.-L., Qiu, L., Wen, Y. and **Hung, M.-C.** Emodin downregulates androgen receptor and inhibits prostate cancer cell growth. *Cancer Res.* 65:2287-2295, 2005\*. \*Selected as a highlight article in the "CANCER RESEARCH Highlights: Selected Articles from this Issue".
217. Shao, R., Lee, D-F., Wen Y., Ding, Y., Xia, W., Ping, B., Yagita, H., Spohn, B. and **Hung, M-C.** E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. *Mol. Cancer Res.* 3:219-226, 2005.

218. Li, Y.M., Zhou, B.P., Deng, J., Pan, Y., Hay, N. and **Hung, M.-C.** A hypoxia-independent HIF-1 activation pathway induced by PI-3K/AKT in HER2 overexpression cells. *Cancer Res.* 65:3257-3263, 2005\*. \*Selected as a highlight article in the "CANCER RESEARCH Highlights: Selected Articles from this Issue".
219. Lo, H-W., Hsu, S-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J-Y. and **Hung, M-C.** Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. *Cancer Cell* 7:575-589, 2005.
220. Ding, Q., Xia W., Liu, J-C., Yang, J-Y., Lee, D-F., Xia, J., Bartholomeusz, Li, Y., Pan, Y., Li, Z., Bargou, RC., Qin, J., Lai, C-C., Tsai, F-J. Tsai, C-H. and **Hung, M-C.** Erk1/2 associates with and primes GSK-3 $\beta$  for its inactivation resulting in upregulation of  $\beta$ -catenin. *Mol. Cell* 19:159-170, 2005\*. \* MD Anderson Special News Release, July 21, 2005.
221. Bisanz, K., Yu, J., Edlund, M., Spohn, B., **Hung, M-C.**, Chung, L.W.K. and Hsieh C-L. Targeting ECM/Integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. *Mol. Ther.* 12:634-643, 2005.
222. Bartholomeusz, C., Itamochi, H., Yuan L.X., Esteva, F.J., Wood, C.G., Terakawa, N. **Hung, M-C.** and Ueno, N.T. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. *Cancer Res.* 12:511-531, 2005.
223. Li, Z., Ding, Q., Li, Y., Miller, S.A., Abbruzzese J.L. and **Hung, M-C.** Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. (Epub online on June 13, 2005), *Cancer Letters* 236:58-63, 2006.
224. Li, M., Wang, Y., **Hung, M-C.** and Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2 $\alpha$  and activates HER-2/neu gene in breast cancer. (Epub online on Aug 17, 2005), *Int. J. Cancer* 118: 802-811, 2006.
225. Cha, T-L., Zhou, BP., Xia, W., Wu, Y., Yang, C-C., Chen, C-T., Ping, B., Otte, A.P. and **Hung, M-C.** Akt-mediated phosphorylation of EZH2 augments methylation of lysine 27 in histone H3. *Science* 310(5746): 306-310, October 14, 2005\*. \*Accompanied by MD Anderson Special News Release and BCN (BreastCancer.Net) News, Oct. 14, 2005.
226. Coombes, K.R., Tsavachidis, S., Morris, J.S., Baggerly, K.A., **Hung, M-C.** and Kuerer, H.M. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. *Proteomics* 5:4107-4117, 2005.
227. Giri, D.K., Ali-Seyed, M., Li, L-Y., Lee, D-F., Ling, P., Bartholomeusz, G., Wang, S-C. and **Hung, M-C.** Endosomal transport of ErbB-2: a mechanism for nuclear entry of cell surface receptor. *Mol. Cell. Biol.* 25:11005-11018, 2005.
228. Hanada, N., Lo, H-W., Day, C-P., Pan, Y., Nakajima, Y., and **Hung, M-C.** Co-regulation of B-Myb expression by E2F1 and EGF receptor. (Epub online on Nov 20, 2005), *Mol. Carcinogen.* 45:10-17, 2006.
229. Bartholomeusz, G., Wu, Y., Ali-Seyed, M., Xia, W., Kwong, K.Y., Hortobagyi, G.N. and **Hung, M-C.** Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. (Epub online on Nov 21, 2005), *Mol. Carcinogen.* 45:73-83, 2006.
230. Ou-Yang, F., Lan, K-L., Chen, C-T., Liu, J-C., Weng, C-L., Chou, C-K., Xie, X., Hung, J-Y., Wei, Y., Hortobagyi G.N. and **Hung, M-C.** Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting cancerous neovascular endothelial cells.

- Cancer Res.* 66: 378-384, 2006.
231. Chen, I-F., Ou-Yang, F., Hung, J-Y., Liu, J-C., Wang, H., Wang, S-C., Hou, M-F., Hortobagyi, G.N. and **Hung, M-C.** AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. *Mol. Cancer Ther.* 5: 1-7, 2006.
  232. Wang, M., Jing, N., Su, C.B., Chou, C-K., **Hung, M-C.**, Chang, K-A. and Kameoka, J. Electrospinning of silica nanochannels for single molecule detection. *Applied Physics Letters*, 88:033106, 2006\*. \*Selected for the Jan 20, 2006 issue of Virtual Journal of Nanoscale Science & Technology.
  233. Chou, C-K., Hung, J-Y., Liu, J-C., Chen, C-T., and **Hung, M-C.** An attenuated *Salmonella* oral DNA vaccine against  $\alpha$ -fetoprotein antigen prevents hepatocellular carcinoma growth. (Epub online on Jan 6, 2006), *Cancer Gene Therapy*, 13:746-752, 2006.
  234. Day, C-P., Rau, K-M., Qiu, L., Liu, C-W., Kuo, H-P., Xie, X., Lopez-Berestein, G., Hortobagyi, G.N. and **Hung, M-C.** Mutant Bik expression mediated by the enhanced minimal Topoisomerase II $\alpha$  promoter selectively suppressed breast tumor in animal model. *Cancer Gene Therapy* (Epub online on March 3, 2006), 13:706-719, 2006.
  235. Konopleva, M., Zhang, W., Shi, Y-X., McQueen, T., Tsao, T., Abdelrahim, M., Munsell, M.F., Johansen, M., Yu, D., Madden, T., Safe, S.H., **Hung, M-C.** and Andreeff, M. Synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. *Mol. Cancer Ther.* 5:317-328, 2006.
  236. Su, J-L., Yang, P-C., Shih, J-Y., Yang, C-Y., Wei, L-H., Hsieh, C-Y., Chou, C-H., Jeng, Y-M., Wang, M-Y., Chang, K-J., **Hung, M-C.** and Kuo, M-L. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. *Cancer Cell* 9:209-223, 2006.
  237. Lo, H-W., Seyed-Mohamed, A., Wu, Y., Bartholomeusz, G., Hsu, S-C. and **Hung, M-C.** Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin  $\beta$ 1 and CRM1. *J. Cell. Biochem.* (Epub online on March 21), 98:1570-1583, 2006.
  238. Yu, Z., Xia, W., Wang, H., Wang, S-C., Pan, Y., Kwong, K.Y., Hortobagyi, G.N. And **Hung, M-C.** Antitumor activity on an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. *Mol. Carcinogen.* (Epub online on May 1), 45:667-675, 2006.
  239. Xia, W., Lien, H-C, Wang, S-C., Pan, Y., Sahin, A., Kuo, Y-H., Chang, K-J., Wang, H., Yu, Z., Hortobagyi, G.N., Shi, D. and **Hung, M-C.** Lack of correlation between PEA3 and HER-2/neu expression in breast cancer. *Breast Cancer Res and Treatment*, (Epub online on June 3), 98:295-301, 2006.
  240. Yang, J-Y., Zong, C.S., Xia, Y., Wei, Y., Ali-Seyed, M., Li, Z., Broglio, K., Berry, D.A. and **Hung, M-C.** MDM2 promotes cell mobility and invasiveness by regulating E-cadherin degradation. *Mol. Cell. Biol.* 26:7269-7282, 2006.
  241. Ping, B., He, X., Xia, W., Lee, D-F., Wei, Y., Yu, D, Mills, G., Shi, D. and **Hung, M-C.** Cytoplasmic expression of p21<sup>CIP1/WAF1</sup> is correlated with IKK $\beta$  overexpression in human breast cancers. *Int. J. Oncol.* 29:1103-1110, 2006.
  242. Jiang, H., Olson, MV., Medrano, DR., Lee, O-H., Xu, J., Piao, Y., Aloson, MM., Gomez-Manzano, C., **Hung, M-C.**, Yung, WKA., Fueyo, J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. *FASEB J.* (Epub online on Oct 25,2006), 20:2603-2605, 2006.
  243. Wang, S-C., Nakajima, Y., Yu, Y-L., Xia, W., Chen, C-T, Yang, C-C., McIntush EW., Li, L-Y., Hawke, D., Kobayashi, R. and **Hung, M-C.** Tyrosine phosphorylation controls

- protein stability of PCNA. *Nat. Cell Biol.* (Epub online on Nov 19, 2006), 8:1359-1368, 2006.
244. Hsu, S-C. and **Hung, M-C.** Characterization of a novel tripartite nuclear localization sequence in the EGFR family. *J. Biol. Chem.* (Epub online on Feb 5), 282: 10432-10440, 2007.
245. Ding, Q., He, X. Hsu, J-M., Xia, W., Chen, C-T., Li, L-Y., Lee, D-F., Liu, J-C. Zhong, Q., Wang, X. and **Hung, M-C.** Degradation of Mcl-1 by  $\beta$ -TrCP mediates GSK3 $\beta$ -induced tumour suppression and chemosensitization. *Mol. Cell. Biol.* (Epub online on March 26) 27: 4006-4017, 2007.
246. Uwagawa, T., Li, Z., Chang, Z., Xiao, Q., Peng, B., Scalabas, G.M., Ishiyama, S., **Hung, M-C.**, Evans, D.B., Abbruzzese J.L. and Chiao, P.J. Mechanism of synthetic serine protease inhibitor (FUT-175)-mediated cell death. *Cancer* (Epub online on April 4) 109: 2142-2153, 2007.
247. Huang, W-C., Ju, T-K., \***Hung, M-C.** and \*Chen, C-C. Phosphorylation of CBP by IKK $\alpha$  promotes cell growth by switching the binding preference of CBP from p53 to NF- $\kappa$ B. *Mol. Cell* 26:75-87, 2007#. \***co-corresponding author.** # chosen by Science STKE's editor, Adler, E.M. "Making life or death choices by CBP". *Sci. STKE*, issue 382, p. tw132, April 17, 2007. *Previews*, "p53 and NF- $\kappa$ B crosstalk: IKK tips the balance", Tergaonkar, V. and Perkins ND. *Molecular Cell* 26:158-159, 2007.
248. Casimiro, M., Rodriguez, O., Pootrakul, L., Aventian, M., Lushina, N., Cromelin C., Ferzli, G., Johnson, K., Fricke, S., Diba, F., Kallakuri, B., Ohanyerenwa, C., Chen, M., Ostrowski, M., **Hung, M-C.**, Rabbani, SA., Datar, R., Cote, R., Pestell, R. and Albanese, C. ErbB-2 induces the *cyclin D1* gene in prostate epithelial cells *in vitro* and *in vivo*. *Cancer Res.* 67:4364-4372, 2007.
249. Ding, Q., He, X., Xia, W., Hsu, J-M., Chen, C-T., Li, L-Y., Lee, D-F., Yang, J-Y., Xie, X., Liu, J-C. and **Hung, M-C.** Mcl-1 inversely correlates with GSK3 $\beta$  activity and associates with poor prognosis in human breast cancer. *Cancer Res.* (Epub online on May 10) 67:4564-4571, 2007.
250. Izzo, J.G., Malhotra, U., Wu, T.T., Luthra, R., Correa, A. M., Swisher, S.G., Hofstetter, W., Chao, K.S., **Hung, M-C.** and Ajani, J.A. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor- $\kappa$ B expression. *Cancer Epidemiol Biomarkers Prev.* 16:1200-1205, 2007.
251. Xie, X., Xia, W., Li, Z., Kuo, H-P., Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and **Hung, M-C.** Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. *Cancer Cell*, 12:52-65, 2007#. # Accompanied by MDACC news release, Science news magazine "Tumor Suicide: gene therapy makes cancer cells self-destruct" by P. Barry and Houston Ch. 13 ABC interview.
252. Lien, HC, Hsaio, YH, Lin, YS, Yao, YT, Juan, HF, Kuo, WH., **Hung, M-C.**, Chang, KJ and Hsieh, FJ. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. *Oncogene* (Epub July 2), 26:7859-7871, 2007.
253. Nakagawa-Goto, K., Yamada, K., Nakamura, S., Chen, T-H., Chiang, P-C., Bastow, KF., Wang, S-C., Spohn, W., **Hung, M-C.**, Lee, F-Y., Lee, F-C. and Lee, K-H. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents. *Bioorg Med Chem Lett.* (Epub online July 4), 17:5204-5209, 2007.

254. Lee, D-F., Kuo, H-P., Chen, C-T., Hsu, J-M., Sun, H-L., Chou, C-K., Wei, Y., Li, L-Y., Ping, B., Huang, W-C., He, X., Hung, J-Y., Lai, C-C., Ding, Q., Su, J-L., Yang, J-Y., Sahin, A.A., Hortobagyi, G.N., Tsai, F-J., Tsai, C-H. and **Hung, M-C.** IKK $\beta$  suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell*, 130:440-455, 2007#. #Selected by Katherine Stevens (*Nature* editor), **Research Highlights:** “Awakening Dormant Tumors”, *Nature Medicine*, 13:1026, 2007.
255. Wang, X., Zheng, M., Liu, G., McKeown-Longo, P.J., **Hung, M-C.** and Zhao, J. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. *Cancer Res.* 67:7184-7193, 2007.
256. Akcakanat A., Singh, G., **Hung, M-C.** and Meric-Bernstam F. Rapamycin regulates the phosphorylation of rictor. *Biochem Biophys Res Comm.* (Epub August 8) 362:330-333, 2007.
257. Lo, H-W., Hsu, S-C., Xia, W., Cao, X., Shi, J-Y., Wei, Y., Abbruzzese, J.L., Hortobagyi, G.N. and **Hung, M-C.** EGFR cooperates with STAT3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. *Cancer Res.* 67:9066-9076, 2007\*. \*Selected by Priya Prakash Budde (*Cell* Editor), **Leading Edge**, Molecular Medicine Select “A new twist in metastasis”, *Cell*, November 2 issue, 131:427, 2007.
258. Tsai, K-L., Sun, Y-J., Huang, C-Y., Yang, J-Y., **Hung, M-C.** and Hsiao, C-D. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. *Nucleic Acids Res.* (Epub Oct 16) 20:6984-6994, 2007.
259. Kang, T., Wei, Y., Honaker, Y., Yamaguchi, H., Appella, E., **Hung, M-C.** and Piwnicka-Worms, H. GSK-3 $\beta$  targets Cdc25A for ubiquitin-mediated proteolysis and GSK-3 $\beta$  inactivation leads to Cdc25A overproduction in human cancers. *Cancer Cell* 13: 36-47, 2008.
260. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H, Adsay, NV., Albarracin, C., Yu, D., Abbruzzese, JL., Mills, GB., Bast, RC. Jr., Hortobagyi, GN. And **Hung, M-C.** Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. *Mol Carcino* (Epub Jan 4), 47:701-706, 2008. (NIHMS76157, PMC2580832)
261. Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Muller, WJ., Mills, GB., Yu, D., Hortobagyi, GN. and **Hung, M-C.** Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. *Nature Cell Biology* (Epub Jan 20) 10:138-148, 2008. (NIHMS46900, PMC2376808)
262. Yamaguchi, H., Ding, Y., Lee, J-F., Zhang, M., Pal, A., Bornmann, W., Yan, D-H. and **Hung, M-C.** Interferon-inducible protein IFIX inhibits cell invasion by upregulating the metastasis suppressor mapsin. *Mol Carcino* (Epub Feb 4), 47:739-743, 2008. (NIHMS76163, PMC2596649)
263. Yen, C-J., Izzo, JG., Lee, D-F., Guha, S., Wei, Y., Wu, T-T., Chen, C-T., Kuo, H-P., Chou, C-K., Hsu, J-M., Sun, H-L., Demars, C., Buttar, NS., Wang, K., Peng, H., Ajani, J. and **Hung, M-C.** Bile acid exposure causes upregulation of TSC1/m-TOR signal pathway in Barrett’s esophagus-associated esophageal adenocarcinoma. *Cancer Res.* 68:2632-2639, 2008. (NIHMS46903, PMC2377413)
264. Weihua, Z., Tsan, R., Wu, Q., Huang, W-C., Chiu, C-H., \*Fidler, I.J. and \***Hung, M-C.** Survival of cancer cells is maintained by kinase-independent EGFR. *Cancer Cell* 13:385-

- 393, 2008#. \*Co-Corresponding authors. #*Cancer Cell Previews* “A Sweet New Role for EGFR in Cancer” Jeffrey A. Engleman and Lewis C. Cantley, *Cancer Cell* 13:375-376, 2008. *Science-Business eXchange* “EGFR’s new tricks” Lev Osherovich, Vol. 1, Number 16, page 1-4, 15 May 2008 issue. *Research Roundup, J Cell Biol.* “Sweeter Tumors with EGFR”, p715, May 20, 2008. *Research Highlights, Nature Medicine* “Cancer: Hold the sugar”, 14 (6): 613, June 2008. *Research Highlights in Signaling, Nature Reviews Cancer* “Survival of the sweetest” Katharine H. Wrighton, Volume 8, July 2008. (NIHMS49635, PMC2413063)
265. Stemke-Hale, K., Gonzalez-Angulo, AM., Lluch, A., Neve, R.M., Kuo, W-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., Symmans, WF., Pusztai, L., Nolden, L., Horlings, H., Berns, K., **Hung, M-C.**, van de Vijver, M., Valero, V., Gray, JW., Bernards, R., Mills, GB. and Hennessy, B.T. An integrative genomic and proteomic analysis of PI3KCA, PTEN and AKT mutations in breast cancer. *Cancer Res.* 68: 6084-6091, 2008. (NIHMS67275)
266. Ding, Q., Huo, L., Yang, J-Y., Xia, W., Wei, Y., Liao, Y., Lai, C-C., Chang, C-J., Yang, Y., Lee, D-F., Chen, Y-J. R., Hsu, J-M., Yen, C-J., Lin, C-Y., Tsai, F-J., Li, L-Y., Tsai, C-H. and **Hung, M-C.** Downregulation of Mcl-1 through inhibiting Erk/Pin 1 pathway by Sorafenib facilitates chemosensitization in breast cancer. *Cancer Res.* 68:6109-6117, 2008. (NIHMS76170)
267. Wang, R-H., Zheng, Y., Kim, H-S., Xu, X., Cao, L., Luhasen, T., Lee, M-H., Xiao, C., Vassilopoulos, A., Chen, W., Gardner, K., Man, Y-G., **Hung, M-C.**, Finkel, T. and Deng, C-X. Interplay among BRAC1, SIRT1 and Survivin during BRAC1-associated tumorigenesis. *Mol. Cell*, 32:11-20, 2008\*. \*Previews: “SIRting through breast cancer is just a survivin’ game” by Jianyuan Luo and Dario C. Altieri, *Mol. Cell* 32:159-160, 2008.
268. Lee, D-F., Kuo, H-P., Chen, C-T., Wei, Y., Chou, C-K., Hung, J-Y., Yen, C-J. and **Hung, M-C.** IKK $\beta$  suppression of TSC1 links mTOR pathway and insulin resistance. *Int J Mol Med* 22:633-638, 2008. (NIHMS76167, PMC2586899)
269. Lee, C., Dhillon, J., Wang, M., Gao, Y., Hu, K., Park, E., Astanehe, A., **Hung, M-C.**, Eirew, P., Eaves, C. and Dunn S. Targeting YB-1 in Her2-overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. *Cancer Res* 68:8661-8666, 2008.
270. Tsou, P-H., Chou, C-K., Saldana SM., **\*Hung, M-C.** and **\*Kameoka, J.** The fabrication and testing of electrospun silica nanofiber membranes for the detection of proteins. *Nanotechnology* 19:445714-445719, 2008. \*Co-corresponding authors. (NIHMS78018, PMC2600432)
271. Izzo, JG., Wu X., Wu, TT., Huang, P., Lee, JS., Liao, Z., Lee, JH., Bhutani, MS., Hofstetter, W., Maru, D., **Hung, M-C.** and Ajani, JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. *Dis Esophagus*, (Epub Nov 19, 2008), 22:127-132, 2009.
272. Xia, W., Wei, Y., Du, Y., Liu, J., Yu, Y-L., Miller, S. and **Hung, M-C.** Nuclear expression of epidermal growth factor receptor is novel prognostic value in patients with ovarian cancer. *Mol Carcino*, (Epub Dec 4, 2008), 2009.
273. Song S., Mazurek, N., Liu, C., Sun, Y., Ding, Q., Liu, K., **Hung, M-C.** and Bresalier, R. Galectin-3 mediates nuclear  $\beta$ -catenin accumulation and Wnt signaling in human coloco cancer cells by regulatio of GSK-3 $\beta$  activity. *Cancer Res* (Epub Feb 3) 69:1343-1349, 2009.



274. Chen, G., Izzo, J., Demizu, Y., Wang, F., Guha, S., Wu, X., **Hung, M-C.**, Ajani, J. and Huang, P. Different redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. *Antioxidants & Redox Signaling* (Epub Jan 12), 11:1083-1095, 2009.
275. Hildebrandt, MAT., Yang, H., **Hung, M-C.**, Izzo, JG., Huang, M., Lin, J., Ajani, JA and Wu, X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. *J. Clin Oncol.* (Epub Jan 21), 27:857-871, 2009.
276. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, **Hung MC**, Wang HG. P53 acetylation is crucial for its transcription-independent proapoptotic function. *J. Biol. Chem* (Epub March 5), 2009.
277. Neal, C.L., Yao, J., Yang, W., Zhou, X., Nguyen, NT., Lu, J., Danes, CG., Guo, H., Lan, K-H., Ensor, J., Hittelman, W., **Hung, M-C.** and Yu, D. 14-3-3 $\zeta$  overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. *Cancer Res.* (Epub March 24), 69: 3425-3432, 2009.
278. Hawthorne, V.S., Tseng, L-M., Huang, W-C., Neal, C., **Hung, M-C.** and Yu, D. ErbB2-mediated Src and STAT3 activation leads to transcriptional upregulation of p21<sup>Cip1</sup> and chemoresistance in breast cancer cells. *Mol Cancer Res (in press)*, 2009.
279. Jiralerspong, S., Palla, S., Girodano, S., Meric-Bernstam, F., Liedtke, C., Barnett, C., Hus, L. **Hung, M-C.**, Hortobagyi, G and Gonzalez-Angulo, A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J. Clin Oncol. (in press)*, 2009.
280. Liao, Y., Wei, Y., Zhou, Z., Yang, J-Y., Dai, C., Chen, Y-J., Agarwal, N.K., Sarbassov, D., Shi, D., Yu, D. and **Hung, M-C.** Peptidyl-prolyl cis/trans isomerase PIN1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. *Oncogene (in press)*, 2009.

**Selected recent publications and their significance: 2001- present,**

(Update: October 28, 2008, Citation Reference:

[http://apps.isiknowledge.com/WOS\\_CitedReferenceSearch\\_input.do?product=WOS&SID=4AgnlhF91dPDogiAop9&search\\_mode=CitedReferenceSearch](http://apps.isiknowledge.com/WOS_CitedReferenceSearch_input.do?product=WOS&SID=4AgnlhF91dPDogiAop9&search_mode=CitedReferenceSearch))

On October 28, 2008, **h-index is 63 (it is 52 from 1996 till present,**

<http://www.scopus.com/scopus/search/form.url?display=authorLookup&clear=t&txGid=nRLmxutFvNqU10DFI-A4G5x%3a2>) **and 33 peer-reviewed papers were cited over 100 times.**

1. Zhou, B.P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H. and **Hung, M.-C.** Cytoplasmic localization of p21<sup>Cip1/WAF1</sup> by Akt-induced phosphorylation in *HER-2/neu*-overexpressing cells. *Nature Cell Biology*. 3:245-252, March 2001\*. \*Accompanied by *News and Views* by El-Deiry, W.S. Akt takes centre stage in cell-cycle deregulation. *Nature Cell Biology* 3:E71-E73, 2001.

The first to demonstrate regulation of cell cycle inhibitor, p21 by *HER2/neu* oncogene through phosphorylation of p21 by Akt, which results in changes in the subcellular localization. This study demonstrates that p21 function in cytoplasm is different from its function in the nucleus. The results have provided a plausible interpretation for many controversial studies on the role of p21 as a prognostic marker. **Time cited: 382.**

- Lin, S.-Y., Makino, K. Xia, W., Matin, A., Wen, Y., Kwong, K.Y., Bourguignon, L.Y.W. and **Hung, M.-C.** Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nature Cell Biology* 3:803-808, September 2001\*. \*Accompanied by *News and Views* by Waugh, M.G., and Hsuan, J.J. EGF receptor as transcription factors: ridiculous or sublime? *Nature Cell Biology* 3: E209-E211, 2001. Accompanied by *Perspective: Signal Transduction* by Heldin, C.-H. and Ericsson, J. RIPPING tyrosine kinase receptors apart. *Science* 294: 2111-2112, 2001. Also accompanied by *News and Comments* by Wong, R. W. C. and Chan, S. Y. EGFR as a transcription factor. *Trends in Genetics* 17: 625-626, 2001.

A critical breakthrough demonstrated that receptor tyrosine kinase such as EGFR, and HER2/*neu* can be translocated into the nucleus, and that it binds to a specific DNA sequence in the promoter to activate transcription. Dr. Hung's group was the first to show rat *neu* (rat version of human HER2 receptors) is associated with transcriptional activity in the nucleus (BBRC 1994, publication # 67, pg. 38); Dr. Hung's lab then demonstrated that EGFR can bind to a specific DNA sequence in the nucleus and that it functions as a transcription factor, which can activate genes required for cell proliferation. This decisive finding has changed the concept of receptor biology and, therefore, has opened a new avenue to understand receptor biology. **Time cited: 278.**

- Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and **Hung, M.-C.** HER-2/*neu* induces ubiquitination via Akt-mediated MDM2 phosphorylation. *Nature Cell Biology* 3:973-982, November 2001\*. \*Accompanied by *Research Round up* by Brooksbank, C. Oncogenes: breaking and entering. *Nature Reviews Cancer* 2001.

The first to demonstrate that *HER2/neu* can suppress expression of tumor suppressor gene, p53, through Akt/MDM2 pathway. This study provides the first molecular mechanism for the inverse relationship between the two well-known cancer-related genes, *HER2/neu* oncogene and p53 tumor suppressor. **Time cited: 290.**

- Deng, J., Miller, S.A., Wang, H.-Y., Xia, W., Wen, Y., Zhou, B.P., Lin, S.-Y., Li, Y. M. and **Hung, M.-C.**  $\beta$ -Catenin interacts with and inhibits NF- $\kappa$ B in human colon and breast cancers. *Cancer Cell* 2:323-334, October 2002.

It is first study to identify a novel role of  $\beta$ -catenin as an inhibitor of NF- $\kappa$ B.  $\beta$ -catenin exerts this function through physical interaction, which is independent of TCF-mediated transcription. Importantly,  $\beta$ -catenin can repress expression of NF- $\kappa$ B target gene Fas. Since deregulated  $\beta$ -catenin and downregulation of NF- $\kappa$ B of Fas play a critical role in tumor progression, the function identified in this study reveals a new direction for understanding the oncogenic roles of  $\beta$ -catenin. **Time cited: 71.**

- Hu, M.C-T, Lee, D.-F., Xia, W., Golfman, L., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S, Hanada, N., Saso, H., Kobayashi R. and **Hung, M.-C.** I $\kappa$ B kinase promotes tumorigenesis through inhibition of Forkhead transcription factor FOXO3a. *Cell* 117:225-237, April 2004\*. \*Accompanied by **Review:** "FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation." Accili, D. and Arden, K. C. *Cell* 117: 421-426, 2004; **Review:** "FoxO:

Linking new signaling pathways.” Arden, K.C. *Molecular Cell* 14:416-418, 2004; and news release from MD Anderson Cancer Center special press release, Eurekalert, Reuters Health, Medical News Today-UK and WBBM-TV (CBS) Chicago.

The first to demonstrate that IKK, another downstream molecular of HER2/*neu*, is an oncogene to induce tumorigenesis by inhibiting the Forkhead transcriptional factor, FOXO3a. This study has important implication in the inflammation-mediated cancer. **Time cited: 182.**

6. Wang, S-C., Lien, H-C., Xia, W., Chen, I-F., Lo, H-W., Wang, Z., Ali-Seyed, M., Lee, D-F., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and **Hung, M.-C.** Binding at and transactivation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. *Cancer Cell* 6:251-261, September 2004\*. \*Accompanied by BCN (BreastCancer.Net) News; MD Anderson Special News Release, Sept 30, 2004.

This is a continuing work on nuclear translocalization of membrane receptor tyrosine kinase; this study discovered that tyrosine kinase receptor HER2/*neu* binds at a specific DNA sequence of COX-2 promoter to regulate transcriptional activity. **Time cited: 68.**

7. Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gundaz, M. and **Hung, M.-C.** Dual regulation of Snail by GSK-3 $\beta$ -mediated phosphorylation in control of epithelial-mesenchymal transition. *Nat. Cell Biolo.* (Epub online on September 26, 2004), 6:931-940, October 2004\*. \*Accompanied by *News and Views* “GSK-3 $\beta$  sets Snail’s pace” Schlessinger K. and Hall, A. *Nature Cell Biology* 6:913-915, 2004; news release: Hindustan Times (largest English Daily in India); BCN (BreastCancer.Net) News; MD Anderson Special News Release, Sept 29, 2004; “*A Snail’s Life In The Fast Lane: Looking Upstream For New Cancer Metastasis Insights*” Breindl, A. BioWorld<sup>®</sup> Today. Vol. 15 No. 212, November 2, 2004.

Snail transcriptional factor is known to induce epithelial-mesenchymal-transition (EMT) and metastasis. This is the first study to identify an upstream kinase namely GSK3 $\beta$  that regulates Snail. A beautiful dual regulation of Snail by GSK3 $\beta$ -mediated phosphorylation was revealed in control of EMT. **Time cited: 151.**

8. Li, Y.M., Pan, Y., Wei, Y., Cheng, X., Zhou, B., Tan, M., Zhou, X., Xia, W., Hortobagyi, G.N., Yu, D. and **Hung, M.-C.** Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. *Cancer Cell* 6:459-469, November 2004\*. \*Accompanied by **Previews:** “A new key in breast cancer metastasis” Benovic, J. L. and Marchese, A. *Cancer Cell* 6:429-430, 2004 and news release from MD Anderson Special News Release on November 15, and BCN (BreastCancer.Net) News. **Research Highlights:** “Metastasis-One step closer” McCarthy N. *Nature Reviews Cancer* 5:4, 2005.

The study demonstrated that the upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. This study provides a rational and molecular mechanism to explain why HER2-mediated metastasis can home to lung. **Time cited: 99.**

9. Lo, H-W., Hsu, S-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J-Y. and **Hung, M-C.** Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. *Cancer Cell* 7:575-589, June 2005.

The study demonstrated that EGFR in the nucleus can interact with Stat3 to co-regulate iNOS transcription. This result provides a new avenue to re-examine STAT-mediated transcription. Traditionally, the STAT family is known to be tyrosine phosphorylated in cell membrane through cytokine receptors and/or receptor tyrosine kinase pathways, then translocates into the nucleus to turn on transcription. The 2005 Cancer Cell report indicates another alternative pathway; namely that STAT3 and EGFR together can be translocated into nucleus from cell membrane and co-regulate gene expression. **Time cited: 61.**

10. Ding, Q., Xia W., Liu, J-C., Yang, J-Y., Lee, D-F., Xia, J., Bartholomeusz, Li, Y., Pan, Y., Li, Z., Bargou, RC., Qin, J., Lai, C-C., Tsai, F-J. Tsai, C-H. and **Hung, M-C.** Erk1/2 associates with and primes GSK-3 $\beta$  for its inactivation resulting in upregulation of  $\beta$ -catenin. *Molecular Cell* 19:159-170, July 2005\*. \* MD Anderson Special News Release, July 21, 2005.

The study also made another important finding that Erk1/2 kinase associates with and primes GSK-3 $\beta$  for its inactivation resulting in upregulation of  $\beta$ -catenin. **Time cited: 70.**

11. Cha, T-L., Zhou, BP., Xia, W., Wu, Y., Yang, C-C., Chen, C-T., Ping, B. Otte, A.P. and **Hung, M-C.** Akt-mediated phosphorylation of EZH2 augments methylation of lysine 27 in histone H3. *Science* 310(5746):306-310, October 14, 2005\*. \* Accompanied by MD Anderson Special News Release and BCN (BreastCancer.Net) News, October 2005.

The first to demonstrate that Akt phosphorylates Enhancer of Zeste homolog 2 (EZH2), a methyltransferase that plays an important role in many biological processes through its ability to trimethylate lysine 27 in histone H3, at serine 21 and suppresses its methyltransferase activity by impeding EZH2 binding to histone H3, which results in a decrease of lysine 27 trimethylation and derepression of silenced genes. The study provides another novel signaling pathway by showing that Akt regulates the methylation activity, through phosphorylation of EZH2, and contributes to oncogenesis. **Time cited: 33.**

12. Wang, S-C., Nakajima, Y., Yu, Y-L., Xia, W., Chen, C-T, Yang, C-C., McIntush EW., Li, L-Y., Hawke, D., Kobayashi, R. and **Hung, M-C.** Tyrosine phosphorylation controls protein stability of PCNA. *Nature Cell Biology* (Epub online on Nov 19, 2006), 8:1359-1368, December 2006.

The first study to demonstrate that nuclear EGFR directly interacts with and phosphorylates PCNA, a well known nuclear protein that can assemble in a homo-trimeric ring structure encircling the DNA double helix and functions as a mobile sliding clamp to recruit other proteins to the chromatin for DNA synthesis and repair. The tyrosine phosphorylation of PCNA by EGFR stabilizes chromatin-bound PCNA protein and enhances its functions including DNA synthesis and repair. This study is the first to show regulation of PCNA by phosphorylation and identification of a novel nuclear mechanism linking receptor tyrosine kinase function with the PCNA sliding clamp. **Time cited: 10.**

13. Huang, W-C., Ju, T-K., \***Hung, M-C.** and \*Chen, C-C. Phosphorylation of CBP by IKK $\alpha$  promotes cell growth by switching the binding preference of CBP from p53 to NF- $\kappa$ B. *Molecular Cell* 26:75-87, 2007#. \***co-corresponding author.** # chosen by Science STKE's editor, Adler, E.M. "Making life or death choices by CBP". *Sci. STKE*, issue 382, p. tw132, April 17, 2007. *Previews*, "p53 and NF- $\kappa$ B crosstalk: IKK tips the balance", Tergaonkar, V. and Perkins ND. *Molecular Cell* 26:158-159, 2007.

The transcriptional co-activator, CBP (CREB-binding protein) plays a central role in coordinating and integrating multiple signaling pathways. Competition between NF- $\kappa$ B and p53 for CBP is a crucial determinant of whether a cell proliferates or undergoes apoptosis. However, how the CBP-dependent crosstalk between these two transcription factors is regulated remains unclear. In this regard, Dr. Hung and his collaborator, Dr. Chin-Chow Chen at National Taiwan University showed that IKK $\alpha$  phosphorylates CBP at serine 1382 and serine 1386 and consequently increases CBP's HAT and transcriptional activities. Importantly, such phosphorylation enhances NF- $\kappa$ B-mediated gene expression and suppresses p53-mediated gene expression by switching the binding preference of CBP from p53 to NF- $\kappa$ B, thus promoting cell growth. The CBP phosphorylation also correlates with constitutive IKK $\alpha$  activation in human lung tumor tissue compared with matched nontumor lung tissue. This study suggests that phosphorylation of CBP by IKK $\alpha$  regulates the CBP-mediated crosstalk between NF- $\kappa$ B and p53 and thus may be a critical factor in the promotion of cell proliferation and tumor growth in TNF $\alpha$  signaling. The study was chosen by Science STKE's (Signal Transduction Knowledge Environment) editor, Dr. Adler, E.M. in the article entitled "Making life or death choices by CBP". **Time cited: 29.**

14. Xie, X., Xia, W., Li, Z., Kuo, H-P., Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D. B., Chiao, P. J., Abbruzzese J. L. and **Hung, M-C.** Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. *Cancer Cell*, 12:52-65, 2007#. # Accompanied by MDACC news release, Science news magazine "Tumor Suicide: gene therapy makes cancer cells self-destruct" by P. Barry and Houston Ch. 13 ABC interview.

Pancreatic cancer is an aggressive malignancy with morbidity rates almost equal to mortality rates because of the current lack of effective treatment options. Dr. Hung in collaboration with Drs. Abbruzzese, Chiao and Evans reported a targeted approach to treating pancreatic cancer with effective therapeutic efficacy and safety in noninvasive imaging models. Dr. Hung's group developed a versatile expression vector "VISA" (VP16-GAL4-WPRE integrated systemic amplifier) and a CCKAR (cholecystokinin type A receptor) gene-based, pancreatic-cancer-specific promoter VISA (CCKAR-VISA) composite to target transgene expression in pancreatic tumors in vivo. Targeted expression of BikDD, a potent proapoptotic gene driven by CCKAR-VISA, exhibited significant antitumor effects on pancreatic cancer and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of pancreatic tumors with virtually no toxicity. The study outcome has drawn attention from scientific community. Drs. Hung and Abbruzzese were interviewed by Houston TV Ch. 13 ABC. In addition, Mr. P. Barry, a writer of Science News magazine also

interviewed Dr. Hung and published an article entitle “Tumor Suicide: gene therapy makes cancer cells self-destruct” (Science News, Vol 172, 2007). **Time cited: 2.**

15. Lee, D-F., Kuo, H-P., Chen, C-T., Hsu, J-M., Sun, H-L., Chou, C-K., Wei, Y., Li, L-Y., Ping, B., Huang, W-C., He, X., Hung, J-Y., Lai, C-C., Ding, Q., Su, J-L., Yang, J-Y., Sahin, A.A., Hortobagyi, G.N., Tsai, F-J., Tsai, C-H. and **Hung, M-C.** IKK $\beta$  suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 130:440-455, 2007#. #Accompanied by **Research Highlights:** “Awakening Dormant Tumors”, *Nature Medicine*, 13:1026, 2007

For over two centuries, it has been generally recognized that inflammatory cells could provide their adjacent tumor cells an advantage by helping them proliferate and metastasize. The molecular mechanism that is accounted for the phenomenon is not yet fully understood. We demonstrated that IKK $\beta$  (inhibitor of NF-kB kinase  $\beta$ ), a critical factor activated during inflammation, directly binds to and suppresses tuberous sclerosis-1 (TSC1). The IKK $\beta$ -mediated TSC1 suppression activates the mammalian target of rapamycin (mTOR) pathway, enhances angiogenesis, and results in tumor development. In multiple tumor types, IKK $\beta$  activation was associated with TSC1 suppression and VEGF production (a key factor to promote angiogenesis), and this correlated with poor clinical outcome for breast cancer patients. Furthermore, recent studies indicate that mTOR and its effector, S6 kinase 1 (S6K1) are involved in obesity and diabetes, in addition to cancer. In summary, this series of beautiful studies has led to novel discoveries of previously unknown signaling pathways/networks that potentially links cancer, obesity and diabetes and play critical roles in cancer progression, which may serve as therapeutic targets for cancer intervention. **Time cited: 20.**

16. Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Muller, WJ., Mills, GB., Yu, D., Hortobagyi, GN. and **Hung, M-C.** Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. *Nature Cell Biology* (Epub Jan 20) 10:138-148, 2008.

RAS-ERK-MAPK is known to play a pivotal role in differentiation, proliferation, and tumor progression. In this study, we showed that ERK downregulated FOXO3a through directly interacting with and phosphorylating FOXO3a at Serine 294, Serine 344, and Serine 425, which consequently promoted cell proliferation and tumorigenesis. The ERK phosphorylated FOXO3a was degraded via an MDM2-mediated ubiquitin-proteasome pathway. However, the non-phosphorylated FOXO3a mutant was resistant to the interaction and degradation by MDM2, thereby resulting in a strong inhibition of cell proliferation and tumorigenicity. Taken together, our study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS-ERK and MDM2. **Time cited: 8.**

17. Weihua, Z., Tsan, R., Wu, Q., Huang, W-C., Chiu, C-H., \*Fidler, I.J. and \***Hung, M-C.** Survival of cancer cells is maintained by kinase-independent EGFR. *Cancer Cell* 13:385-393, 2008#. \*Co-Corresponding authors. #*Cancer Cell Previews* “A Sweet New Role for EGFR in Cancer” Jeffrey A. Engleman and Lewis C. Cantley, *Cancer Cell* 13:375-376, 2008. *Science-Business eXchange* “EGFR’s new tricks” Lev Osherovich, Vol. 1, Number 16, page

1-4, 15 May 2008 issue., *Research Roundup, J Cell Biol.* “Sweeter Tumors with EGFR”, p715, May 20, 2008. *Research Highlights, Nature Medicine* “Cancer: Hold the sugar”, 14 (6): 613, June 2008. *Research Highlights in Signaling, Nature Reviews Cancer* “Survival of the sweetest” Katharine H. Wrighton, Volume 8, July 2008.

Overexpression/activation of EGFR, which is often found in tumors of epithelial origin, is associated with metastasis, poor prognosis, and resistance to chemotherapy. Multiple clinical trials using EGFR tyrosine kinase inhibitors in cancer therapy have been conducted, however, blockage of tyrosine kinase activity alone does not seem to reach maximum therapeutic efficacy. We report here that EGFR, independent of its kinase activity, maintains the basal intracellular glucose level, thereby preventing cells from undergoing autophagic death. This function of EGFR may endow tumor cells with an increased survival capacity even in the presence of chemotherapeutic agents and tyrosine kinase inhibitors. This study could explain why some drugs that target what was previously thought to be EGFR’s only role in cancer proliferation have had limited success in patients. It may be necessary to knock down both EGFR’s glucose-related role and its growth-inducing kinase activity in order to attack cancers of the epithelium -- tissue that lines the surfaces and cavities of the body's organs. Epithelial cancers, or carcinomas, make up 80 percent of all cancers. **Time cited: 5**

#### **Published and Accepted Invited Journal Articles/Reviews:**

1. Wensink, P.C., Garabedian, M.J., Shepherd, B.M. and **Hung, M.-C.** DNA elements determining the differentiated expression pattern of drosophila yolk protein genes. *Current Communications in Molecular Biology* (Eucaryotic Transcription, the Role of Cis- and Trans-acting Elements in Initiation) Cold Spring Harbor, 185-188, 1985.
2. Sheperd, B.M., Garabedian, M.J., **Hung, M.-C.** and Wensink, P.C. Developmental control of drosophila yolk protein I gene by cis-acting DNA element. *Cold Spring Harbor Symp. Quant. Biol.* (Molecular Biology of Development), 50:521-526, 1985.
3. **Hung, M.-C.**, Schechter, A.L., Vaidyanathan, L., Stern, D.F. and Weinberg, R.A. Isolation of the molecular clone of the *neu* oncogene from the B103 rat neuro/glioblastoma cell line. *Biochemical and Molecular Epidemiology of Cancer*, 40:391-395, 1986.
4. **Hung, M.-C.** The *neu* proto-oncogene and breast cancer. *Cancer Bulletin*, 40:300-303, 1988.
5. Greenberg, N.M., Reding, T.V., Lee, K-F., **Hung, M.-C.** and Rosen J.M. The regulation of tissue-specific casein gene expression in transgenic animals. *Breast Cancer: Progress in Biology, Clinical Management and Prevention*, Kluwer Academic Publishers, 15-26, 1989.
6. **Hung, M.-C.** Activation mechanism of the *neu* oncogene. *The 10<sup>th</sup> Proc. Sci. Eng. Tech. Seminars*, S4-12, 1989.
7. Yu, D. and **Hung, M.-C.** Suppression of *neu* oncogene induced transformation and metastasis. *The 1991 Proc. Sci. Eng. Tech. Seminars*, BS1-3, 1991.
8. Yan, D-H. and **Hung, M.-C.** The regulation of the *neu* oncogene expression. *The 1991 Proc. Sci. Eng. Tech. Seminars*, BS1-23, 1991.
9. Klostergaard, J., Utsumi, T., Macatee, S., Suen, T-C., Leroux, E., Levitan, A., and **Hung, M.-C.** Characterization and modeling of monocyte/macrophage presentation of membrane TNF. *Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application*, 101-110, 1992.

10. Zhou, X.Y. and **Hung, M. C.** Negative autoregulation of the *neu* oncogene. *The 1992 Proc. Sci. Eng. Tech. Seminars*, BM-I-9-11, 1992.
11. Yu, D. and **Hung, M.-C.** *Neu* oncogene and metastasis. *The 1992 Proc. Sci. Eng. Tech. Seminars*, BMII-3-4, 1992.
12. Xie, Y., Kiyokawa, N., Matin, A. and **Hung, M.-C.** Signal transduction of HER-2/*neu* receptor tyrosine kinase. *Cancer Bulletin*, 47:109-118, 1995.
13. **Hung, M.-C.**, Matin, A., Zhang, Y., Xing, X., Sorgi, F., Huang, L. and Yu, D. HER-2/*neu*: targeting gene therapy. *Gene*, 159:65-71, 1995.
14. Chang, C-J., Ashendel, C.L., Geahlen, R.L., **Hung, M.-C.**, McLaughlin, J.L. and Waters, D.L. Oncogene-Modulated Signal Transduction Inhibitors from Plants. *The Royal Society of Chemistry*, 170-178, 1997.
15. Yu, D. and **Hung, M.-C.** The *erbB2* gene as a cancer therapeutic target and the tumor-and metastasis-suppressing function of E1A. *Cancer and Metastasis Reviews*, 17:195-202, 1998.
16. Hortobagyi, G.N., **Hung, M.-C.** and Lopez-Berestein, G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/*neu* or epithelial ovarian cancer. *Human Gene Therapy*, 9:1775-1798, 1998.
17. **Hung, M.-C.** Tumor Suppression Activity of Adenovirus 5 E1A in Prostate Cancer. *Cancer Research Therapy Control*, 7:221-223, 1998.
18. Hortobagyi, G.N., **Hung, M.-C.** and Buzdar, A.U. Recent Developments in Breast Cancer Therapy. *Seminars in Oncology*, 26 (12):11-20, 1999.
19. Pusztai, L., Hortobagyi, G.N., **Hung, M.-C.** and Buzdar, A.U. Advances and Future Directions in Breast Cancer Therapy. *Proc. of the 22<sup>nd</sup> Congress of the International Association for Breast Cancer Research*, Bologna, Italy, 79-83, 1999.
20. **Hung, M.-C.** and Ueno, N.T. Targeting HER-2/*neu* overexpression: Transcriptional repression of HER-2/*neu* by adenovirus type 5 E1A as a cancer gene therapy. *Proc. of the "22<sup>nd</sup> Congress of the International Association for Breast Cancer Research*, 85-95, 1999.
21. **Hung, M.-C.** and Lau, J.Y-K. Basic Science of HER-2/*neu* - A review. *Seminars in Oncology*, 26:51-59, 1999.
22. Pusztai, L., Esteva, F., Cristofanilli, M., **Hung, M.-C.** and Hortobagyi, G.N. Chemo-signal therapy, an emerging new treatment modality for cancer. *Cancer Treatment Reviews*. 25:271-277, 1999.
23. Lin, S.-Y. and **Hung, M.-C.** Cancer: Current concepts. *J. Clin. Ligand Assay* 22:1-5, 1999.
24. Yu, D. and **Hung, M.-C.** Role of *erbB2* in breast cancer chemosensitivity. *Bioassay* 22:673-680, 2000.
25. **Hung, M.-C.** and Hu, M. C-T. Basic science of HER2/*neu*: A review. *Physician's Education Resource* 1:5-8, 2000.
26. Shen, Y.C., Chen, C.Y. and **Hung, M.-C.** Tazane diterpenoids from seeds of *Taxus mairei*. *Chem. Pharm. Bull. (Tokyo)* 48:1344-1346, 2000.
27. Yu, D., and **Hung, M.-C.** Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. *Oncogene* 19:6115-6121, 2000.
28. Wang, S.-C. and **Hung, M.-C.** Transcriptional targeting of the HER-2/*neu* oncogene. *Drugs of Today* 36:835-843, 2000.
29. Wang, S.-C., Zhang, L., Hortobagyi, G.N. and **Hung, M.-C.** Targeting HER-2: recent Developments and Future Directions for Breast Cancer Patients. *Seminars in Oncology* 28:21-29 Suppl., 2001.



30. Wang, S.-C. and **Hung, M.-C.** HER2 overexpression and cancer targeting. *Seminars in Oncology* 28:115-124 Suppl. 2001.
31. Ueno, N.T., Yu, D.-H. and **Hung, M.-C.** E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. *Breast Cancer* 8:285-294, 2001.
32. **Hung, M.-C.** Translational Research: E1A cancer gene therapy and  $\beta$ -catenin prognostic marker. *Drugs of Today* 38: 21-35 Suppl. 2002.
33. Meric, F., **Hung, M.-C.**, Hortobagyi, G.N. and Hunt, K.K. HER2/*neu* in the management of invasive breast cancer. *J. Amer. Coll. Surgeons* (Collective Review), 194:488-501, 2002.
34. Zhou, B.P. and **Hung, M.-C.** Novel targets of Akt, p21<sup>cip1/WAF1</sup> and Mdm2. *Seminars in Oncology* 29:62-70, 2002.
35. Zhou, B.P., and **Hung, M.-C.** Oncogene and Apoptosis. *Breast Disease* 2002
36. Zhou, B.P., Li, Y. M. and **Hung, M.-C.** HER-2/*neu* signaling and therapeutic approaches in breast cancer. *Breast Disease* "Novel Targets in Breast Disease"15:13-24, 2002
37. Kaye, S.B., Gershenson, D., **Hung, M.-C.** and Seiden M. "Discussion: Molecular Therapeutics & Pharmacogenomics" *Gynecologic Oncology* (Collective Review) 2002.
38. Chen, J.-S., Lan, K., and **Hung, M.-C.** Strategies to target HER2/*neu* overexpression for cancer therapy. *Drug Resistant Updates* 6:129-13, 2003.
39. Zhou, B.P. and **Hung, M.-C.** Dysregulation of cellular signaling by HER2/*neu* in breast cancer. *Seminars in Oncology* 30:38-48, suppl. 2003.
40. Wang, S-C. and **Hung, M.-C.** Commentary - "Finding the bEST routes to cancer" on "Identification of Novel Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas through a Bioinformatics Analysis of Expressed Sequence Tags" by Cao, D. et al. *Cancer Biology and Therapy* 3:1090-1091, 2004.
41. Hu, M.C-T. and **Hung, M.-C.** Role of I $\kappa$ B kinase in tumorigenesis. *Future Oncology* launch issue, 1:67-78, 2005.
42. Kumar, R. and **Hung, M.-C.** Signaling intricacies take center stage in cancer cells. *Cancer Research* 65:2511-2515, 2005.
43. Zhou, BP. and **Hung, M.-C.** Extra-Reviews/Perspective "Wnt, Hedgehog and Snail: sister pathways that control by GSK-3 $\beta$  and  $\beta$ -Trecp in the regulation of metastasis." *Cell Cycle* 4:772-776, 2005.
44. **Hung, M.-C.** Profiles and Legacies "When all colonies are blue". *Cancer Biology & Therapy* 4:612-614, 2005.
45. Rau, K-M., Kang, H-Y., Cha, T-L., Miller, S.A. and **Hung, M.-C.** The similarities and differences of mechanisms of resistance to antihormone therapies in breast cancer and prostate cancer\*. *Endocrine-related cancer* 12:511-532, 2005. \*Peer-reviewed.
46. Lo, W-H., Hsu, S-C. and **Hung, M.-C.** EGFR signaling pathway in breast cancer: from traditional signal transduction to direct nuclear translocation. *Breast Cancer Res and Treatment*, (Epub on Nov 1, 2005) 95:211-218, 2006.
47. Lo, H-W. and **Hung, M.-C.** Nuclear EGFR signaling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival\*. *British J. Cancer*, 94: 184-188, 2006. \*Peer-reviewed.
48. Nahta, R., Yu, D., **Hung, M.-C.**, Hortobagyi, GN. and Esteva, FJ. Mechanisms of Disease: understanding resistance of HER2 therapy in human breast cancer. *Nat Clin Pract Oncol* 3:269-280, 2006.
49. Meric-Bernstam, F and **Hung, M.-C.** Advances in targeting HER2 signaling in cancer therapy. *Clinical Cancer Res.*12: 6326-6330, 2006.

50. Su, J.-L., Yen, C.-J., Chen, P.-S., Chuang, S.-E., Hong, C.-C., Kuo, I.-H., Chen, H.-Y., Hung, M.-C., and Kuo, M.-L. The role of the VEGF-C/VEGFR-3 axis in cancer progression\*. *Br. J. Cancer* (Epub December 12, 2006) 96:541-545, 2007. \*Peer-reviewed.
51. Izzo, JG., Luthra, R., Wu, TT., Correa, AM., Luthra, M., Anandasabapathy, S., Chao, KS., **Hung, M.-C.**, Aggarwal, B., Hittelman, WN. and Ajani, JA. Molecular mechanism in Barrett's metaplasia and its progression. *Semin. Oncol.* 34 (2 Suppl 1): S2-6, 2007.
52. Brugge J, Hung, M-C and Mills GB. Previews "A new mutational *aktivation* in the PI3K pathway". *Cancer Cell*, 12:104-107, 2007.
53. Cheng, X-Y and **Hung, M.-C.** Breast cancer brain metastasis. Special edition of Cancer Metastasis Reviews (Impact Factor 8.04) entitled "40 Years of Metastasis Research", (Epub August 24), 26(3-4):635-643, 2007.
54. Lee, D-F and **Hung, M.-C.** All roads lead to mTOR: integrating inflammation and tumor angiogenesis. *Cell Cycle*, (Epub Sept 20) 6:3011-3014, 2007.
55. Lee, D-F and **Hung, M.-C.** Advances in targeting IKK and IKK-related kinases for cancer therapy. *Clinical Cancer Research* (Sep 15) 14:5656-5662, 2008. (NIHMS76174)
56. **Hung, M.-C.**, Mills, G.B. and Yu, D. Oxygen sensor boosts growth factor signaling. *Nature Medicine, News and Views*, 15:246-247, 2009.
57. Yang, J-Y and **Hung, M.-C.** A new fork for clinical application: targeting forkhead transcription factors in cancer. *Clinical Cancer Research* 15:752-757, 2009. (NIHMS106695)
58. Huang, W-C. and **Hung, M.-C.** Induction of Akt activity by chemotherapy confers acquired resistance. *J Formos Med Asso* 108:180-194, 2009.

#### **Invited Articles/Reviews (submitted/in preparation)**

1. Wang, S-C. and Hung, M-C. Emerging functions of membrane tyrosine kinase receptors in the nucleus\*.

#### **Published or Accepted Book Chapters:**

1. Yu, D. and **Hung, M.-C.** HER-2/*neu* gene in human cancer. *In: Molecular Basis of Oncology* E.J. Freireich and S.A. Stass (Eds.), Blackwell Science Inc, pp.131-162, 1995.
2. **Hung, M.-C.**, Chang, J.Y. and Xing, X. Preclinical and Clinical Study of HER-2/*neu*-targeting Cancer Gene Therapy. *In: Advanced Drug Delivery Reviews*, E. Tomlinson, S. Hirota, Lee, V.H.L., Pouton, C.W. (Eds.), Elsevier Science B.V., Vol. 30, pp.219-227, 1998.
3. Hortobagyi, G.N. and **Hung, M.-C.** The Role of the HER-2 Gene and its Product in the Management of Primary and Metastatic Breast Cancer Educational Book, M.-C. Perry (Ed.), American Society of Clinical Oncology, pp.146-154, 1998.
4. **Hung, M.-C.** and Wang, S.-C. Transcriptional Repression in Cancer Gene Therapy: Targeting HER-2/*neu* overexpression as an example. *In: Gene Therapy and Molecular Biology*, vol 3, Teni Boulikas (Ed.), Gene Therapy Press, Palo Alto, CA. pp.3:1-11, 1998.
5. Yu, D. and **Hung, M.-C.** Translational Research in Breast Cancer. *In: Breast Cancer in the M.D. Anderson Solid Tumor Series*, E. Singletary (Ed). Springer-Verlag New York, Inc., pp.345-356, 1999.
6. **Hung, M.-C.**, Wang, S.-C., and Hortobagyi, G.N. Targeting HER-2/*neu*-overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome. *In: Cancer Gene Therapy using Cationic Liposome: Preclinic and Clinic Studies*, L. Huang, M.-C. Hung, E. Wagner (Eds.). Academic Press, San Diego, CA, pp.357-377, 1999.

7. **Hung, M.-C.** and Wang, S.-C. Suppressing HER-2/neu-mediated cell transformation by transcriptional repressors. *In: Breast Disease*, E. Liu and Y. Yarden (Eds.), IOS Press, The Netherlands, pp.133-144, 2000.
8. **Hung, M.-C.**, Hortobagyi, G.N., and Ueno, N.T. Development of clinical trial of *E1A* gene therapy targeting HER-2/*neu*-overexpressing breast and ovarian cancer. *In: Cancer Gene Therapy*, N.A. Habib (Ed.), Kluwer Academic/Plenum Publishers, pp.171-180, 2000.
9. **Hung, M.-C.** and Yu, D. Therapeutic resistance of erbB2-overexpressing cancers and strategies to overcome this resistance. *In: DNA alterations in cancer: Genetic and epigenetic changes*, M. Ehrlich (Ed.), Bio Techniques Books, Eaton Publishing, pp.457-470, 2000.
10. **Hung, M.-C.**, Yan, D.-H., and Zhang, S. *E1A*-mediated gene therapy. *In: Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols*, J.M.S. Bartlett (Ed.), Human Press, Inc., pp.775-782, 2000.
11. Yu, D. and **Hung, M.-C.** Anti-tumor Effects of Adenoviral *E1A* on HER2-overexpressing Tumor Cells. *In: Oncogenes Directed Therapies*, Aizen J. Marrogi, Scott M. (Eds.), 2001.
12. Yan, D.-H., Shao, R. and **Hung, M.-C.** *E1A* cancer gene therapy. *In: Gene therapy of cancer*, 2<sup>nd</sup> Ed, Panner, C. (Ed.), Academic Press, San Diego, CA. pp.465-477 2001.
13. Hu, M.C-T., Xia, W. and **Hung, M.-C.** Maspin, a Potential Prognostic Marker for Human Cancers. *In: Maspin*. Hendrix, M.J.C. (Ed.), Landes Biosciences, TX. pp.125-129, 2002.
14. Wen, Y. and **Hung, M.-C.** Chapter 39: Beta-catenin and maspin as tumor markers. *In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications*. Diamandis, E.P. et al. (Ed.), AACC Press, Washington, DC, pp437-440, 2002.
15. Yan, D.-H., Spohn, B. and **Hung, M.-C.** Chapter 9: Delivery of DNA to tumor cells using cationic liposomes. *In: Methods in Molecular Biology, Vol. 245: Gene Delivery to Mammalian Cells: Vol. 1: Nonviral Gene Transfer Techniques*. Heiser, W.C. (Ed.), Humana Press Inc. Totowa, N.J. pp.125-135, 2003.
16. Yan, D.-H., Rau K.-M. and **Hung, M.-C.** Chapter 19: Antimetastasis. *In: From Contemporary Cancer Research: Cancer Gene Therapy*, Curiel, D.T. and Douglas, J.T. (Eds), Humana Press Inc. Totowa, N.J. pp.287-298, 2004.
17. Lo, H-W., Day C.-P. and **Hung, M.-C.** Section 3: Animal Model and Clinical Study, Chapter 10: Cancer-specific gene therapy. *In: Non-Viral Vectors for Gene Therapy*. 2<sup>nd</sup> Edition: Part II. Huang, L., **Hung, M.-C.**, and Wagner, E. (Eds), Elsevier Academic Press, pp. 235-255, 2005.
18. Wang, S-C. and **Hung, M.-C.** Cytoplasmic/nuclear shuttling and tumor progression. *In: Tumor Progression and Therapeutic Resistance*, Vol. 1059: 11-15, *Ann. N. Y. Acad. Sci.* El-Deiry W.S. (Ed.), New York Academy of Sciences, 2005.
19. Ueno, U.T., Wolf, J.K., Gershenson, D.M., Hortobagyi, G.N. and **Hung, M.-C.** Chapter 21: Trials and tribulations in developing clinical trials of gene therapy: *E1A* for breast or ovarian cancer. *In: Cancer Drug Discovery and Development: Gene Therapy for Cancer*. Kelly Hunt, Stephan A. Vorburger and Stephen G. Swisher (Eds), Humana Press Inc., Totowa, NJ, pp. 387-398, 2007.
20. **Hung, M.-C.** and Yan, D-H. Chapter 24: Development of therapeutic genes for breast cancer treatment. *In: Cancer Drug Discovery and Development: Gene Therapy for Cancer*. Kelly Hunt, Stephan A. Vorburger and Stephen G. Swisher (Eds), Humana Press Inc., Totowa, NJ, pp. 435-446, 2007.
21. Rau, K-M., Day C-P and **Hung, M.-C.** Chapter 34: Breast Cancer Gene Therapy. *In: Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches*. Piccart, M.J.,

- Wood, W., **Hung, M.-C.**, Solin, L., and Cardoso, F. (Eds), Springer-Verlag, Heidelberg, Germany, pp 705-740, 2007.
22. Lo, H-W, Wang, S-C. and **Hung, M.-C.** Chapter 38: Novel Signaling Pathways in Breast Cancer. *In: Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches.* Piccart, M.J., Wood, W., **Hung, M.-C.**, Solin, L., and Cardoso, F. (Eds), Springer-Verlag, Heidelberg, Germany, pp. 823-839, 2007.
  23. Liao, Y., Yu, D. and **Hung, M.-C.** Chapter 11: Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story. *In: Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, Vol. 608.* Yu, D. and **Hung, M.-C.** (Eds), Landes Bioscience, pp.144-169, 2007.

#### **Book Chapters (submitted/in preparation)**

- 1.

#### **Serving as an Editor in Book**

1. Huang, L., **Hung, M.-C.** and Wagner, E. Non-Viral Vectors for Gene Therapy. Academic Press, 1999.
2. Huang, L., **Hung, M.-C.** and Wagner, E. Non-Viral Vectors for Gene Therapy. 2<sup>nd</sup> Edition Part I & Part II. Elsevier Academic Press, 2005.
3. Piccart, M.J., Wood, W., **Hung, M.-C.**, Solin, L. and Cardoso, F. Breast Cancer Management in the Era of Molecular Medicine-towards tailored approaches. Springer-Verlag, Heidelberg, Germany, 2007.
4. Yu, D. and **Hung, M.-C.** Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, Vol. 608. Landes Bioscience, 2007.

#### **Abstracts:**

8 in 1989; 12 in 1990; 18 in 1991; 18 in 1992; 18 in 1993; 18 in 1994; 20 in 1995; 20 in 1996, >20 in 1997, >20 in 1998; >20 in 1999; >20 in 2000; >20 in 2001

#### **Letter to Editors:**

1. **Hung, M.-C.** Inhibition of Breast Cancer Progression by an Antibody to a Thrombospondin-1 Receptor. *Breast Diseases*, 8:27, 1997.
2. **Hung, M.-C.** and Zhou, B.P. Recombinant Humanized Anti-HER2 Antibody (Herceptin<sup>TM</sup>) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts. *Breast Diseases*, 1999.
3. Hortobagyi, G.N., Ueno, N.T. and **Hung, M.-C.** E1A is an oncogene and may immortalize normal cells especially in combination with other oncoproteins. *J. Clin. Oncol.* 19:4183-4184, 2001.
4. Bourguignon, L.Y.W., Lan, K-H., Singleton, P., Lin, S-Y., Yu, D. and **Hung, M.-C.** Localizing the EGF receptor-Reply. *Nature Cell Biol.* 4:E22-23, 2002.
5. **Hung, M.-C.**, Fong, K. and Li, J.K. Asian scientists and the “glass ceiling”. *Science* Dec 16, 310:1767-1768, 2005.

6. Su, J-L, Chen, P-S., Chien, M-H., Chen PS B, Chen, Y-H., Lai, C-C., \*Hung, M-C., \*Kuo, M-L. Further evidence for expression and function of VEGF-C/VEGFR-3 axis in cancer cells. *Correspondence, Cancer Cell* 13:557-560, 2008. \*Co-corresponding authors.

**Editorships and Editorial Board Memberships:**

Oncology Reports, 1994-present.

Biomedical Journal, 1994 – 1996.

Gene Therapy and Molecular Biology, 1998 – present.

Cancer Letters, 1999-present.

Clinical Cancer Research, 1999 – present.

**The ScientificWorld, Principal Editor in Molecular and Gene Therapy, 2000 – present.**

Cancer Biology and Therapy, Editorial Board, 2001-present.

**Cancer Cell (by Cell Press), Founding Editorial Member, February 2002 – present.**

China Oncology (published by Cancer Hospital, Fudan University, Shanghai, PRC), March 2002 – present.

International Journal of Oncology, June 2002 – present.

**Cancer Research, Associate Editor, October 21, 2002-December 31, 2009.**

Molecular Cancer Research, Editorial Member, February 2003 – present.

Molecular Carcinogenesis, Associate Editor, April 2003 – present.

Current Cancer Therapy Reviews, Editorial Member, January 2005- present.

**American Journal of Translational Research, Associate Editor-in-Chief, January 2009 - present.**

**Referee for manuscript publication in many journals including:**

*Cell,*  
*Science*  
*New England Journal of Medicine*  
*Nature Genetics,*  
*Nature Medicine,*  
*Nature Reviews Molecular Cell Biology,*

*Proc. Natl. Acad. Sci.,*  
*Cancer Cell,*  
*Molecular Cell,*  
*Mol. Cell. Biol.,*  
*J. Biol. Chem.,*  
*Cancer Res.,*  
*Clinical Cancer Res.,*  
*Federation of American Societies for Experimental Biology (FASEB) Journal,*  
*Cell Death and Differentiation,*  
*Molecular Cancer Research (Formerly CG&D),*  
*Oncogene,*  
*Br. J. Cancer,*  
*Cancer Gene Therapy (Nature publishing),*  
*J. Cell. Biochem.,*  
*J. Cell Sci.,*  
*Cell Growth & Differentiation,*  
*American Journal of Pathology*  
*Bioassays,*  
*Biotechniques,*  
*Breast Cancer Research and Treatment,*  
*Biol. of the Cell,*  
*Life Science J.,*  
*Intl J. Cancer,*  
*Clinical and Experimental Metastasis,*  
*Cancer,*  
*Cancer Biology and Therapy*  
*Oncology,*  
*JAMA,*  
*Breast Diseases,*  
*Cancer Letters,*  
*European Journal of Gastroenterology & Hepatology,*  
*Journal of Molecular Medicine,*  
*Oral Oncology*  
*J. Clin Invest.*

**Formal Teaching:**

**a. Courses Taught:**

Summer Course in UTSPH, "The Foundations of Modern Human Genetics II," Oncogene--Cancer-Inducing Gene, July 20, 2001.

GSBS 0113 Mechanisms of Carcinogenesis "Molecular Therapeutics II, Spring semester, 2001, Austin, TX.

Seminar Series, Core Curriculum, 1998 – present.

Seminar Course (Coordinator) "Current Topics on Oncogene Research" Spring semester, 1989-2005.

Human Gene Therapy Course: Basic Science to Clinical Trial - 1 hr, Spring 1998 – present.

Molecular Basis of Oncogenes (Coordinates with Dr. Gary Gallick and Lecturer), 12 hrs, Fall semester, 1987-2005.

Introductory Cell Biology - 2 hrs Spring 1988.

Virology II - 2 hrs Spring 1989-1990.

Molecular/Cellular Approaches to Human Genetics 2 hrs -Spring 1989-1998.

Special Seminar Courses for M.D./Ph.D. students - 4 hrs Fall, 1989.

Seminar Series for Regulatory Biology Program, 3 hrs, Fall 1993.

Molecular Genetics Seminar, 1 hr., Fall, 1993.

Cancer Cell Signaling (Formerly Molecular Basis of Oncogenes, Coordinates with Dr. Gary Gallick), 2 hours, Spring Semester, 2005- present.

Current Topics in Oncogene Research (Coordinator), 16 hours, Spring Semester, 2005-present.

**b. Training Programs:**

U.S. Army Training Programs in Breast Cancer Research at the UTMDACC, U.S. Army Medical Research, Grant No. DAMD17-99-1-9264-1, M.-C. Hung, P.I., September 1999 - August 2004\*. (\*an one-time one year no cost extension from September 2003-Aug 2004).

Training Grant in Bioimmunotherapy, BITG Grant, October 1998 – present.

Training Grant in Molecular Pathology, CA67759 (T32Grant) May 1998 – present.

Training in Interdisciplinary Studies of Cancer Biology, CA60440, (T32 Grant) September 1993 – present.

Training Program in General Surgery, NIH CA09599, Training of Academic Surgical Oncologists (T32 Grant), April, 1992 – present.

Training Grant for Academic Gynecologic Oncologists, T-32 Training Grant in Gynecologic Oncology (July 1996 - present).

Training Program in Molecular Genetics of Cancer, CA-09299-11, October 1989 – present.

Program in Training of Academic Thoracic Surgical Oncologist, 5T32CA 09611, July 1988 - June 1993.

**c. Other GSBS Educational Programs:**

Cancer Biology Program, GSBS, 1986-present.  
Virology Program, GSBS, 1986-1996.  
Molecular Pathology Program, GSBS, 1998-present.  
Virology and Gene Therapy Program, GSBS, 1996-present.  
Environmental and Mol Carcinogenesis Program, GSBS, 1999-5/2005.  
Molecular Carcinogenesis Program, GSBS, 5/2005- present.

**d. Supervisory Teaching:**

**1. Advisory and Supervisory Committees**

**Advisory Committees (82)**

1. Member, Sterner, Deborah, Ph.D./May 1990, 10/1986–5/1990
2. Chair, Yan, Duen-Hwa, Ph.D./May 1991, 4/1987–12/1988
3. Member, Yu, Dihua, Ph.D./May 1991, 6/1987–4/1990
4. Member, Li, Li, Ph.D./Dec 1991, 6/1987–6/1990
5. Chair, Zhao, Xiaoyan, Ph.D./May 1992, 6/1987–10/1990
6. Member, Zamaniyan, Farideh, Ph.D./August 1991, 8/1987–10/1989
7. Member, Lagoo-Deenadlayan, Sandhya, Ph.D./August 1990, 9/1987–9/1989
8. Member, Chiocca, Susanna, Ph.D./August 1989, 11/1987–2/1989
9. Member, Goodacre, Angela, Ph.D./August 1989, 2/1988–1/1989
10. Member, Ridall, Amy, Ph.D./May 1995, 3/1988–9/1989
11. Chair, Suen, Ting-Chun, Ph.D./Dec 1990, 4/1988–6/1989
12. Member, Bai, Weinlong, Ph.D./May 1992, 4/1988–11/1989
13. Chair, White, Margaret, Ph.D./Dec 1994, 6/1988–6/1992



14. Chair, Chou, Marian, Ph.D., 12/1988–5/1990
15. Member, Narayana, Lakshmi, M.S./May 1990, 6/1989–12/1989
16. Mmember, Camacho, Tres, Ph.D., 6/1989–6/1991
17. Chair, Reardon, Dean, Ph.D./Dec 1994, 6/1989–12/1991
18. Member, Neiderreither, Karen, Ph.D./Aug 1993, 6/1989–7/1992
19. Member, Cheng, Tse-Chang, Ph.D./Aug 1993, 9/1989–10/1992
20. Chair, Yen, Rong-Lang, Ph.D./May 1994, 10/1989–3/1992
21. Chair, Russell, Kerry, M.D., Ph.D./May 1992, 2/1990–5/1991
22. Member, D'Souza, Ian, M.S./May 1996, 3/1990–9/1993
23. Chair, Miller, Susan, Ph.D./Aug 1994, 6/1990–9/1992
24. Member, Huang, Jianyl, Ph.D./Dec 1997, 6/1990–9/1993
25. Chair, Doyle, Barbara, Ph.D., 9/1990–4/1992
26. Member, Newell, Christine J, Ph.D./Aug 1993, 10/1990–11/1991
27. Member, Marini, Frank, Ph.D./May 1995, 11/1990–6/1993
28. Chair, Marin-Vieira, Maria, Ph.D./May 1996, 7/1991–2/1993
29. Member, Kruzelock, Russell, Ph.D./Aug 1995, 7/1991–3/1994
30. Member, Tang, Ping, Ph.D./Aug 1995, 2/1992–9/1994
31. Member, Tu, Shi-Ming, Ph.D., 6/1992–5/1993
32. Member, Ainsworth, Jerry, Ph.D./Aug 1995, 6/1992–4/1994
33. Member, Cheng, Ann Joy, Ph.D./Dec 1995, 6/1992–7/1994
34. Member, Chang, Hung-Junn, Ph.D./Aug 1995, 6/1992–11/1994
35. Member, Fisk, Bryan, M.S./Sept 1993, 8/1992–1/1993
36. Member, Wolf, Judith, M.S./Dec 1993, 9/1992–4/1993
37. Chair, Brown, Mary Elizabeth, Ph.D./July 1993, 10/1992–7/1993
38. Member, Lo, Hui-Wen, M.S./May 1994, 6/1993–5/1994
39. Member, Li, Xiaoli, M.S./Jan 1994, 6/1993–9/1994

40. Chair, Xie, Youming, Ph.D./May 1996, 6/1993–5/1995
41. Member, Zhao, Bin, Ph.D., 12/1993–12/1995
42. Chair, Guo, Qian, M.S., 8/1994–8/1995
43. Chair, Chang, Yujiao, Ph.D., 8/1994–3/1996
44. Member, Montoya, Roselina, Ph.D./Aug 1999, 8/1994–5/1998
45. Chair, Xing, Xiangming, Ph.D., 10/1994–5/1997
46. Chair, Deng, Jiong, Ph.D., 10/1994–7/1997
47. Chair, Li, Kaiyi, Ph.D., 10/1994–6/1998
48. Chair, Kwong, Ka-Yin Simon, Ph.D., 2/1995–4/1999
49. Chair, Lau, Yiu-Keung James, M.D., Ph.D., 8/1995–3/1997
50. Chair, Wang, Sung-Ling, Ph.D./Dec 1999, 12/1995–9/1996
51. Chair, Lee, Eun Kyung, M.D., Ph.D., 2/1996–1/2000
52. Chair, Lin, Shiao-Yih Phoebus, Ph.D., 10/1996–1/1999
53. Chair, Lee, Wei-Ping, Ph.D., 8/1997–5/1999
54. Chair, Von Lindern, Ryan, Ph.D., 10/1998–5/2002
55. Chair, Miller, Stephanie, Ph.D., 12/1998–11/2002
56. Chair, Wen, Yong, Ph.D., 2/1999–3/2001
57. Member, Ghunye, Shilpa, Ph.D./Dec 2003, 2/1999–10/2001
58. Chair, Yu, Zhenming, Ph.D., 4/1999–1/2002
59. Chair, Li, Yan, Ph.D., 1/2001–7/2003
60. Member, Bartholomeusz, Chandra, Ph.D./May 2004, 6/2001–9/2003
61. Chair, Day, Chi-Ping, Ph.D., 8/2001–7/2003
62. Chair, Lee, Christine, M.S., 3/2002–10/2002
63. Chair, Cha, Tai-Lung, Ph.D., 9/2002–7/2004
64. Chair, Lee, Dung-Fang, Ph.D., 9/2003–3/2006
65. Chair, Chou, Chao-Kai, Ph.D., 10/2004–2/2007
66. Chair, Cheng, Xiaoyun, Ph.D.C, 12/2004–8/2007
67. Member, Christianson, Dawn, Ph.D., 3/2005–3/2006
68. Chair, Yang, Jer-Yen, Ph.D., 3/2005–10/2007
69. Chair, Kuo, Hsu-Ping, Ph.D., 11/2005–10/2007
70. Member, Aguilar, Richard Jason, Ph.D., 12/2005–8/2006
71. Chair, Trinh, Bon Quy, Ph.D., 12/2005–8/2006
72. Chair, Hsu, Jung-Mao, Ph.D., 12/2005–3/2008
73. Chair, Yang, Cheng-Chieh, Ph.D., 12/2005–5/2008
74. Chair, Du, Yi, Ph.D., 11/2006–present
75. Chair, Song, Hui, Ph.D., 11/2006–09/2008
76. Chair, Chen, Chun-Te, Ph.D., 7/2007–present
77. Chair, Saldana, Sandra, Ph.D., 7/2007–present
78. Chair, Liu, Mo, Ph.D., 10/2007-present
79. Chair, Labaff, Adam, Ph.D., 10/2007-present
80. Chair, Shen, Jia, Ph.D., 5/2008-present
81. Chair, Hong-Jen, Lee, Ph.D., 5/2008-present
82. Chair, Heng-Huan, Lee, Ph.D., 5/2008-present

### **Supervisory Committees (77)**

1. Member, Krizman, David, Ph.D./Dec 1988, 4/1987–12/1988
2. Member, Hwang, Bih-Chen Charles, Ph.D./May 1989, 7/1987–5/1989
3. Member, DeMars, Maryellen, Ph.D./ December 1989, 11/1987–12/1989
4. Member, Hu, Jingshan, Ph.D./August 1989, 1/1988–8/1989
5. Member, Rachal, Mack, M.D., Ph.D. /May 1989 Graduation, 4/1988–5/1989
6. Member, Chiao, Paul, Ph.D./May 1991, 8/1988–8/1991

7. Member, Gan, Lin, Ph.D./Dec 1992, 9/1988–10/1988
8. Member, Sterner, Deborah, Ph.D./May 1990, 9/1988–5/1990
9. Chair, Matin, Angabin, Ph.D./May 1993, 11/1988–5/1993
10. Member, Chiocca, Susanna, Ph.D./May 1990, 2/1989–7/1990
11. Chair, Suen, Ting-Chun, Ph.D./ Dec 1990, 6/1989–12/1990
12. Member, Ridall, Amy, Ph.D./May 1995, 9/1989–5/1995
13. Member, Zamaniyan, Farideh, Ph.D./August 1991, 10/1989–8/1991
14. Member, Narayana, Lakshmi, M.S./May 1990, 12/1989–5/1990
15. Member, Jin, Li, Ph.D./Aug 1992, 2/1990–8/1992
16. Member, Hinkley, Craig, Ph.D./Aug 1992, 3/1990–8/1992
17. Chair, Yu, Dihua, Ph.D./May 1991, 4/1990–5/1991
18. Chair, Chou, Marian, M.S., 5/1990–2/1991
19. Member, Li, Li, Ph.D./Dec 1991, 6/1990–12/1991
20. Chair, Zhao, Xiaoyan, Ph.D./May 1992, 10/1990–5/1992
21. Chair, Russell, Kerry, M.D., Ph.D./May 1992, 5/1991–5/1992
22. Member, Pierceall, William, Ph.D./Aug 1992, 5/1991–8/1992
23. Member, Xie, Keping, Ph.D./May 1995, 7/1991–6/1994
24. Chair, Reardon, Dean, Ph.D./Dec 1994, 8/1991–12/1994
25. Member, Newell, Christine J, Ph.D./Aug 1993, 11/1991–8/1993
26. Member, Ohannesian, David, Ph.D./Dec 1994, 2/1992–12/1994
27. Member, Zhang, Wei, Ph.D./Dec 1992, 3/1992–12/1992
28. Chair, White, Margaret, Ph.D./Dec 1994, 6/1992–12/1994
29. Member, Zhang, Xiaohong, Ph.D., 7/1992–11/1993
30. Chair, Miller, Susan, Ph.D./Aug 1994, 9/1992–8/1994
31. Chair, Yen, Rong-Lang, Ph.D./May 1994, 12/1992–5/1994
32. Member, Fisk, Bryan, M.S./Sept 1993, 1/1993–9/1993
33. Member, Wolf, Judith, M.S./Dec 1993, 4/1993–12/1993
34. Member, Marini, Frank, Ph.D./May 1995, 6/1993–5/1995
35. Chair, Brown, Mary Elizabeth, M.S./ Dec 1993, 7/1993–11/1993
36. Huang, Jianyi, M.S./ Dec 1993, 9/1993–12/1993
37. Member, Zhang, Xiaohong, M.S./May 1998, 11/1993–2/1994
38. Member, Tang, Ping, Ph.D./Aug 1995, 1/1994–8/1995
39. Member, Lo, Hui-Wen, Ph.D./May 2002, 5/1994–4/2000
40. Member, Xie, Keping, Ph.D./May 1995, 6/1994–5/1995
41. Member, Li, Xiaoli, M.S./May 1998, 9/1994–8/1995
42. Chair, Xie, Youming, Ph.D./May 1996, 5/1995–5/1996
43. Chair, Guo, Qian, M.S./Aug 1995, 8/1995
44. Member, Tan, Ming, Ph.D./May 2000, 12/1995–5/1998
45. Chair, Chang, Yujiao, Ph.D./May 1997, 3/1996–5/1997
46. Chair, Lau, Yiu-Keung James, M.D., Ph.D./May 2002, 3/1997–5/2002
47. Chair, Xing, Xiangming, Ph.D./May 1998, 5/1997–5/1998
48. Member, St. John, Lisa, Ph.D./May 1999, 5/1997–5/1999
49. Chair, Deng, Jiong, Ph.D./May 1998, 7/1997–4/1998
50. Chair, Ueno, Naoto, Ph.D./May 1999, 3/1998–6/1999
51. Chair, Li, Kaiyi, Ph.D./Aug 1999, 6/1998–8/1999
52. Chair, Yan, Duen-Hwa, Ph.D./May 1991, 12/1998–5/1991
53. Chair, Lin, Shiaw-Yih Phoebus, Ph.D./Dec 1999, 1/1999–11/1999
54. Chair, Lee, Wei-Ping, Ph.D./May 2000, 5/1999–5/2000
55. Chair, Lee, Eun Kyung, M.D., Ph.D., 1/2000–5/2000
56. Chair, Kwong, Ka-Yin Simon, Ph.D./May 2001, 4/2000–6/2001
57. Chair, Wen, Yong, Ph.D./Aug 2001, 3/2001–8/2001
58. Chair, Yu, Zhenming, Ph.D./May 2003, 1/2002–5/2003

59. Chair, Von Lindern, Ryan, M.S./Dec 2002, 5/2002–12/2002
60. Chair, Lee, Christine, M.S./May 2003, 10/2002–5/2003
61. Chair, Miller, Stephanie, Ph.D./Aug 2003, 11/2002–8/2003
62. Member, Lan, Keng-Hsueh, Ph.D./May 2005, 1/2003–5/2005
63. Chair, Li, Yan, Ph.D./May 2004, 7/2003–5/2004
64. Chair, Day, Chi-Ping, Ph.D./Aug 2005, 7/2003–8/2005
65. Chair, Cha, Tai-Lung, Ph.D./Aug 2005, 7/2004–8/2005
66. Member, Song, Chunying, Ph.D./May 2007, 11/2004–5/2007
67. Member, Hawthorne, Valerie, Ph.D./Dec 2006, 4/2005–12/2006
68. Member, Lu, Jing, Ph.D./May 2008, 9/2005–5/2008
69. Chair, Lee, Dung-Fang, Ph.D./June 2008, 3/2006–6/2008
70. Chair, Chou, Chao-Kai, Ph.D., 2/2007–present
71. Member, Yang, Jun, Ph.D., 5/2007–present
72. Chair, Cheng, Xiaoyun, Ph.D., 8/2007–present
73. Chair, Yang, Jer-Yen, Ph.D., 10/2007–present
74. Chair, Kuo, Hsu-Ping, Ph.D., 10/2007–present
75. Chair, Hsu, Jung-Mao, Ph.D., 3/2008–present
76. Chair, Yang, Cheng-Chieh, Ph.D., 5/2008–present
77. Chair, Song, Hui, Ph.D., 9/2008–present

## 2. GSBS Tutorial 10 Weeks Lab Rotation: (83)

1. Yu, Dihua	Summer	1987
2. Zhao, Guangquan	Winter	1987
Zhao, Guangquan	Fall	1988
3. Abuhamad	Spring	1988
4. Bianchi, Albert	Summer	1988
5. Holzmacher, Elizabeth	Spring	1988
6. Matin, Angabin	Spring	1988
7. Ridall, Amy	Spring	1988
8. Smith, Monica	Spring	1988
9. White, Margaret	Spring	1988
10. Zhao, Guangquan	Fall	1988
11. Reardon, Dean	Spring	1989
12. Yen, Rong-Lang	Spring	1989
13. Doyle, Barbara	Spring	1990
14. Hao, Mingming	Spring	1990
15. Heckman, Caroline	Fall	1990
16. Miller, Susan	Spring	1990
17. Xie, Keping	Spring	1990
18. Chen, Zhoufeng	Spring	1991
19. Kruzelock, Russell	Spring	1991
20. Marin, Carmen	Spring	1991
21. Tang, Ping	Spring	1991
22. Brown, Mary Elizabeth	Spring	1992
23. Cheng, Ann Joy	Spring	1992
24. Lau, Yiu-Keung, James	Summer	1992
25. Nataraj, Arun Jayaraman	Spring	1992
26. Tu, Shi-Ming	Spring	1992
27. Xie Youming	Fall	1992
28. Zhang, Yujiao	Fall	1993
29. Zhou, Ge	Summer	1993
30. Garcia Bravo, Roselina	Spring	1994

31. Kwong, "Simon" Ka-Yin	Spring	1994
32. Li, Kaiyi	Fall	1994
33. Wang, Sung-Ling	Fall	1994
34. Xing, Xiangming	Spring	1994
35. Zhang, Hong	Spring	1994
36. Jiang, Weidong	Spring	1995
37. Tan, Ming	Spring	1995
38. Ueno, Naoto	Summer	1995
39. Uppugunduri, Indira	Spring	1995
40. Huang, Wendong	Spring	1996
41. Lin, Phoebus Shiaw-Yih	Spring	1996
42. Goodacre, Angela	Spring	1997
43. Lee, Wei-Ping	Spring	1997
44. Wen, Yong	Fall	1997
45. Von Lindern, Ryan	Spring	1998
46. Yin, Shenmin	Spring	1998
47. Yu, Zhenming	Summer	1998
48. Day, Chi-ping	Fall	2000
49. He, Qiang	Spring	2000
50. Heng, Shuling	Spring	2000
51. Mak, Soleida	Spring	2000
52. Ranganathan	Spring	2000
53. Lazzell, Diana	Spring	2001
54. Bartholomeusz, Chandra	Spring	2001
55. Cha, Tai-Lung	Fall	2001
56. Qi, Wei	Fall	2002
57. Lee, Dung-Fang	Fall	2002
58. Liu, Xiuping	Summer	2003
59. Chou, Chao-Kai	Fall	2003
60. Cheng, Xiaoyun	Fall	2003
61. Yang, Jun	Spring	2004
62. Cho, Kyucheol	Spring	2004
63. Lin, Pei-Chun	Summer	2004
64. Yang, Jer-Yen	Summer	2004
65. Yang, Cheng-Chieh	Fall	2004
66. Kuo, Hsu-Ping	Fall	2004
67. Hsu, Yen-Michael	Fall	2004
68. Hsu, Jun-Mao	Fall	2004
69. Grabiner, Brian	Spring	2005
70. Song, Hui	Fall	2005
71. Liu, Qian	Spring	2006
72. Su, Ying-Wen	Spring	2006
73. Du, Yi	Summer	2006
74. Saldaña, Sandra	Summer	2006
75. Chen, Chun-Te	Fall	2006
76. Liu, Mo	Spring	2007
77. LaBaff, Adam	Spring	2007
78. Lee, Hong-Jen	Fall	2007
79. Lee, Heng-Huan	Fall	2007
80. Pu, Xia Sammi	Spring	2008
81. Shen, Jia	Spring	2008
82. Zhao, Fanmao	Summer	2008
83. Liao, Hsin-Wei	Fall	2008

**3. Participating in GSBS Ph.D. Qualifying Examine Committees: (48)**

1. Member, Hwang, Bih-Chen Charles, 3/1987
2. Member, DeMars, Maryellen, 5/1987
3. Member, Chiao, Paul, 3/1988
4. Member, Sterner, Deborah, 4/1988
5. Member, Yan, Duen-Hwa, 5/1988
6. Member, Chiocca, Susanna, 11/1988
7. Member, Zamaniyan, Farideh, 3/1989
8. Member, Ridall, Amy, 4/1989
9. Member, Suen, Ting-Chun, 4/1989
10. Member, Bai, Weinlong, 5/1989
11. Chair, Jin, Li, 5/1989
12. Member, Kania, Mary, 7/1989
13. Member, Hinkley, Craig, 8/1989
14. Member, Yu, Dihua, 8/1989
15. Member, Clifford, John, 10/1989
16. Member, James, Guy, 11/1989
17. Member, Li, Li, 11/1989
18. Member, Zhao, Xiaoyan, 11/1989
19. Member, Edmondson, Diane, 1/1990
20. Member, Li, Daijun, 3/1990
21. Chair, Sikes, Robert, 4/1990
22. Member, Russell, Kerry, 7/1990
23. Member, Pierceall, William, 3/1991
24. Member, Reardon, Dean, 4/1991
25. Member, Newell, Christine J, 6/1991
26. Member, Sanchez, Yolanda, 6/1991
27. Member, Tsui, Lisa, 7/1991
28. Member, Shyue, Song-Kun, 9/1991
29. Member, Ligon, Azra, 10/1991
30. Member, Zhang, Wei, 11/1991
31. Member, Marini, Frank, 2/1992
32. Member, D'Souza, Ian, 9/1992
33. Member, Touchman, Jeffrey, 9/1992
34. Member, Darmon Kern, Elizabeth, 10/1992
35. Member, Schubert, Elizabeth, 5/1993
36. Member, Huang, Jianyi, 6/1993
37. Member, Street, Marlene, 6/1993
38. Member, Whitaker, Laura, 7/1993
39. Chair, Kruzelock, Russell, 8/1993
40. Member, Xie, Keping, 9/1993
41. Chair, Tang, Ping, 1/1994
42. Member, Yang, Yandan, 10/1994
43. Member, St. John, Lisa, 8/1996
44. Chair, Gao, Chuan, 10/1996
45. Chair, Tan, Ming, 3/1998
46. Chair, Shi, Qian, 11/2000
47. Chair, Lan, Keng-Hsueh, 12/2001
48. Chair, Bartholomuesz, Chandra, 10/2002

**4. From Other Institutions (Non-GSBS):**

1. Ulf Vogt, The University of Munster/Germany, Ph.D. Thesis, September 1994.
2. Yumei Chen, The University of Texas Health Science Center, San Antonio, Ph.D. Thesis, March 1997.
3. Leung Wing Cheung Tommy, Member, External Examiner, Department of Biochemistry, The University of Hong Kong, 1999.
4. Eric C. Wooten, Department of Molecular and Cell Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, Houston, TX, Ph.D. Thesis, 2001-2003.
5. John Hutchinson, Ph.D. thesis in Biology, entitled "Akt-1 Roles in Mammary Gland Development and Tumorigenesis", McMaster University, Ontario, Canada, July 2003.
6. Guikai Wu, Department of Molecular Medicine, Institute of Biotechnology, UTHCSA. Ph.D. Thesis, July 2004.
7. Catherine Huang, Department of Molecular and Cellular Biology, Baylor College of Medicine, member of Ph.D. Thesis Committee, 2006.
8. Hui-Lung Sun, visiting Ph.D. student, Pharmacology Institute, National Taiwan University, May 2006 - April 2008.
9. Pei-Sheng Chen, Ph.D. student, Toxicology Institute, National Taiwan University, May 2006 - present
10. Yun-Ju Chen, Ph.D. student, National Cheng Kung University, July 2007 – June 2009.

#### 5. GSBS Graduate Students Directly Supervised: (49)

Names	Program	Degree	Duration
1. Yan, Duen-Hwa	Ph.D.		04/87 - 05/91 Ph.D.
2. Zhao, Xiaoyan	Ph.D.		06/87 - 05/92 Ph.D.
3. Yu, Dihua	M.D./Ph.D.		10/88 - 05/91 Ph.D.
4. Matin, Angabin	Ph.D.		11/88 - 05/93 Ph.D.
5. Suen, Ting Chun	Ph.D.		04/88 - 09/90 Ph.D.
6. White, Margaret	Ph.D.		06/88 - 05/91 M.S., Ph.D. 12/94
7. Reardon, Dean	Ph.D.		06/89 - 12/94 Ph.D.
8. Yen, Rong-Lang	Ph.D.		10/89 - 03/94 Ph.D.
9. Russell, Kerry	M.D./Ph.D.		08/89 - 03/90 Ph.D.
10. Miller, Susan	Ph.D.		06/90 - 08/94 Ph.D.
11. Brown, Mary Elizabeth	Ph.D.		10/92 - 11/93 M.S.
12. Xie, Youming	Ph.D.		01/93 - 05/96 Ph.D.
13. Xing, Xiangming	Ph.D.		01/94 - 05/98 Ph.D.
14. Li, Kaiyi	Ph.D.		03/94 - 06/99 Ph.D.
15. Lee, Eun Kyung	M.D./Ph.D.		04/94 - 05/98 M.D./Ph.D.
16. Ueno, Naoto	Ph.D.		07/94 - 03/98 Ph.D.
17. Chang, Yujiao	Ph.D.		08/94 - 05/97 Ph.D.
18. Guo, Qian	Ph.D.		08/94 - 08/95 M.S.
19. Deng, Jiong	Ph.D.		09/94 - 05/98 Ph.D.
20. Kwong, Ka-Yin	Ph.D.		02/95 - 06/01 Ph.D.

21. Lau, Yiu-Keung, James	M.D./Ph.D.	08/95 - 12/01 Ph.D.
22. Lin, Shiaw-Yih	Ph.D.	10/96 - 12/99 Ph.D.
23. Lee, Wei-Ping	Ph.D.	01/97 - 04/00 Ph.D.
24. Wen, Yong	Ph.D.	09/97 - 08/01 Ph.D.
25. Yu, Zhenming	Ph.D.	07/98 - 01/03 Ph.D.
26. Von Lindern, Ryan	M.S.	06/98 - 08/02 M.S.
27. Miller, Stephanie	Ph.D.	06/98 - 07/03 Ph.D.
28. Day, Chi-Ping	Ph.D.	08/00 - 07/05 Ph.D.
29. Li, Yan	Ph.D.	09/00 - 12/03 Ph.D.
30. Cha, Tai-Lung	Ph.D.	08/01 - 06/05 Ph.D.
31. Lee, Christine M.	M.S.	09/01 - 05/03 M.S.
32. Lee, Dung-Fang	Ph.D.	09/02 - 06/08 Ph.D.
33. Chou, Chao-Kai	Ph.D.	08/03 - present
34. Cheng, Xiaoyun	Ph.D.	08/03 - present
35. Hsu, Jung-Mao	Ph.D.	08/04 - present
36. Kuo, Hsu-Ping	Ph.D.	08/04 - present
37. Yang, Jer-Yen	Ph.D.	08/04 - present
38. Yang, Cheng-Chieh	Ph.D.	08/04 - present
39. Trinh, Bon Quy	Ph.D.	05/05 - 07/06
40. Song, Hui	Ph.D.	06/06 - present
41. Du, Yi	Ph.D.	07/06 - present
42. Chen, Chun-Te	Ph.D.	07/06 - present
43. Liu, Mo	Ph.D.	03/07 - present
44. Saldaña, Sandra	Ph.D.	03/07 - present
45. LaBaff, Adam	Ph.D.	05/07 - present
46. Lee, Hong-Jen	Ph.D.	08/07 - present
47. Lee, Heng-Huan	Ph.D.	08/07 - present
48. Shen, Jia	Ph.D.	01/08 - present
49. Liao, Hsin-Wei	Ph.D.	08/08- present
50.		

**6. Postgraduates Directly Supervised: (100)**  
**(Postdoctors/ Visiting Scientists/ NT Faculties)**

Names	Degree	Duration	Status
1. Ming-Der Lai	Ph.D.	02/87 - 10/87	
2. Xin Zhang	M.D	11/87 - 12/89	
3. Larry Rosenberg	Ph.D.	05/88 - 07/89	
4. Kathy Scorsone	Ph.D.	05/89 - 11/90	
5. Tineke B. Sexton	Ph.D.	01/90 - 06/93	
6. Duen-Hwa Yan	Ph.D.	06/91 - 06/92	
7. Dihua Yu	M.D./Ph.D.	06/91 - 12/93	09/02 Promoted to Professor in Dept Surgical Oncology.
8. Raphael Pollock	M.D./Ph.D.	07/92 - 12/92	Visiting Professor from Dept. of Surgical Oncology.
9. Maw-Sen Chang	MD	06/92 - 12/92	Visiting scientist from Kaoshiung Medical College, Taiwan.
10. Larry Xie	Ph.D.	03/93 - 12/93	
11. Angabin Matin	Ph.D.	04/93 - 09/94	
12. Shan-Shue Wang	Ph.D.	02/93 - 12/93	Visiting Scientist from Development Center of Biotechnology at Taiwan.
13. Ming-Ching Kao	Ph.D.	03/93 - 09/93	Visiting Professor from National Defense Medical College, Taiwan.



14. Nobutaka Kiyokawa	M.D./Ph.D.	04/92 - 05/95	Promoted to Section Chief, Dept. of Pathology, National Children's Hospital, Tokyo, Japan.
15. Hongyun Wu	M.D./Ph.D.	05/94 - 07/95	
16. Hua Chen	Ph.D.	04/94 - 04/97	
17. Weiya Xia	M.D.	11/93 - present	Instructor since 1997, 09/02 promoted to Assistant Professor, Dept. Mole. & Cell. Oncol. (NT)
18. Lisha Zhang	Ph.D.	01/94 - 09/97	Promoted to Instructor, Dept. of Blood & Marrow Transplantation, 1998
19. Ru-Ping Shao	M.D.	04/95 - 08/04	Visiting Professor from Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China; Promoted to Instructor, Dept. Mol. And Cell. Oncol.
20. Devarajan Karunagaran	Ph.D.	06/95 - 06/97	
21. Duen-Hwa Yan	Ph.D.	09/95 - 07/99	Promoted to Assistant Prof, Dept. Surgical Oncology & Mol. & Cell. Oncol.
22. Ruey-Long Hong	M.D./Ph.D.	11/95 - 11/96	Visiting Scientist from National Taiwan Univ. Medical School, Taiwan.
23. Shao-Chun Wang	Ph.D.	01/96 – 03/07	09/02, promoted to NT Assistant Prof, Dept. of Mol. & Cell. Oncol.; 03/07 Tenured Track Assistant Professor, University of Cincinnati School of Medicien.
24. Binhua “Peter” Zhou	Ph.D.	08/96 - 08/05	09/02, promoted to NT Assistant Prof, Dept. of Mol. & Cell. Oncol.; 08/05 Tenured Track Assistant Prof, UTMB at Galveston.
25. Hua Peng	Ph.D.	11/96 - 05/99	
26. Su-Shun Lo	M.D.	12/96 - 11/97	Visiting Scientist from General Veteran Hospital, Taipei, Taiwan.
27. Jeong Soo Kim	M.D.	03/97 - 08/98	Visiting Scientist from U. Jong Bu St. Mary’s Hospital, Seoul, South Korea.
28. Heng Yin Yang	Ph.D.	01/97 - 05/02	
29. Yong Liao	M.D./Ph.D.	03/98 - 08/06	Promoted to Instructor 09/02, NT Assistant Professor, 09/05 Dept of Mol. & Cell. Oncol.
30. Keishi Makino	M.D./Ph.D.	04/98 - 04/01	
31. Jiong Deng	Ph.D.	06/98 - 09/04	Promoted to Instructor, Dept of Mol. & Cell. Oncol.
32. Yiyu Zou	Ph.D.	09/98 - 06/02	NT Assistant Professor, Dept. of Mol. & Cell. Oncol.
33. Mickey Hu	Ph.D.	04/99 - 04/01	NT Assistant Professor, Dept. of Mol. & Cell. Oncol.
34. Keng-Li Lan	Ph.D.	05/99 - 01/01	
35. Geoffrey Bartholomuesz	Ph.D	09/99 - 09/04	Promoted to Instructor, Dept of Mol. & Cell. Oncol.
36. Eing-Mei Tsai	M.D./Ph.D.	10/99 - 12/00	Visiting Scientist from Kaoshiung Medical College, Kaoshiung, Taiwan.
37. Yun-Houng Chen	Ph.D.	09/00 - 08/01	
38. Hong-Yin Wang	Ph.D.	09/00 - 10/02	
39. Seyed Najafi	Ph.D.	01/01 - 11/02	
40. Norihisa Hanada	Ph.D.	04/01 - 07/03	
41. Zheng Li	Ph.D.	08/01 - 08/04	
42. Jaw-Ching Liu	Ph.D.	03/01 - 04/05	4/18/05 Research Scientist, MCO.
43. Yong Pan	Ph.D.	01/01 - 07/03	
44. Lin Qiu	Ph.D.	03/01 - 06/04	
45. Dipak K. Giri	Ph.D.	05/01 - 05/04	Instructor, Dept. Mol. & Cell. Oncol.
46. Yong Wen	Ph.D.	08/01 - 02/02	

47. Hung-Bo Wu	M.D.	08/01 - 07/02	Visiting scientist from General Veteran Hospital, Kaoshiung, Kaoshiung, Taiwan.
48. Qing Qing Ding	Ph.D.	09/01 - present	Promoted to Instructor, 01/06, Dept MCO. Promoted to NT Assistant Professor, 12/08
49. Daren Shi	M.D.	11/01 - 02/02	Visiting Professor from Cancer Institute, Fudan U., Shanghai, China.
50. Huang-Chun Lien	M.D.	12/01 - 12/02	Visiting scientist from National Taiwan U. Hospital, Taipei, Taiwan.
51. Fu Ou-Yang	M.D.	03/02 - 02/04	Visiting scientist from Kaoshiung Medical College, Kaoshiung, Taiwan.
52. Wen-Hui Lo	Ph.D.	07/02 - 04/06	Promoted to Instructor, MCO 01/05. Tenured track Assistant Professor, Duke University.
53. Yusuke Nakajima	D.D.S.	08/02 - 02/06	
54. Chin-Hsing Chen	M.D.	08/02 - 07/03	Visiting scientist from National Taiwan U. Hospital, Taipei, Taiwan.
55. Kun-Ming Rau	M.D.	08/02 - 07/04	Visiting scientist from Chung Geng Memorial Hospital, Kaoshiung, TW.
56. Lei Shen	M.D.	09/02 - 02/03	Visiting scientist from Fudan University, Shanghai, China.
57. Ping Ling	Ph.D.	10/02 - 11/03	Assistant Prof. NCKU, Tainan, TW 08/05.
58. Ali Seyed-Mohamed	Ph.D.	01/03 - 12/04	Instructor, Emory U, GA. 01/05.
59. Yongkun Wei	M.D.	03/03 - present	Promoted to Instructor, 06/2008
60. Cong Susan Zong	Ph.D.	03/03 - 12/06	NT Assistant Prof. Dept of Mol. & Cell Oncol.
61. Pingyu Zhang	Ph.D.	06/03 - 04/05	
62. Xiaoming Xie	M.D./Ph.D.	06/03 - 08/08	Research Scientist
63. Mehmet Gunduz	M.D./Ph.D.	06/03 - 08/04	
64. I-Fen Chen	Ph.D.	06/03 - 02/04	
65. Wen-Bin Tsai	Ph.D.	07/03 - 09/04	
66. Bo Ping	M.D.	07/03 - 09/05	Visiting Ph.D. student from Fudan University, Shanghai, China. Ph.D. June 2006.
67. Xianghuo He	Ph.D.	08/03 - 04/06	
68. Long-Yuan Li	Ph.D.	08/03 - 05/06	
69. Jen-Yu Hung	M.D.	08/03 - 08/05	Visiting scientist from Kaoshiung Medical College, Kaoshiung, Taiwan.
70. Sheng-Chieh Hsu	Ph.D.	09/03 - present	
71. Yadi Wu	Ph.D.	03/04 - 03/06	
72. Tiebang Kang	Ph.D.	06/04 - 12/04	
73. Yan Li	M.D./Ph.D.	12/03 - 07/05	
74. Jin-Yuan Shih	M.D./Ph.D.	12/04 - 12/05	Visiting scientist from National Taiwan University Hospital, Taipei, Taiwan.
75. Yung-Luen Yu	Ph.D.	01/05 - 01/07	
76. Jen-Liang Su	Ph.D.	08/05 - 03/07	Taiwan Merit Scholarship
77. Chia-Jui Yen	M.D.	12/05 - 12/07	Visiting Scientist from NCUK, Tainan, Taiwan.
78. Ying-Nai Wang	Ph.D.	12/05 - present	Taiwan Merit Scholarship
79. Jing-Yu Lang	Ph.D.	12/05 - present	
80. Hongmei Wang	Ph.D.	01/06 - 01/09	
81. Wei-Chien Huang	Ph.D.	03/06 - 10/07	Taiwan Merit Scholarship
82. Mingew Choi	M.D.	06/06 - 06/07	Visiting Scientist from Samsung Medical Center, Seoul, S. Korea
83. Min-Liang Kuo	Ph.D.	07/06 - 08/07	Visiting Professor from National Taiwan University Hospital, Taipei, Taiwan.
84. Shih-Ching Chang	M.D.	08/06 - 07/07	Visiting Scientist from Veteran General Hospital, Taipei, Taiwan.
85. Yan Yang	Ph.D.	08/06 - present	
86. Bin Shi	Ph.D.	08/06 - 11/08	

87. Su-Peng Yeh	M.D.	09/06 - 08/07	Visiting Scientist from China Medical University Hospital, Taichung, Taiwan
88. Chao-Hua Chiou	M.D.	11/06 – 05/08	Visiting Scientist from Veteran General Hospital, Taipei, Taiwan.
89. Hirohito Yamaguchi	Ph.D.	12/06 - present	Non-tenure track Assistant Professor
90. Cheng-Wen Wu	M.D., Ph.D.	01/07 - 03/07	Visiting Professor from National Health Research Institute, Zhunan, Taiwan.
91. Longfei Huo	Ph.D.	02/07 - present	
92. Yi Bao	Ph.D.	03/07 -08/08	
93. Chun-Ju Alice Chang	Ph.D.	05/07 - present	
94. Yen-Chao Eric Chen	M.D.	08/07 - 11/07	Visiting Scientist from Chang Gung Memorial Hospital at Lin-Kuo.
95. Jennifer Hsu	Ph.D.	08/07- present	
96. Chia-Wei Jerry Li	Ph.D.	11/07- present	
97. Yan Wang	Ph.D.	03/08- present	
98. Tze-Hsuan Leon Huang	Ph.D.	08/08- present	
99. Min-Juan Hsu	Ph.D.	11/08- present	
100. Chi-Hong Chao	Ph.D.	01/09 - present	
101.			
102.			

**7. MDACC Clinical Fellows Directly Supervised: (11)**

Name	Degree	Duration	Status
1. Barbara Doyle	M.D.	09/90 - 05/91	
2. Shi-Ming Tu	M.D.	01/92 - 06/92	
3. Nuhad Ibrahim	M.D.	07/92 - 06/93	Promoted to Assistant Prof. Breast Medical Oncology Dept.
4. Michele Gadd	M.D.	07/92 - 06/93	
5. Naoto Ueno	M.D./Ph.D.	04/98 - 06/99	Promoted to Associate Professor Dept. of Blood & Marrow Transplantation.
6. Kelly Hunt	M.D.	01/96 - 12/96	Promoted to Professor, Department of Surgical Oncology
7. Ralph Zinner	M.D.	07/97 - 06/99	Promoted to Assistant Professor Thoracic Head & Neck Medical Oncology.
8. Massimo Cristofanilla	M.D.	07/97 - 06/98	Promoted to Assistant Professor Breast Medical Oncology Dept.
9. Melanie Royce	M.D.	10/98 - 06/00	Promoted to Assistant Professor Breast Medical Oncology Dept.
10. Funda Meric-Bernstam	M.D.	03/99 - 06/01	Promoted to Associate Professor, Department of Surgical Oncology.
11. Christine M. Lee	M.D./M.S.	07/01 - 06/03	
12.			

**8. Mentor for the Physician Scientist Program: (9)**

1. Linus Ho, M.D., Ph.D. (Assistant Professor, Department of GI Medical Oncology).
2. Funda Meric-Bernstam, M.D. (Associate Professor, Department of Surgical Oncology).
3. Joe Y. Chang, M.D., Ph.D. (Assistant Professor, Department of Radiation Oncology).
4. Constance Albarracin, M.D. (Assistant Professor, Department of Pathology).
5. Ana M. Gonzalez-Angulo, M.D. (Assistant Professor, Department of Breast Medical Oncology).

6. Lajos Pusztai, M.D., Ph.D. (Associate Professor, Department of Breast Medical Oncology).
7. Sao Jiralespong, M.D. (Fellow, Medical Oncology).
8. Zhen Fan, M.D. (Associate Professor, Department of Experimental Therapeutics).
9. Paul Corn, M.D., Ph.D. (Assistant Professor, Department of Genitourinary Medical Oncology)

## 9. Undergraduate students:

- |                       |                   |                                 |
|-----------------------|-------------------|---------------------------------|
| 1. Edwin Ou           | 07/91 - 08/91     |                                 |
| 2. Saayika Uppal      | 06/92 - 08/92     |                                 |
| 3. Gabriel Lopez, Jr. | 06/97 - 08/97     |                                 |
| 4. Racheal Theriault  | 06/97 - 08/97     |                                 |
| 5. Freke Kloosterboer | 12/96 - 06/97     | (Visiting student from Holland) |
| 6. Jane Tseng         | 01/97 - 02/97     | (Visiting Student from Taiwan)  |
| 7. Gabriel Lopez, Jr. | 06/98 - 08/98     |                                 |
| 8. Racheal Theriault  | 06/98 - 08/98     |                                 |
| 9. Kevin Wei          | 06/00 - 08/00     |                                 |
| 10. Justin Fang       | 06/05 - 08/05     |                                 |
| 11. Andy Chen         | 05/29/07-08/03/07 | MDACC Summer Programs           |

## 10. High School students

- |                       |                                 |
|-----------------------|---------------------------------|
| 1. Amy Cheng          | 06/95 - 08/95                   |
| 2. Gabriel Lopez, Jr. | 07/95 - 08/95 and 06/96 - 08/96 |
| 3. Christina Huang    | 07/04 - 08/04                   |
| 4. Michael Hung       | 06/05 - 08/05                   |
| 5. Kristy Hong        | 06/05 - 08/05                   |
| 6. Elizabeth Moniers  | 06/06 - 07/06                   |
| 7. Jack Yeh           | 07/07 - 08/07                   |

## Organization of National or International Conferences

### a. Administrative/Organizing Committee:

1. Organizer and Lecturer, Workshop on Oncogene Research, National Science Council, Taiwan, June 18-25, 1990.
2. Organizer, The 1991 Science, Engineering, and Technology Seminars (The Association of American Chinese Professionals), Houston, Texas, 5/91.
3. Organizer and Lecturer, Workshop on Molecular Biology Approaches in Cancer Research, National Defense Medical College, Taiwan, 7/91-8/91.
4. Organizer, 1992 Science, Engineering, and Technology Seminars, Houston, Texas, 5/92.
5. Organizer, 1994 Medical Symposium on Tumor Biology, North American Taiwanese Professors' Association Annual meeting, Taiwan, 6/94.

6. Organizer and Lecturer, Workshop on Cancer Biology, Shanghai Cancer Hospital, Shanghai -Medical University, Shanghai, China, June 20-26, 1994.
7. Lecturer, Workshop on Gene Diagnosis and Therapy of Cancer, Muenster, Germany, October 27, 1994.
8. Lecturer, Workshop on Gene Therapy, National Defense Medical College, Taipei, Taiwan, September 18 - 25, 1995.
9. Chairperson, Education Committee of the 88th Annual Meeting of the American Association for Cancer Research, San Diego, California 1997-1998.
10. Program Member of Annual Symposium, American Association for Cancer Research, 1997-1999.
11. Member, Cancer Gene Therapy Committee, American Society of Gene Therapy, 1998-2002
12. Member, Scientific Committee and International Advisory Board, 10<sup>th</sup> International Congress on Anti-Cancer Treatment, Europa Organisation, Palais Des Congres, Paris, France, 1999.
13. Organizer and Lecturer, Symposium for Gene Therapy, Academia Sinica, Taipei, Taiwan, March 5-6, 2000.
14. Lecturer, International Breast Cancer Symposium, Breast Cancer Research Foundation, Taipei, Taiwan, October 13-14, 2000.
15. Co-Chair, Poster Discussion, Pharmacology and Experimental Therapeutics, 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000.
16. Co-Chair, Organizing Committee for Breast Cancer Symposium, Taipei, Taiwan, October 13-14, 2000.
17. Member, Scientific Committee and International Advisory Board, 12<sup>th</sup> International Congress on Anti-Cancer Treatment, Palais des Congrès, Paris, France, February 4-7, 2002.
18. Member, the International Advisory Committee of the 10th SCBA International Symposium, Beijing, P.R.C., August 16-22, 2003 postponed to July 2004.
19. Member, Steering Committee Tri-Conference "Medicine in the 21<sup>st</sup> Century", July 25-27, 2004, Shanghai, P.R.C.
- 20. Co-chairman, MDACC 57<sup>th</sup> Annual Symposium on Fundamental Cancer Research "Signal Transduction: From Pathways to Networks", Houston, TX, Oct. 12-15, 2004.**

21. Member, Organizing Committee, First International Conference on Tumor Progression and Therapeutic Resistance, Philadelphia, PA, November 8-9, 2004.
22. Member, Organizing Committee, Second International Conference on Tumor Progression and Therapeutic Resistance, Burlington, MA. September 18-20, 2005.
23. Member, Conference Steering Committee, National Foundation for Cancer Research BioFunding Summit – International Think-Tank Forum on Anti-Cancer Innovations and Global Collaborations, Beijing, China, October 13-15, 2005
24. Member, 2005 MDACC Basic Science Research Symposium Organizing Committee, Houston, TX, October 25-27, 2005.
25. **Co-chairman**, the 11th SCBA International Symposium, San Francisco, CA, July 19-23, 2006.
26. Member, Program Committee, MDACC 60th Annual Symposium on Cancer Research “Personalized Risk Assessment and Management”, October 10-14, 2007.
27. Member, Organization Committee, First International Symposium on Cancer Research, China Medical University Hospital, Taichung, Taiwan, November 16-17, 2007.
28. Conference Chair, Organization Committee, China Medical University Hospital 28<sup>th</sup> Anniversary and M. D. Anderson Cancer Center Mini-symposium, Taichung, Taiwan, November 16, 2008.
29. Member, Program Committee, MDACC Symposia in Cancer Research “Cellular Energy, Metabolism and Cancer”, April 3-4, 2009.
30. Co-chair, Scientific Program of the 12<sup>th</sup> SCBA International Symposium, Academia, Sinica, Taipei, June 15-18, 2009.

**b. Session Chairmanships:**

1. Co-Chairman, Plasma Membrane Targets Section Cellular and Molecular Targets of Cancer Therapy (Forty-second Annual Symposium on Fundamental Cancer Research), 10/89.
2. Co-Chairman, Growth Factors and Their Receptors in Cancer: Basic Mechanisms and Therapy (Forty-third Annual Symposium on Fundamental Cancer Research), 12/90.
3. Chairman, Third Annual Symposium of Society of Chinese Bioscientists in America, Houston Chapter, 12/89.
4. Chairman, Biomedical Section (Cancer and Chinese Herbal Medicine) of the 1991 Science, Engineering, and Technology Seminars, Houston, Texas, 5/91.

5. Chairman, Biomedical Section of the 1992 Science, Engineering and Technology Seminars, Houston, Texas, 5/92.
6. Co-Chairman, Fourth International Symposium & Workshop of SCBA, Singapore, 6/92.
7. Co-Chairman, Fifth International Symposium & Workshop of SCBA, Maryland, 6/93.
8. Co-Chairman, Third Texas Triangle Meeting, Dallas, Texas, 3/94.
9. Co-Chairman, Annual Meeting of North American Taiwanese Professors' Association, Medical Symposium on Tumor Biology, Taipei, Taiwan, 1994.
10. Co-Chairman, Cell Death in Development and Cancer (Forty-seventh Annual Symposium on Fundamental Cancer Research), 10/94.
11. Chairman, Fourth Texas Triangle Meeting, San Antonio, Texas, 4/95.
12. Chairman, Gene Therapy Workshop, Karmanos Cancer Institute, Detroit, Michigan, 12/8/95.
13. Co-Chairman, Poster Discussion Section, The Ninth International Congress on Breast Diseases, Houston, Texas, 5/2/96.
14. Chair, Cambridge Healthtech Institute's Third Annual Artificial Self-assembling Systems for Gene Delivery, Coronado, California, 11/17-19/96.
15. Chairman, 50th Annual Symposium on Fundamental Cancer Research - Molecular Determinants of Cancer Metastasis, Houston, Texas, 10/ 28-31/97.
16. Co-Chairman, Poster Discussion Section, 50th Annual Symposium on Fundamental Cancer Research - Molecular Determinants of Cancer Metastasis, Houston, Texas, 10/28-31/97
17. Chair, Biotechnology Section Society for Chinese Bioscientists in America, Galveston, Texas, 4/11/98.
18. Chair, Scientific Session, First Annual Meeting American Society of Gene Therapy, Seattle, Washington, 5/28-31/98.
19. Co-Chairman, The University of Texas M.D. Anderson Cancer Center Medical Oncologist Consensus Conference, Wailea, Maui, 7/15-18/98.
20. Chairman, First Annual International Conference for Ovarian Cancer, The University of Texas M. D. Anderson Cancer Center, 2/3-5/99.
21. Co-Chairman, Poster Discussion Session: Pharmacology and Experimental Therapeutics, 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 4/1-5/00.

22. Co-Chairman, Organizing Committee, International Breast Cancer Symposium, Taipei, Taiwan, 10/13-14/00.
23. Co-Chairman, “Molecular Targeting of HER-2/neu overexpression,” 4<sup>th</sup> Annual Meeting of the Chinese Society of Clinical Oncology, Beijing, P.R. China, 10/19-22/00.
24. Moderator, American Society of Gene Therapy 4<sup>th</sup> Annual Meeting (Cell Cycle Control and Angiogenesis Sessions), Seattle, Washington, June 1 - 3, 2001.
25. Co-Chairman, Sections of Growth Factor Receptor, 4<sup>th</sup> Annual Opinion Leader Round Table Meeting, Colorado Springs, CO, July 25-29, 2001.
26. Member, Cancer Gene Therapy Committee, Sessions and Speakers for the Program Committee, Fifth Annual Meeting of the Cancer Gene Therapy, 2001.
27. Session Chair, Session: Modulators of Apoptosis, the Fifth Annual Opinion Leader Summit: “Targeted Therapies in the Treatment of Breast Cancer”, Maui, Hawaii, July 24-28, 2002.
28. Session Co-chair, Session: Gene Therapy for cancer, The 10<sup>th</sup> SCBA International Symposium, Beijing, China, August 14-23, 2003\*. \*Due to SARS outbreak, it is postponed to July 18-23, 2004.
29. Co-Chair, Symposium Session 8: “Biological Pathway Discovery and Targeted Interference”, the fourth U.S. Department of Defense (DOD) Breast Cancer Research Program (BCRP) Era of Hope meeting, Philadelphia, PA, June 9, 2005.
30. Co-Chair, Session: “Gene Discovery and Drug Development”, 6<sup>th</sup> Human Genome Organization (HUGO)-Pacific meeting & 7<sup>th</sup> Asia-Pacific Conference on Human Genetics “Toward Human Health”. Taipei, Taiwan, March 7-10, 2006.
31. Session Co-chair, Session: Gene Therapy for Cancer, The 11<sup>th</sup> SCBA International Symposium, San Francisco, CA, July 19-23, 2006.
32. Session Chair: “proteases and the EGFR” 2008 Growth Factor and Signal Transduction Symposium on the theme of “Proteases in Cell Signaling”, Ames, Iowa, September 18-21, 2008.
33. Session Co-chair, National Cancer Institute Translational Science Meeting on Saturday, Washington DC, November 8<sup>th</sup>, 2008.
34. Chair, Cancer Biology Workshop, the 12<sup>th</sup> SCBA International Symposium, Academia Sinica, Taipei, Taiwan, June 15-18, 2009.

**Invitations to National or International Conferences:**



1. A member of the five person U.S. delegation to participate in the US/Japan Cooperative Research Program on Advances in Bladder Cancer Research in Nagoya, Japan, March 24-26, 1986.
2. Invited Lecturer, FISS Workshop organized by the Spanish Department of Health, Barcelona, Spain, June 7-9, 1990.
3. Selected Speaker, Eighty-second Annual Meeting of the American Association for Cancer Research, Houston, TX, May 15-18, 1991.
4. Invited Speaker, Molecular and Genetics Workshop, Kaohsiung, Taiwan, June 14, 1992.
5. Invited Speaker, Fourth International Symposium & Workshop of SCBA, Singapore, June 15-19, 1992.
6. Invited Speaker, CAP Conference XXIV: Molecular Pathology Vancouver, British Columbia, Canada, August 19-21, 1992.
7. Invited Speaker, Fifth International Symposium & Workshop of SCBA Baltimore, MD, June 15-20, 1993.
8. Invited Speaker, Annual Meeting of Chinese Society of Clinical Oncology, Taipei, Taiwan, January 14-16, 1993.
9. Selected Speaker, NCI-Sponsored SPORE Annual Meeting, Rockville, MD, July 17-19, 1994.
10. Selected Speaker, Keystone Symposia on Molecular and Cellular Biology "Molecular Basis of Cancer Therapy", Tamarron, CO, March 4-10, 1994.
11. Invited Speaker, Annual Meeting of North American Taiwanese Professors' Association, Taipei, Taiwan, June 17-19, 1994.
12. Invited Speaker, The Fifth International Congress of the Metastasis Research Society, Rockville, MD, September 21-October 1, 1994.
13. Invited Speaker, Symposium on gene diagnosis of cancer, Muenster, Germany, October 25-26, 1994.
14. Invited Speaker, the U.S./Japan Cooperative Research Program on "New Drugs and Drug Resistance," Maui, HI, February 10-11, 1995.
15. Invited Speaker, Symposium on HER-2/*neu* Oncogene, Chinese Society of Clinical Oncology, Taipei, Taiwan, September 23, 1995.
16. Invited Speaker, 1<sup>st</sup> World Congress on Advances in Oncology. Athens, Greece, October 22-26, 1995.
17. Keynote Speaker, The First National Health Research Institute Annual Symposium, Taoyuan, Taiwan, August 24-25, 1996.
18. Invited Speaker, The 2<sup>nd</sup> Annual Scientific Meeting, Novel Approaches in Blood and Marrow Transplantation, San Diego, CA, October 2-6, 1996.
19. Invited Speaker, 18<sup>th</sup> Annual Pharmacy Symposium on Cancer Chemotherapy, Houston, TX, October 13, 1996.
20. Invited Speaker, Artificial Self-Assembling Systems for Gene Delivery, San Diego, Ca, November 17-19, 1996.
21. Invited Speaker, Fifth Annual Genitourinary Oncology Conference Advances in the Biology and Therapy of Prostate Cancer, Houston, TX, February 20-21, 1997.
22. Invited Speaker, NIH Ovarian Cancer Biology Workshop, Washington, DC, April 7-8, 1997.
23. Invited Speaker, The 1997 Annual Meeting of the American Association for Cancer Research, April 12-16, 1997.
24. Invited Speaker, 7<sup>th</sup> SCBA International Symposium Meeting, Toronto, Canada, July 8-11, 1997.

25. Invited Speaker, Proceedings of the First Annual Retreat Molecular & Genomic Medicine Division, Pacific Green Bay, Taipei, Taiwan, September 3-4, 1997.
26. Invited Speaker, 2<sup>nd</sup> World Congress on Advances in Oncology, Athens, Greece, October 16-18, 1997.
27. Invited Speaker, 50<sup>th</sup> Annual Symposium on Fundamental Cancer Research - Molecular Determinants of Cancer Metastasis, Houston, TX, October 28-31, 1997.
28. Invited Speaker, U.S. Army Medical Research and Materiel Command, Breast Cancer Research Program: An Era of Hope, Washington, DC, October 31 – November 4, 1997.
29. Invited Speaker, Keystone Symposia on Molecular & Cellular Biology, “Tumor Suppression Activity of *E1A* for HER-2/*neu*-overexpressing Cancer Cells,” Keystone, CO, January 19-25, 1998.
30. Invited Speaker, NIH Pathology B- Experimental Therapeutics II Joint Workshop on Translational Research and Gene Therapy, San Diego, CA, March 4-5, 1998.
31. Invited Speaker, Society of Chinese Bioscientists of America (SCBA)-Texas Chapter, Galveston, TX, April 11, 1998.
32. Keynote Speaker, The 1<sup>st</sup> Annual Meeting of the American Society of Gene Therapy, Seattle, WA, May 28-31, 1998.
33. Invited Speaker, The University of Texas M.D. Anderson Cancer Center Medical Oncologist Consensus Conference, Wailea, Maui, HI, July 15-18, 1998.
34. Invited Speaker, International Conference on Gene Therapy and Molecular Biology, Island of Crete, Greece, August 16-24, 1998.
35. Invited Speaker, International Association for Breast Cancer Research, Athens, Greece, September 22-27, 1998.
36. Invited Speaker, 1<sup>st</sup> International Symposium on Molecular Medicine, Island of Crete, Greece, October 15-17, 1998.
37. Invited Keynote Speaker, The 2<sup>nd</sup> Annual Terry Fox-Chang Gung Memorial Hospital International Cancer Symposium, Chang Gung University, Taipei, Taiwan, October 17, 1998.
38. Invited Speaker, “Drug Activation Systems: Broadening the Applications of Gene Therapy, Genetic Vaccines, and Cell Signaling,” La Jolla, CA, November 2-3, 1998.
39. Invited Participant, The NHRI Scientific Review Committees and Scientific Council Meetings, Taipei, Taiwan, November 16-19, 1998.
40. Invited Discussant, “The Breast Cancer Care Looking Towards the Next Millennium,” The Marriott River Center, San Antonio, TX, December 15, 1998.
41. Invited Speaker, UTMDACC, “Tumor Markers at the Millennium,” Santa Barbara, CA, February 26-28, 1999.
42. Invited Discussant, “Gene Targets in Female Cancer,” 1999 Texas Biomedical Investment Conference (The Genomics Revolution in Cancer Therapy: What Does it Mean and How Will it be Used?), UTMDACC, March 1, 1999.
43. Invited Speaker by Biocyte Therapeutics, Inc., 35<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.
44. Invited Speaker, Second Annual Meeting of The American Society of Gene Therapy, Washington, D.C., June 3-12, 1999.
45. Invited Speaker, “Transcriptional Repression as a Way to Define Tumor Suppressor Genes,” 8<sup>th</sup> International Symposium of Society of Chinese Bioscientists in America (SCBA), Hong Kong Convention and Exhibition Center, Hong Kong, China, August 14-19, 1999.
46. Invited Speaker, “Novel Approach for Cancer Gene Therapy,” Kaohsiung University, Taiwan, August 21, 1999.

47. Keynote Speaker, "Gene therapy: A new therapeutic approach for the next century," 23<sup>rd</sup> Annual Joint Business Conference of US-ROC Business Council, San Antonio, Texas, November 19, 1999.
48. Invited Speaker, "Development of Cancer Gene Therapy Using Molecular Biology Approach," 10<sup>th</sup> International Congress on Anti-Cancer Treatment, Paris, France, Jan. 31 – February 3, 2000.
49. Invited Speaker, American Society of Gene Therapy 3<sup>rd</sup> Annual Meeting, Denver, CO, May 31-June 4, 2000.
50. Invited Speaker, NATMA 2000 Annual Convention, "Gene Therapy: A novel therapy for the next century," University City, CA, June 23-25, 2000.
51. Invited Speaker, Controlled Release Society, Inc., Paris, France, July 7-13, 2000.
52. Invited Speaker, 8<sup>th</sup> SPORE Investigator's Workshop, "The E1A gene therapy on breast and ovarian cancers: A two way translational research," Chantilly, VA, July 8-11, 2000.
53. Invited Speaker, The 20<sup>th</sup> Annual Convention National Taiwan University Medical College Alumni Association, "Molecular Therapy in Cancer," Philadelphia, PA, August 12-13, 2000.
54. Invited Speaker, International Symposium of DNA Vaccine and Gene Therapy Technology, "Anti-oncogene therapy," Taipei, Taiwan, September 13-15, 2000.
55. Invited Speaker, International Breast Cancer Symposium at Taiwan, "Novel prognostic markers in breast cancer," Taipei, Taiwan, October 14-15, 2000.
56. Invited Speaker, "Molecular Targeting of HER-2/neu overexpression," 4<sup>th</sup> Annual Meeting of the Chinese Society of Clinical Oncology, Beijing, P.R. China, October 19-22, 2000.
57. Invited Speaker, "The E1A Cancer Gene Therapy: A Two Way Transcriptional Research," Medicine in 21<sup>st</sup> Century First Sino-US Symposium, Houston, TX, December 13, 2000.
58. Invited Speaker, "Cancer: Current Concept of Cancer: Molecular Markers and Therapeutic Targets," UTMDACC, Tumor Markers – A New Era Conference, Santa Barbara, CA, March 2-6, 2001.
59. **Keynote Speaker**, "E1A cancer gene therapy and tumor marker,  $\beta$ -catenin," European Institute of Healthcare – The Patient Beyond the Disease, Barcelona, Spain, March 9-10, 2001.
60. Invited Speaker, Tumor Suppressor Gene and Therapeutic Targets, "Cancer Treatment with Adenovirus Expressing Tumor Suppressor Genes," 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.
61. Invited Speaker, 5<sup>th</sup> Biotech SRB Meeting, Science and Technology Advisory Group, Taipei, Taiwan, May 21, 2001.
62. **Keynote Speaker**, Association of American Chinese Professionals, Commercialization of Innovation, 2001 Science, Engineering and Technology Seminar (SETS) and Diversity Summit, Houston, TX, May 26, 2001.
63. Invited Speaker, American Society of Gene Therapy, Seattle, Washington, June 1-3, 2001.
64. Invited Speaker, 2<sup>nd</sup> International Conference/MDA, North Falmouth, MA, June 4-6, 2001.
65. **Plenary Speaker**, "Therapeutic Approaches," The 17<sup>th</sup> Annual Meeting on Oncogene, Frederick, MD, June 19-24, 2001.
66. Invited Speaker, "The E1A Cancer Gene Therapy, 9<sup>th</sup> SPORE Investigator's Workshops, Washington, D.C., July 15-17, 2001
67. Invited Speaker, 4<sup>th</sup> Annual Opinion Leader Round Table Meeting, "Novel Targets of Akt, MDM2, and p21<sup>Cip1/WAF1</sup>," Colorado Springs, CO, July 25-29, 2001.
68. Invited Speaker, The 9<sup>th</sup> SCBA International Symposium, "Frontier of Biotechnology and Biomedical Science in the New Millennium, Taipei, Taiwan, August 6-10, 2001.

69. Invited Speaker, The 12<sup>th</sup> International Congress on Anticancer Treatment, “The E1A Cancer Gene Therapy”, Paris, France, February 4-7, 2002.
70. Invited Speaker, The 7<sup>th</sup> Taiwan Joint Cancer Conference, “Development of Novel Gene Therapy in Ovarian Cancer”, Taichung, Taiwan, May 4th, 2002.
71. **Invited Speaker as a Plenary Lecture**, “Cancer Gene Therapy: Now and Future” the Sino-America Hi-Tech Symposium, Houston, Texas, May 10-12, 2002.
72. Invited as a faculty member and a session chair: Modulators of Apoptosis “Novel Targets of Akt, MDM2 and p21<sup>cip1/WAF1</sup>”, The Fifth Annual Opinion Leader Summit: “Targeted Therapies in the Treatment of Breast Cancer”, Maui, Hawaii, July 24-28, 2002.
73. Invited Speaker, The Taiwan-American Biotechnology Conference (TABC), “Development of Cancer Gene Therapy and Prognostic Marker” University of San Diego, San Diego, August 22-25, 2002.
74. Invited Speaker, International Symposium on Gene Therapy, Industrial Technology Intelligence Services, Development Center for Biotechnology, Department of Industrial Technology, MOEA, Taiwan “Development of gene therapy through systemic delivery”, Taipei, Taiwan, September, 19, 2002.
75. Invited Speaker as a Plenary Lecture, the 16<sup>th</sup> FAOBMB (Federation of Asian and Oceanian Biochemists and Molecular Biologists) Symposium, “Inactivation of tumor suppressors, p53 and p21<sup>cip1</sup> by oncogenes, HER-2/Akt-mediated pathway”, Academia Sinica, Taipei, Taiwan, September 20-22, 2002.
76. Invited Speaker, “Novel Targets of Akt, MDM2, and p21<sup>cip1/WAF1</sup>”, The Cell Cycle as a Target in Chemoprevention and Cancer Therapy Conference sponsored by UTMDACC and International Society for Translational Research, Austin, Texas, October 3-4, 2002.
77. Invited Speaker, “E1A cancer gene therapy and molecular prognostic markers” 2<sup>nd</sup> Shanghai Pathologists Association Annual Meeting, Shanghai, P. R. China, December 6-10, 2002.
78. Invited Speaker, "Development of Cancer Gene Therapy", the 2<sup>nd</sup> International Symposium on DNA Vaccine and Gene Therapy Technology, Taipei, Taiwan, December 12-14 2002.
79. **Keynote Speaker**, “Life Science: From bench to bedside; From membrane to nucleus”, Interchange of Advanced Life Science Research, National Yang-Ming University, Taipei, Taiwan. December 14, 2002.
80. **Keynote Speaker**, “Novel signaling pathways in human cancer: Akt, p21<sup>cip1/WAF1</sup>, MDM2 and  $\beta$ -catenin” Eleventh Symposium on Recent Advances in Cellular and Molecular Biology, Kenting, Taiwan, January 20-22, 2003.
81. Invited Speaker, “E1A Gene Therapy Targeting HER-2/neu” the 44<sup>th</sup> Annual Clinical Conference “Molecular Therapeutics for Cancer Metastasis”, Houston, TX, March 18-21, 2003.
82. Invited Speaker, “Novel signaling in breast cancer: potential predicative markers” 6<sup>th</sup> Annual Opinion Leader Summit: Targeted therapies for the treatment of breast cancer, Kona, Hawaii, July 9-13, 2003.
83. Invited Speaker, “MDM2-mediated E-Cadherin Ubiquitination and Degradation in Breast Cancer Cells” 2<sup>nd</sup> International MDM2 Workshop, Washington DC, October 18-20, 2003.
84. Invited Speaker, “E1A Gene Therapy” the Annual Symposium of Taiwan Otolaryngological Society, Tainan, Taiwan, November 8-9, 2003.
85. Invited Speaker, “Cancer Gene Therapy: our experience and future directions” and “ Signaling Network of Cancer Cells: importance in the development of cancer therapy, prognosis and prevention” the 3<sup>rd</sup> Samsung Medical Center-MDACC Joint Clinical Cancer

- Symposium “Translational Research in Cancer Management”, Sung Kyun Kwan University Hospital, Seoul, S. Korea, December 4-6, 2003.
86. Invited Speaker, “The Pro-apoptotic Gene, *Bik* and its Mutants in Cancer Gene Therapy” Sidney Kimmel Cancer Center, Meeting in how to apply functional genomics and proteomics to the development of new directions in targeting therapy of cancer, San Diego, CA, February 16-18, 2004.
  87. **Keynote Speaker**, “HER2-mediated Signaling and Metastasis in Breast Cancer” “Biology of Breast Cancer”, the 4<sup>th</sup> Asian Breast Cancer Conference and the 2<sup>nd</sup> Taipei International Breast Cancer Symposium, Taipei, Taiwan, February 27, 2004.
  88. Invited Speaker, “The Pro-apoptotic Gene, *Bik* and its Mutants in Cancer Gene Therapy” “Gene Therapy of Breast Cancer-Update” Session VII-New Approaches to Breast Cancer” the 4<sup>th</sup> Asian Breast Cancer Conference and the 2<sup>nd</sup> Taipei International Breast Cancer Symposium, Taipei, Taiwan, February 29, 2004.
  89. Co-Chair, “Cancer Gene Therapy” session, and invited speaker “Cancer gene therapy: From bench to bedside”, 10<sup>th</sup> SCBA International Meeting, Beijing, P.R. China, July 21, 2004.
  90. Invited Speaker, Tri-Conference “The Pro-apoptotic Gene, *Bik* and its Mutant in Cancer Gene Therapy” “Medicine in the 21<sup>st</sup> Century”-Sessions “Globalization of Chinese Herbal Medicine”, “Innovation in Drug Discovery and Development” and “Intellectual Property/Venture Capital” Shanghai, P.R.C., July 25-27, 2004.
  91. Invited Speaker, “Cytoplasmic/nuclear shuttle: transcriptional factors – FOXO3a and Snail and membrane receptors – EGFR and HER2”, “Signaling Transduction: from pathways to networks”, Session IV: Nuclear Signaling, 57<sup>th</sup> Annual Symposium on Fundamental Cancer Research MDACC, Houston, TX, October 12-15, 2004.
  92. **Keynote Speaker**, “Novel Signaling Transduction in Cancer Cells and Development of Cancer Gene Therapy”, Formosan Medical Association Annual Meeting, Taipei, Taiwan, November 4-7, 2004.
  93. Invited Speaker, “IKK and CXCR4 in tumor progression”, International Conference on Tumor Progression and Therapeutic Resistance, Philadelphia, PA, November 8-9, 2004.
  94. Invited Speaker, “Cellular Localization and Protein Functions: Receptor Tyrosine Kinases, FOXO3a and GSK-3 $\beta$ ”, Session 2: Biomarkers-functional roles in breast cancer, 13th annual Radiation Workshop: “Cell Cycle and Breast Cancer”, Round Top, TX, April 21-23, 2005.
  95. **Invited Discussant**, Thematic Poster Discussion Session II: Molecular Targets and Novel Therapies II (Pancreatic SPORE) & Session I: Apoptosis Thematic Poster Discussion Session (Ovarian SPORE), 13<sup>th</sup> SPORE Investigators' Workshop, Washington DC, July 9-11, 2005.
  96. Invited Speaker, “Novel signaling pathway-mediated by receptor tyrosine kinase”, Federation of American Societies for Experimental Biology (FASEB) 2005 Summer Research Conference: “Growth Factor Receptor Tyrosine Kinases in Mitogenesis, Morphogenesis and Tumorigenesis”, Tucson, AZ., August 6-11, 2005.
  97. Invited Speaker, “Critical events in tumor progression” session, “GSK-3 $\beta$ /Snail in epithelial-mesenchymal transition and nuclear EGFR/Stat3 coregulation of iNOS”, the 2<sup>nd</sup> Tumor Progression & Therapeutic Resistance conference, Burlington, MA, September 18-20, 2005.
  98. Invited Speaker, the 2<sup>nd</sup> International Epithelial Mesenchymal Transition (EMT) Conference, “The role of GSK-3 $\beta$  and Snail in EMT”, Vancouver, BC, Canada, October 1-3, 2005.
  99. Invited Speaker, Session One: Molecular Targets and New Drug Discoveries “Novel Signaling Pathways in Cancer Cells and Development of Targeted Cancer Therapy”,

National Foundation for Cancer Research, Biofunding Summit 2005-International Think-Tank Forum on Anti-Cancer Innovations and Global Collaborations, Beijing, China, October 13-15, 2005.

100. **Invited Speaker**, “*Assessing Progress, Advancing Change: Challenges in Translational Research*”, **President’s Cancer Panel, Washington, D.C., October 24, 2005.**
101. Invited Speaker, “Translocation of membrane EGF receptor to nucleus: function and mechanism”\*, Special Interest Subgroup Conference selected by ASCB Program Committee "Regulation of cell development by nuclear FGF and EGF receptors", 45<sup>th</sup> Annual Meeting of American Society for Cell Biology, San Francisco, CA, December 10-12, 2005. \*Abstract selected for poster presentation.
102. Invited Speaker, “Development of targeted cancer gene therapy”, Session: “Gene Discovery and Drug Development”, 6<sup>th</sup> Human Genome Organization (HUGO)-Pacific meeting & 7<sup>th</sup> Asia-Pacific Conference on Human Genetics “Toward Human Health”. Taipei, Taiwan, March 9, 2006.
103. **Keynote Speaker**, “Novel signaling pathway in cancer cells”, 21<sup>st</sup> Joint Annual Conference of Biomedical Sciences, Taipei, Taiwan, March 17-18, 2006.
104. **Invited Speaker**, Professional Advancement Series Roundtable Session: “Careers in Clinical and Translational Cancer Research”, 97<sup>th</sup> Annual Meeting of the American Association for Cancer Research, Washington DC, April 1, 2006.
105. **Invited Speaker**, Sunrise Session: “Translocation of Membrane EGF Receptor to the Nucleus: Function and Mechanism”, 97<sup>th</sup> Annual Meeting of the American Association for Cancer Research, Washington DC, April 2, 2006.
106. **Invited Speaker**, “Novel Signaling of EGFR/HER2: from membrane to nucleus”, Session “HER2: Herceptin and Beyond”, 97<sup>th</sup> Annual Meeting of the American Association for Cancer Research, Washington DC, April 5, 2006.
107. Invited Speaker, “Novel signaling in cancer cells and development of targeted gene therapy”, 3<sup>rd</sup> Symposium on Frontier Biomedical Sciences, Taichung, Taiwan, July 8-9, 2006.
108. Invited Speaker, “Intranuclear signaling by ErbB receptor”, "Growth Factors and GF Receptors as Therapeutic Targets" session, Development of Molecular Therapeutics in Breast Cancer Retreat, American Society of Clinical Oncology, Aspen, CO, August 11-13, 2006.
109. Invited Speaker, “Novel signaling in cancer cells and development of targeted therapy”, Taipei Breast Cancer Symposium, Taipei, Taiwan, September 2-3, 2006.
110. Invited Speaker, “Novel signaling in Barrett’s Esophagus and development of gene therapy for pancreatic cancer”. Emerging Science Workshop, 3<sup>rd</sup> Annual Meeting of International Society of Gastrointestinal Oncology, Arlington, Virginia, September 21-23, 2006.
111. Invited Speaker, “Shuttling of membrane receptors and cytoplasmic molecules to the nucleus: importance to tumor progression”, 3<sup>rd</sup> International Conference on Tumor Progression and Therapeutic Resistance, Baltimore/Washington DC, October 22-24, 2006.
112. Invited Speaker, “Novel signaling in Barrett’s Esophagus carcinoma”, Third Esophageal Cancer and Barrett's Metaplasia Research Summit, Las Vegas, NV, November 10-11, 2006.
113. Invited Speaker, “VISA to cancer therapy”, “New Targets and Delivery Systems in Cancer Diagnosis and Treatment”, Annual Scientific Conference of Sidney Kimmel Cancer Center, San Diego, CA, March 5-7, 2007.
114. Invited Speaker, “Novel Signaling in Cancer Cells” Forty Years of Metastasis Research, Symposium in Honor of Dr. Isaiah J. Fidler, Houston, TX, March 23-24, 2007.

115. Invited Speaker, "Cell signaling pathways that target harmatin", Annual Lymphangiomyomatosis (LAM) Meeting, Cincinnati, OH, April 20-22, 2007.
116. Invited Speaker, "Novel functions and mechanisms for translocation of membrane receptor to the nucleus", 2007 Symposium on Frontier Biomedical Sciences, National Yang-Ming University, Taipei, Taiwan, Aug 11-12, 2007.
117. Invited Speaker, "Nuclear role for the EGFR and ErbB2", 2007 FASEB Summer Research Conference entitled "Growth Factor Receptor Tyrosine Kinases in Mitogenesis, Morphogenesis & Tumorigenesis", Tucson, AZ, August 12-16, 2007.
118. **Plenary Speaker**, "Emodin, a chemopreventive agent for prostate cancer" Traditional Herbal Symposium, Taipei Medical University, Taipei, Taiwan, October 4-6, 2007.
119. Invited Speaker, "Novel signaling links cancer/obesity/diabetes and development of targeted gene therapy", Session 3: Targeted Cancer Therapies and Personalized Medicine, 4th International Think-Tank Forum: Anti-Cancer Innovation and Global Collaboration, National Foundation for Cancer Research and 14th Hong Kong International Cancer Congress (HKICC) with Center for Cancer Research of University of Hong Kong, Hong Kong, November 14, 2007.
120. Invited Speaker, "Novel signaling links cancer/obesity/diabetes and development of targeted gene therapy", First International Symposium on Cancer Research, China Medical University Hospital, Taichung, Taiwan, November 16-17, 2007.
121. **Keynote Speaker**, "Novel pathways linking cancer and diabetes, the development of targeted cancer therapy", 2007 Biotechnology Forum, Industrial Technology Research Institute, Hsinchu, Taiwan, November 21, 2007.
122. Invited Speaker, "Novel pathways linking cancer/obesity/diabetes and the development of targeted cancer therapy", The 50<sup>th</sup> Anniversary of National Research Institute of Chinese Medicine and Symposium, Taipei, Taiwan, November 24, 2007.
123. Invited Speaker, "Strategies for Therapeutic Targeting GSK3beta, ERK and beta-catenin" Keystone Symposium "Wnt/beta-catenin signaling in development and disease", Keystone, CO., February 17-22, 2008.
124. Invited Speaker, Meet-the-Expert Sessions on the topic of "Breast Cancer Progression and Metastasis", 2008 Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12-16, 2008.
125. **Keynote Speaker**, "Overview: Herbal Medicine and Vaccine Technology", International Symposium: Biotechnology for Better Crops, Energy and Health: ABRC 10th Anniversary, 10<sup>th</sup> Anniversary of Agricultural Biotechnology Research Center at Academia Sinica, Taipei, Taiwan, May 1, 2008.
126. **Keynote Speaker**, "Development of Targeted Cancer Gene Therapy", Symposium for the Frontier of Asia-Pacific Pharmaceutical Sciences, China Medical University and Hospital, Taichung, Taiwan, May 3, 2008.
127. Invited Speaker, "A Novel Signaling Pathway Linking Cancer, Obesity and Diabetes", 2008 13<sup>th</sup> Taiwan Joint Cancer Conference, and Educational Lecture (a second one), Taipei, Taiwan, May 4, 2008.
128. Invited Speaker, "Three Onco Kinases: Akt, Erk and IKK and Cancers", Spring Conference of Formosan Medical Association, China Medical University and Hospital, Taichung, Taiwan, May 11, 2008.
129. Invites Speaker, " How to write a fundable grant application and an acceptable manuscript, my experience ", Annual Meeting of Taiwanses Society of Investigative Dermatology, Taichung, Taiwan, May 31, 2008.

130. Invites Speaker, "Skin Cancer, Onco-kinases and Personalized Medicine", Spring Conference of Taiwanese Dermatological Association, Taichung, Taiwan, June 1, 2008,
131. Invited Speaker, "Three Onco Kinases: Akt, Erk and IKK and Cancers", 2008 Symposium on Frontier Biomedical Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan, June 27, 2008.
132. Invited Speaker, "Recent Development in Breast Cancer Progression and Metastasis", Cancer Metastasis Symposium, Chinese Medical Association, National Yang-Ming University, Taipei, Taiwan, June 28, 2008.
133. Invited Speaker, "Cancer-Targeting Gene Therapy", Session: "Clinical Applications of Nanomedicine", 2008 American Academy of Nanomedicine Conference, Bolger Center in Protomac, Maryland, September 4-7, 2008.
134. Participant, Academia Sinica-Academy Presidents' Forum, "Role of the Academies in Creating a Better Role", Academia Sinica, Taipei, Taiwan, December 6-8, 2008.
135. Keynote Speaker, "Three oncokines, Akt, IKK and Erk, in the development of human cancers; and recent development of cancer stem cells", Taiwan Bone Regeneration Symposium, February 14, 2009.
136. Invited Speaker, "To believe or not to believe: novel functions of EGFR family", Symposium on Cancer Development and Therapeutic Target, National Health Research Institute, Zhunan, Taiwan, April 10, 2009.
137. Roundtable Mentor, Grant Writing Workshop for early-career scientists, AACR 100<sup>th</sup> Annual Meeting, Denver, Colorado, April 18, 2009.
138. Roundtable Discussion Leader, Topics: Oral Presentations, Women in Cancer Research Council of AACR, AACR 100<sup>th</sup> Annual Meeting, Denver, Colorado, April 20, 2009.
139. Invited Speaker, "Three oncokines, Akt, IKK and Erk in the development of human cancers", Biennial M.D. Anderson Cancer Center-Fudan University Pathology Conference, Shanghai, China, June 5-8, 2009.
140. Invited Speaker, "Chromatin function-regulated by Receptor Tyrosine Kinases", Theme: Epigenetics and Epigenomics—Session: Chromatin epigenetic modification and cancer, 12<sup>th</sup> SCBA International Symposium, Taipei, Taiwan, June 18, 2009.

#### **Seminar Invitations from Other Institutions:**

1. University of Pennsylvania, Pennsylvania, PA, March 1988.
2. Tanox Biosystem, Houston, TX, July 14, 1988.
3. The second Annual Symposium of Chinese Bioscientists in America, Baylor College of Medicine, Houston, TX, November 12, 1988.
4. The 10th Annual Science Engineering Technology Seminars, Houston, TX, May 26-28, 1989.
5. Research Division of Bristol Myers, Connecticut, June 7, 1989.
6. Invited Speaker, American Society of Microbiology, Texas Branch, The University of North Texas, March 23, 1990.
7. Lilly Research Laboratories, Indiana, April 27, 1990.
8. National Children's Medical Research Center, Tokyo, Japan, June 27, 1990.
9. Mitsubishi Kasei Corporation Research Center, Tokyo, Japan, June 28, 1990.
10. National Taiwan University, Taipei, Taiwan, June 22, 1990.
11. Institute of Zoology, Academia Sinica, Taipei, Taiwan, June 30, 1990.
12. Kaohsiung College of Medicine, Kaohsiung, Taiwan, July 6, 1990.



13. Oncogene Science Inc., New York, September 26, 1990.
14. Schering - Plough Research, New Jersey, November 28, 1990.
15. Baylor College of Medicine, Dept. of Cell Biology, Houston, TX, April 24, 1991.
16. The 1991 Science Engineering Technology Seminars, Houston, TX, May 25-26, 1991.
17. Chang Gung Medical College, Taoyuan, Taiwan, July 31, 1991.
18. Development Center for Biotechnology, Taipei, Taiwan, July 31, 1991.
19. Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, August 6, 1991.
20. National Taiwan University College of Medicine, Taipei, Taiwan, August 6, 1991.
21. Veteran General Hospital, Medical Research Center, Taipei, Taiwan, August 7, 1991.
22. Baylor College of Medicine, Dept. of Pathology, Houston, TX, October 23, 1991.
23. The University of Texas Health Science Center at San Antonio, TX, December 5, 1991.
24. St. Louis University, St. Louis, MO, April 1, 1992.
25. The University of Florida, Gainesville, FL April 17, 1992.
26. The 1992 Science Engineering Technology Seminars, Houston, TX, May 24-25, 1992.
27. Amgen, Inc., Thousand Oaks, CA, June 2, 1992.
28. National Taiwan University Medical College, Taipei, Taiwan, June 9, 1992.
29. Development Center of Biotechnology, Taipei, Taiwan, June 10, 1992.
30. Research Center, Tzu-chi General Hospital, Hua-Lien, Taiwan, June 11, 1992.
31. National Chen-Kung University, Medical School, Taiwan, June 12, 1992.
32. Kaohsiung Medical College, Kaohsiung, Taiwan, June 13, 1992.
33. Chang Gung Medical College, Taoyuan, Taiwan, June 22, 1992.
34. Veteran General Hospital, Taipei, Taiwan, June 22, 1992.
35. Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, June 23, 1992.
36. National Taiwan University Hospital, Taipei, Taiwan, June 23, 1992.
37. The University of Texas Health Science Center, Houston, TX. Department of Pharmacology, Houston, November 23, 1992.
38. Triplex Pharmaceutical Corporation, The Woodlands, TX, February 5, 1993.
39. North American Taiwanese Professor's Association, Houston Chapter, July 31, 1993.
40. Argus Pharmaceuticals, Inc., The Woodlands, TX, August 31, 1993.
41. Houston Biotech. Morning Club, Houston, TX, September 8, 1993.
42. Essex, Inc., Chicago, IL, September 9, 1993.
43. Baylor College, Dept. of Medicine, Houston, TX, October 12, 1993.
44. University of Wisconsin Department of Human Oncology, Madison, WI, December 1993.
45. Baylor College of Medicine, Dept. of Biochem, Houston, TX, January 6, 1994.
46. Texas Triangle Meeting, Dallas, TX, March 18-19, 1994.
47. Univ. of Wisconsin Medical School, Dept. of Human Oncology, Madison, WI, April 6, 1994.
48. Radiation Workshop on Apoptosis, Round Top, TX, May 5-8, 1994.
49. Wayne State Univ., Dept. of Pathology, Detroit, MI, May 18, 1994.
50. Development Center of Biotechnology, Taipei, Taiwan, June 14, 1994.
51. Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China, June 24, 1994.
52. Shanghai Medical University, Cancer Hospital, Shanghai, China, June 22, 1994
53. Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China, June 24, 1994.
54. University of Miami, Dept. of Cell Biol. and Anatomy, Miami, FL, September 23, 1994.
55. Institute of Zellbiologie (Tumorforschung), University - Gesamthochschule, Essen, Germany, October 27, 1994.
56. Sennes Drug Innovations, Inc. - Houston, TX, November 18, 1994.
57. Case Western Reserve University, Cleveland, OH, December 6, 1994.

58. University of Pittsburgh School of Medicine, Department of Pharmacology, Pittsburgh, PA., January 19, 1995.
59. Oligo Therapeutics Inc., New York. February 28, 1995.
60. Wayne State University, Division of Hematology and Oncology, Harper Hospital, Detroit, MI, March 9, 1995.
61. Bristol-Meyer, Gene Therapy Group, New York, NY, May 19, 1995.
62. National Cheng-Kung Univ., Tainan, Taiwan, September 18, 1995.
63. National Medical College, Taipei, Taiwan, September 19-20, 1995.
64. National Taiwan University, School of Medicine, Taipei, Taiwan. September 21, 1995.
65. Institute of Biomedical Sciences, Academia Sinica, Taiwan. September 22, 1995.
66. Lombardi Cancer Center, Georgetown University, Washington, D.C., October 13, 1995.
67. Karmanos Cancer Institute, Wayne State University, Detroit, MI, October 16, 1995.
68. Harper Hospital, Detroit Medical Center, Wayne State University, Detroit, MI, October 16, 1995.
69. Transkaryotic Therapies Inc., Cambridge, MA, October 24, 1995.
70. Ohio State University, Columbus, OH, January 19, 1996.
71. Rice University, Houston, TX, February 19, 1996.
72. Mayo Clinic, Rochester, Minnesota, April 25, 1996.
73. Targeted Genetics Corporation, Seattle, Washington, May 9, 1996.
74. University of Pittsburgh, PA, August 12, 1996.
75. Mayo Cancer Center, Rochester, Minnesota, July 18-20, 1996.
76. National Taiwan University Hospital, Taipei, Taiwan, August 26, 1996.
77. Invited Speaker, Breast Cancer Program (Sylvester Comprehensive Cancer Center), Miami, FL, December 9-10, 1996.
78. Invited Speaker, University of Texas Medical Branch at Galveston, Texas, December 16, 1996.
79. Targeted Genetics Corporation, Seattle, Washington, January 10, 1997.
80. Invited Speaker, the Symposium in Honor of Professor Tun-Bing Lo's Retirement. Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, February 17-19, 1997.
81. Invited Speaker, Laboratoires Fournier, Paris, France, February 25-28, 1997.
82. Amgen, Inc., Thousand Oaks, California, April 17, 1997.
83. Targeted Genetics Corporation, Seattle, Washington, July 13-15, 1997.
84. Invited Speaker, National Taiwan University Hospital, September 2, 1997.
85. Invited Speaker, The University of Houston, Houston, TX, September 15, 1997.
86. Invited Speaker, Laboratoires Fournier, London, September 23-24, 1997.
87. Invited Speaker, The University of Essen, Germany, September 25, 1997.
88. Invited Speaker, "HER-2/neu targeted cancer gene therapy," The University of Pittsburgh, Pittsburgh, PA, November 24, 1997.
89. Invited Speaker, Baylor College of Medicine, December 17, 1997.
90. Invited Speaker, "E1A tumor suppression activity for HER-2/neu overexpressing cancer cell" and "Mechanism of HER-2/neu induced malignancy," Univ. of Hong Kong as a Kadoorie Fund Visiting Professor, Hong Kong, January 5-6, 1998.
91. Invited Speaker, "HER-2/neu targeting gene therapy in breast and ovarian cancer," Vancouver, BC, Canada, March 23-24, 1998.
92. Invited Speaker, "E1A gene therapy for HER-2/neu-overexpressing cancer," SUNY Health Science Center, Syracuse, NY, April 21, 1998.

93. Radiation Workshops on Growth Factors: biological and clinical aspects, "E1A gene therapy for HER-2/neu-overexpressing cancer," Round Top, TX, April 30-May 3, 1998.
94. Invited Speaker, "Anti-tumor activity of E1A for HER-2/neu-overexpressing cancer cell," Johns Hopkins Oncology Center, May 11, 1998.
95. Invited Speaker, Kaohsiung Medical University, October 19, 1998.
96. Invited Speaker, "E1A gene therapy in breast and ovarian cancer," Rotary Club of Kaohsiung Grand Harbor, October 20, 1998.
97. Invited Speaker, "The E1A gene therapy for HER-2/neu-overexpressing tumors: A story from bench to bedside," Markey Cancer Center Distinguished Visitor Seminar Series, Kentucky, November 11-12, 1998.
98. Invited Speaker, Biotechnology & Pharmaceutical Program Office, Asia-Pacific Regional Operations Center, Taipei, Taiwan, November 14-20, 1998.
99. Invited Speaker, "Anti-tumor activity of E1A on HER-2/neu-overexpressing cancer," Division of Molecular Virology, Baylor College of Medicine, Houston, TX, January 19, 1999.
100. Invited Speaker, "PEA3 is a tumor suppressor," Gene Medicine, Woodlands, TX, February 16, 1999.
101. Invited Speaker, "E1A cancer gene therapy on HER-2/neu-overexpressing cancer," Loyola University Medical Center, Chicago, IL, March 12, 1999.
102. Invited Speaker, "E1A gene therapy in breast and ovarian cancer," Shanghai Medical University, Shanghai, China, March 24-25, 1999.
103. Invited Speaker, "Cancer gene therapy: breast and ovarian cancer," Cancer Institute and Hospital/Chinese Academy of Medical Sciences, Beijing, China, March 26-27, 1999.
104. Invited Speaker, "Cationic lipid-mediated gene therapy for cancer," University of Oklahoma, College of Medicine, Oklahoma City, Oklahoma, April 8-9, 1999.
105. Invited Speaker, "E1A gene therapy on HER-2/neu-overexpressing cancer," Lineberger Cancer Research Center, Chapel Hill, North Carolina, April 28, 1999.
106. Invited Speaker, "Development of novel cancer gene therapy," TANOX Company, Houston, TX, September 16, 1999.
107. Invited Speaker, "Development of novel gene therapy," Department of Pathology, The University of Texas Medical School, Houston, TX, November 10, 1999.
108. Invited Speaker, "Her-2/neu-targeting Cancer Therapy," Wyeth-Ayerst Research, Pearl River, NY, Dec. 5- 6, 1999.
109. Invited Speaker, "E1A cancer gene therapy: A two-way translational research," Department of Tumor Genetics and Biology, Kumamoto School of Medicine, Kumamoto, Japan, September 18, 2000.
110. Invited Speaker, National Cheng-Kung University - Tainan, Taiwan October 17, 2000.
111. Invited Speaker, "HER-2 signaling and taxol resistance," Hematology Oncology Research Conference, University of Pennsylvania, PA, October 31, 2000.
112. Invited Speaker, The Houston Spore Retreat, "Gene therapy and novel molecular marker for breast cancer," Baylor College of Medicine Breast Center, Pharmacology Department, Houston, TX, November 11, 2000.
113. Invited Speaker, "The E1A cancer gene therapy: A two way transcriptional research," Baylor College of Medicine, Houston, TX, December 13, 2000.
114. Invited Speaker, "E1A cancer gene therapy and tumor marker, -catenin," Enchira, Houston, TX, January 18, 2001.

115. Invited Speaker, "The E1A gene therapy and a novel prognostic markers,  $\beta$ -catenin," H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, February 7, 2001.
116. Invited Speaker, Mao-Sen Biotechnology, Inc., Taiwan Gene Therapy Consortium, Taipei, Taiwan, February 13-14, 2001.
117. Invited Speaker, "E1A cancer gene therapy and  $\beta$ -catenin tumor marker: from transcriptional regulation and signal transduction to clinic applications," Mayo Clinic Center, Rochester, MN, February 22-23, 2001.
118. Invited Speaker, E1A cancer gene therapy and  $\beta$ -catenin: tumor marker in breast cancer," Arkansas Cancer Research Center Forum, Little Rock, AR, March 12, 2001.
119. Invited Speaker, National Defense Medical College, Taipei, Taiwan, August 8, 2001.
120. Invited, Speaker, Chang-Gung Medical School, Lin-Kuo Medical Center, Taipei, Taiwan, August 9, 2001.
121. Invited Speaker, National Taiwan University, "Translational Research: Cancer Gene Therapy and Novel Signal Transduction" Taipei, Taiwan, October 22, 2001.
122. Invited Speaker, National Cheng Kung University, "E1A Cancer Gene Therapy and It's Anti-Tumor," Tainan, Taiwan, October 23, 2001.
123. Invited Speaker, "The E1A cancer gene therapy and AKT/MDM2 signaling", Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei, Taiwan, November 28, 2001.
124. Invited speaker, "E1A Cancer Gene Therapy and Novel Signaling of AKT", Department of Pathology, in conjunction with the Oklahoma Center for Neuroscience, the Oklahoma for Toxicology, and Department of Cell Biology and Physiology, Interdisciplinary Seminar Series at the University of Oklahoma Health Science Center, Oklahoma City, OK, January, 3<sup>rd</sup>, 2002.
125. Invited Speaker, "E1A gene therapy and MDM2 as a target of Akt", Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA., March 11, 2002.
126. Invited Speaker, "Development of Cancer Gene Therapy: E1A and Bik as Anticancer Genes", Taipei Veterans General Hospital, Taipei, Taiwan, May 6<sup>th</sup>, 2002.
127. Invited Speaker, "How to ask question in the laboratory to address clinical problems: Identification o prognostic markers and development of caner gene therapy", Taichung Veterans General Hospital, Taichung, Taiwan, May 7<sup>th</sup>, 2002.
128. Invited Speaker, "How to write a program project grant." Academia Sinica, Taipei, Taiwan, September 4<sup>th</sup>, 2002.
129. Invited Speaker, " Novel signaling pathways in human cancers: Akt, p21<sup>cip1</sup>, MDM2 and  $\beta$ -catenin" Breast Disease Research Group at Baylor College of Medicine, Houston, TX, November 13, 2002.
130. Invited Speaker, "E1A cancer gene therapy and novel signaling pathway in cancer cells" Recent Advances in Genomic Medicine Symposium, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, December 2, 2002.
131. Invited Speaker, "Development of cancer gene therapy and prevention for breast cancer" Industrial Technology Research Institute, Hsingchu, Taiwan, December 5<sup>th</sup>, 2002.
132. Invited Speaker, "Novel Signaling Pathways in Human Cancer Cells" Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Shanghai, China, December 9, 2002.
133. Invited Speaker, "E1A cancer gene therapy and molecular prognostic markers" Shanghai Second Medical University, Shanghai, China, December 9, 2002.

134. Invited Speaker, “E1A cancer gene therapy and novel molecular prognostic markers” The way from gene to cellular therapy symposium. Kaohsiung Medical University, Kaohsiung, Taiwan, December 11, 2002.
135. Invited Speaker, “Novel Targets of Akt, MDM2, and p21<sup>Cip1/WAF1</sup>”, Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, January 17, 2003.
136. Invited Speaker, “Novel signaling pathways in human cancers: Akt, p21<sup>Cip1/WAF1</sup> and MDM2” School of Medicine, National Cheng-Kung University, Tainan, Taiwan, February 15, 2003.
137. Invited Speaker, “Novel Signaling Pathways involving Akt, MDM2, and p21<sup>Cip1/WAF1</sup>”, Tumor Biology Seminar Series, Lombardi Cancer Center, Georgetown University, Washington, DC, March 7, 2003.
138. Keynote Speaker, “Novel Signaling Pathways in Human Cancers: Akt, p21<sup>Cip1/WAF1</sup>, MDM2, and  $\beta$ -catenin” 7<sup>th</sup> Annual Life Science Symposium at UTMB, Galveston, TX, May 23, 2003.
139. Invited Speaker, “Development of Cancer Therapy and Chemoprevention”, Center for Drug Evaluation, Taipei, Taiwan, August 14, 2003.
140. Invited Speaker, “Development of Cancer Gene Therapy”, Graduate Institute of Clinical Medical Sciences, Divisions of General Medicine and of Hematology-Oncology, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan. August 16, 2003.
141. Keynote Speaker, “Receptor Tyrosine Kinase from Cell Surface to Nuclear” Cancer Center Research Symposium, UC Davis Cancer Center, Sacramento, CA, October 9-10, 2003.
142. Invited Speaker, “Novel Signaling in Breast Cancer” Department of Biochemistry and Molecular Genetics, University of Colorado Health Science Center, Denver, Co, October 14, 2003.
143. Keynote Speaker, “Novel Signaling Pathways and their Applications in Human Cancers”, Cancer Symposium: Beyond Cancer Research-Celebration of the 30<sup>th</sup> Military Academic Symposium, National Defense Medical Center, Taipei, Taiwan. November 7, 2003.
144. Invited Speaker,, “Novel signaling pathways in cancer cells” National Chung-Kung University, Tainan, Taiwan, November 10, 2003.
145. Invited Speaker, “Novel Signaling in Breast Cancer” Mouse Model for Human Breast Cancer Consortium, NCI, NIH, Washington, DC, November 19, 2003.
146. Invited Speaker, For the Hospital-“Development of Cancer Gene Therapy: our experience, current status and future directions” and For the University-“ Signal Transduction: its application to cancer prognosis and metastasis”, China Medical University, Taichung, Taiwan, December 9, 2003.
147. Invited Speaker, “HER2-induced invasion requires CXCR4” Annual Meeting of Angiogenesis Research Center, National Taiwan University, Taipei, Taiwan, December 10, 2003.
148. Invited Speaker, “ Signaling network of cancer cells and cancer gene therapy”, Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan, December 12, 2003.
149. Invited Speaker, “Novel signaling in cancer cells” Neurosurgery Grand Rounds, University of Ill. College of Medicine-Peoria, Ill, Peoria, January 9, 2004.
150. Invited Speaker, “HER2-induced homing metastasis requires CXCR4 and tumor-targeting therapy” China Medical University and Hospital, Taichung, Taipei, February 23, 2004.

151. Invited Speaker, “Novel signaling in cancer cells---episode 3” 20<sup>th</sup> Anniversary of National Cheng Kung University Medical College Symposium “New Development in Biomedicine”, Tainan, Taiwan, February 25-26, 2004.
152. Invited Speaker, “Novel signaling in cancer cells: its implication in cancer therapy and prognosis”, Baylor College of Medicine, Department of Cell Biology, Houston, TX., March 3, 2004.
153. Invited Speaker, “Novel signaling pathways in cancer cells: their implications in cancer therapy and prognosis” Department of Pathology, Wayne State University School of Medicine, Detroit, MI., April 7, 2004.
154. Invited Speaker, “Tumor targeting cancer gene therapy and homing metastasis” Grand Round Seminar Series, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, April 8, 2004.
155. Invited Speaker, “Novel Signaling in Cancer Cells and Emodin as an Androgen Receptor for Prostate Cancer” Cancer Center Prostate Program Investigator, Baylor College of Medicine, Houston, TX, May 25, 2004.
156. Invited Speaker, “Novel signaling in cancer cells: its implication in cancer therapy and prognosis” in the meeting for “The Recent Advances in Biomedical & Biological Sciences.” Academia Sinica, Taipei, Taiwan, July 3, 2004.
157. Invited Speaker, “Novel Signaling in Cancer Cells and its clinical implication”, Symposium on Frontier Biomedical Sciences and Retirement Ceremony for Professor Juan-Yaw Lin, National Taiwan University, Taipei, Taiwan, July 9-10, 2004.
158. Invited Speaker, “Experience Sharing: grant writing and manuscript submission”, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, July 16, 2004.
159. Invited Speaker as an Honorary Professorship, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P.R. China, July 24, 2004.
160. Invited Speaker, “Novel Signaling in Cancer Cells: its clinical implication and development of targeted gene therapy”, Winship Cancer Institute, Emory University, Atlanta, GA., August 30-31, 2004.
161. Invited Speaker, “Novel Signaling Pathways in Cancer Cells and Development of Targeted Cancer Gene Therapy” Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE., October 7-8, 2004.
162. Invited Speaker, “Novel Signaling Pathways in Cancer Cells and Development of targeted Gene Therapy” Cancer Center Grand Rounds, **Julia and Patricia Kingsbury Memorial Lecture , Yale Cancer Center, New Haven, CT., October 18-19, 2004.**
163. Invited Speaker, “Experience Sharing: Grant Writing”. China Medical University, Taichung, Taiwan, December 20, 2004.
164. Invited Speaker, “Translational research: a bridge between basic and clinical medicine” Internal Medicine Grand Rounds, Chang Gung Memorial Hospital, Kaoshiung, Taiwan, December 21, 2004.
165. Invited Speaker, “Novel signaling pathways in cancer cells and their clinical implication” H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, February 8-9, 2005.
166. Invited Speaker, “Signaling transduction pathways in cancer cells and novel gene therapy” Kaoshiung Medical University, Kaoshiung, Taiwan, March 16, 2005.
167. Invited Speaker “Development of novel gene therapy from laboratory to bedside” Center for Drug Evaluation, Taipei, Taiwan, March 17, 2005.
168. Invited Speaker, “Novel Signaling Pathway in Cancer Cells and Development of Target Therapy”, Genomic Research Center, Academia Sinica, Taipei, Taiwan, March 18, 2005.

169. Invited Speaker, “Novel Signaling Pathways in Cancer Cells and Development of Targeted Therapy” Department of Cancer Biology, University of Mass Medical School, Worcester, MA, April 25-27, 2005.
170. **Keynote Speaker**, “Novel Signaling Pathways in Cancer Cells”, the first SCBA Oregon Chapter annual meeting, Portland, Oregon, April 30, 2005.
171. Invited Speaker, “Novel Signaling in Cancer Cells”, China Medical University Hospital, Taichung, Taiwan, May 4, 2005.
172. Invited Speaker, “Novel Signaling in Cancer Cells”, National Taiwan University College of Medicine, Taipei, Taiwan, May 6, 2005.
173. **Plenary Speaker**, National Cancer Institute, “Cellular localization, a critical factor for cancer biomarkers” Center for Cancer Research, Retreat of the Cancer Prevention, Breast Cancer and Gynecological Cancer Faculties, Flinstone, MD, July 20-22, 2005.
174. Invited Speaker, “Novel Signaling in Cancer Cells and Development of Targeted Therapy”, Breast Cancer Research Program at the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, August 15-17, 2005.
175. **Invited Speaker, “Signaling of Receptor Tyrosine Kinases: from membrane to nucleus” Elkin Distinguished Cancer Lectureship Series, Winship Cancer Institute, Emory University School of Medicine, August 21-22, 2005.**
176. Invited Speaker, “Novel Signaling in Cancer Cells”, Division of Cancer Biology, Department of Medicine, Evanston Northwestern Healthcare Research Institute, Feinberg School of Medicine, Northwestern University, Evanston, IL, September 12-14, 2005.
177. Invited Speaker, “Signal Transduction, Cancer Prognosis and Targeted Gene Therapy”, Shanghai Cancer Hospital, Fudan University, Shanghai, China, October 9-12, 2005.
178. **Invited Speaker, “Novel Signaling in Cancer Cells” 2005-2006 Distinguished Lecture Series, Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, NJ, November 15-17, 2005.**
179. Invited Speaker, “Novel signaling in cancer cells”, Professor T.B. Lo 80<sup>th</sup> Birthday Symposium, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, February 16-17, 2006.
180. Invited Speaker, Department of Pharmacology, College of Medicine, National Taiwan University, March 6, 2006.
181. Invited Speaker, “Novel signaling in cancer cells”, Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan, March 13, 2006.
182. Invited Speaker, “Novel signaling in cancer cells”, China Medical University Hospital, Taichung, Taiwan, March 15, 2006.
183. Invited Speaker, “The origin of cancer: from oncogenes o tumor suppressor genes”, Asia University, Taichung, Taiwan, March 16, 2006.
184. Invited Speaker, “Novel signaling in cancer cells”, Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan, March 17, 2006.
185. Invited Speaker, “Novel Signaling in Cancer Cells”, Molecular Pathology Seminar Series, Johns Hopkins University, Baltimore, MD, April 11-13, 2006.
186. Invited Speaker, “Novel signaling in cancer cells” Department of Pharmacology, Loyola University Medical Center, Chicago, IL, April 26, 2006.
187. **Keynote Speaker**, “Cancer therapy by targeting angiogenesis”, Angiogenesis Center, Ribbon Cutting Ceremony, National Taiwan University, Taipei, Taiwan, May 20, 2006.

188. Invited Speaker, “Pancreatic cancer-specific gene therapy and membrane receptors in the nucleus”, China Medical University Hospital, Taichung, Taiwan, June 30, 2006.
189. Invited Speaker, “Experience sharing: proposal preparation and grant writing”, Hong Kong University, Hong Kong, China, September 12, 2006.
190. Invited Speaker, “Novel signaling pathways in cancer cells and development of cancer-targeted therapy”, Hong Kong University, Hong Kong, China, September 13, 2006.
191. Invited Speaker, “Shuttling of membrane receptors and cytoplasmic molecules to the nucleus: importance to tumor progression”, New York University Cancer Institute Seminar, New York City, New York. October 18, 2006.
192. **Invited Speaker**, “Shuttling of membrane receptors and cytoplasmic molecules to the nucleus: importance to tumor progression”, Short Course-“New Frontiers in Signal Transduction”, Cellular and Molecular Biology Program and Human Genetics Program, University of Michigan-Ann Arbor, Ann Arbor, Michigan, October 24-25, 2006.
193. Invited Speaker, “Experience Sharing: Grant Writing”, National Science Council, Taipei, Taiwan, November 27, 2006.
194. Invited Speaker, “Novel signaling pathways in cancer cells: nucleocytoplasmic shuttling of membrane receptor tyrosine kinase”, Wednesday Department Seminar, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, March 28, 2007.
195. Invited Speaker, ‘Novel Signaling Pathways in Cancer Cell and Targeted Cancer Therapy’, Louisiana Cancer Research Consortium Speaker Series, Tulane University, New Orleans, LA, June 21, 2007.
196. Invited Speaker “Novel signaling pathway, cancer, diabetes and obesity; and targeted cancer therapy”, Kaohsiung Medical University, Kaohsiung, Taiwan, August 7, 2007.
197. **Endowed Lectureship**, “Novel signaling pathways: cancer, obesity, diabetes and longevity”, Taipei Medical University, Taipei, Taiwan, October 3, 2007.
198. Invited Speaker, “Erk and IKK-mediated tumor progression and membrane receptor in the nucleus”, Cell Biology Program Research Seminar Series, Memorial Sloan-Kettering Cancer Center, NYC, NY, April 9-10, 2008.
199. **Distinguished Guest Speaker**, “Signal network of three oncogenic kinases and membrane receptor in the nucleus”, Department of Molecular and Cellular Biology, Graduate Student Symposium, Baylor College of Medicine, Houston, TX, May 15, 2008.
200. Invited Speaker, ‘Novel Signaling Pathways in Cancer Cell and Targeted Cancer Therapy’, Uniformed Services University of the Health Sciences, Bethesda, MD, February 18, 2009.
201. Invited Speaker, “Signal Network of Three Oncogenic Kinases and Membrane Receptor in the Nucleus”University of Texas Health Sciences Center at Houston, March 30, 2009.
202. **Distinguished Speaker**, Distinguished Seminar, Markey Cancer Center, University of Kentucky, Lexington, KY, October 8, 2009.
203. **Distinguished Speaker**, “To believe or not to believe: novel functions of EGFR family”, University of Virginia, Charlottesville, VA, October 23, 2009.

#### **Seminar Invitation Inside Institution (1996 - present)**

1. Genitourinary Medical Oncology, January 1, 1996.
2. Department of Neuro-oncology, February 22, 1996.
3. Breast Cancer Research Group Retreat, March 9, 1996.
4. Department of Laboratory Medicine, July 8, 1996.



5. Breast Cancer Research Group Retreat, September 7, 1996.
6. Cancer Therapeutics Discovery Retreat, January 10, 1997.
7. Ovarian Cancer Research Retreat, January 11, 1997.
8. Tumor Biology Wednesday Seminar Series, January 25, 1997.
9. Advanced in Oncology, Division of Medicine Grand Rounds, February 25, 1997.
10. Prostate Cancer Research Retreat, June 25, 1997.
11. Science Park- Research Division, November 14, 1997.
12. Advanced in Oncology, Division of Medicine Grand Rounds, December 5, 1997.
13. Lecture Series for Medical Oncology Fellows, February 12, 1998.
14. Brain Tumor Center Research Seminar, June 25, 1998.
15. Thoracic/Head and Neck Medical Oncology, Journal Club Conference, July 23, 1998.
16. Media Symposium: "Cancer in the 21<sup>st</sup> Century", November 6, 1998.
17. Advanced in Oncology Institutional Grand Rounds, December 4, 1998.
18. Department of Cancer Biology, February 1, 1999.
19. Houston Technology Conference, March 1, 1999.
20. Advanced in Oncology, Institutional Grand Rounds, April 23, 1999.
21. Protocol Research Meeting, "Anti-tumor Activities of Adenoviral E1A Gene," September 22, 1999 (Morning).
22. Radiation Oncology, "Anti-tumor Activity and Radiation Sensitization of E1A," September 22, 1999 (Afternoon).
23. Bioimmunotherapy, "Anti-tumor Activities of E1A," November 15, 1999.
24. SPORE Investigators Scientific Meeting, "HER-2-mediated signaling in breast cancer cells," September 29, 2000.
25. Gastrointestinal Medical Oncology, October 25, 2000.
26. Division of Medicine Ground Rounds, January 16, 2001.
27. Core Curriculum Lecture, "Tumor Cell Biology" September 24, 2001.
28. British Embassy Gene Therapy and Biotechnology, March 25, 2002.
29. Breast Medical Oncology Journal Club, March 27, 2002.
30. Pancreatic Cancer Research Retreat, March 29, 2002.
31. Ovarian Cancer Spore Retreat, May 24, 2002.
32. Core Curriculum Lecture on Tumor Immunology, November 4, 2002.
33. Scientific Excellence: Streamlining Your Career Path. "Unleashing Creativity: Using innovative solutions in the labs and in groups" Presentation: Creativity in the Labs May 6, 2003.
34. Breast Cancer Research Program Retreat, "Growth factor signaling and their potential for targeting therapy", Houston Hilton Plaza, May 10, 2003.
35. Pancreatic Cancer Working Group, "Development of gene therapy for pancreatic cancer", June 13, 2003.
36. Career Development for postdoctoral fellows co-sponsored by Trainee Support Services and Faculty Development Series title "Transition... What will science and research be like when you return to your country?" Second event in the series: title "Science In China", July 25, 2003.
37. Breast Cancer Research Group, Fall Retreat, Presents "Bone Metastasis" title "CXCR4 is required for HER2-induced tumor metastasis" Houston Marriott Medical Center, October 25, 2003.
38. Department of Molecular Genetics weekly research seminar series "Information Exchange", "Novel Signaling of Cancer Cells: Location, Location, Location", May 16, 2004.

39. Surgery Grand Rounds Seminar- Pancreatic Cancer “Development of Gene Therapy for Pancreatic Cancer”, June 23, 2004.
40. Executive Council meeting, Division of Cancer Medicine, June 25, 2004.
41. **Chair**, Advances in Oncology Institutional Grand Rounds “Cellular Localization: critical factors for protein functions and prognostic values, January 7, 2005.
42. Division of Cancer Medicine Grand Rounds, “Translational Research: From signal transduction to prognostic therapy and prevention”, January 18, 2005.
43. Hematology Grand Rounds, “Novel signaling pathways and targeted therapy”, August 23, 2006.
44. Department of Experimental Therapeutics, “Novel cell signaling and targeted cancer therapy”, Departmental Seminar, January 17, 2007.
45. **Chair**, Institutional Grand Rounds, “Cellular Energy/Metablism and Cancer” September 7, 2007.
46. Department of Cancer Biology, “Novel pathways linking cancer and diabetes, the development of targeted cancer therapy”, October 23, 2007.
47. Division of Cancer Medicine and the Center for Cancer Immunology, Mini-retreat: "Inflammation and Cancer", December 1, 2007.
48. Keynote lecture, Postdoctoral SiRNA Consortium of UC Berkeley, Lawrence Berkeley National Lab, UC San Francisco, UC San Diego and MD Anderson Cancer Center on Targeted Therapy, December 17, 2007.
49. **Distinguished Lectureship**, Center for Cancer Immunology Research and Immunology Program of GSBS, May 20, 2008.
50. Advances in Oncology Institutional Grand Rounds, The M. D. Anderson Cancer Center SPORE in Pancreatic Cancer -2008, “Gene Therapy of Pancreatic Cancer”, August 15, 2008.
51. Co-chair: “Successful Research Carrer”, MADCC First Annual Mentoring Day, September 29, 2008.
52. MADCC Trainee Course--“Writing and Publishing Scientific Articles” Workshop, February 4, 2009.
53. 2009 MDACC Symposium on Cancer Research: Cellular Energy, Metabolism and Cancer. “Novel signaling pathways linking cancer and glucose transport”, Session IV: Targeting Pathways. April 4, 2009.

#### **Lectureships and Visiting Professorships:**

Guest Professor, Xiaman University, P.R.C., 1991-1993.

Guest Professor, Shanghai Medical University, P.R.C., 1994-1996.

#### **Society Memberships with Offices Held:**

American Association for Cancer Research,  
American Association for Gene Therapy,  
American Association for the Advancement of Science,  
American Society for Cell Biology,  
American Society for Clinical Oncology,  
American Society of Microbiology,  
Metastasis Research Society,

Society of Chinese Bioscientists in America (SCBA),  
American Taiwanese Professor's Association,

**Other Community Activities:**

1. Vice-President, Houston Chapter - Society of Chinese Bioscientists in America, 1988-1989.
2. President, Houston Chapter - Society of Chinese Bioscientists in America, 1989-1990.
3. President, Houston Chapter - North American Taiwanese Professor's Association, 1989-1990.
4. President, Houston Chapter - North American Taiwanese Professor's Association, 1992-1993.
5. Organizer for the Second Biennial Poster Competition of Society of Chinese Bioscientists in America, Houston Chapter, January 20, 1990.
6. Organizer for the Fourth Annual Symposium of Society of Chinese Bioscientis in America, Houston Chapter, November 3, 1990.
7. Selected for interview in Houston by Radio Television Hong Kong for Public Education Scientific Documentary Film and overseas radio broadcast, October 3-4, 2000.
8. Participation in the Breast Cancer Research Foundation's Sixth Annual Luncheon & Symposium, New York City, NY, October 4, 2001.
9. Participation in Era of Hope, US Army/DOD Breast Cancer Research Program, Orlando, FL, September 25-26, 2002.
10. Participation in the Breast Cancer Research Foundation Annual Luncheon & Symposium, New York City, New York, October 9-10, 2002.
- 11. President (International) - Society of Chinese Bioscientists in America, 2004-2005.**
12. Keynote Speaker, the 2003 Annual Meeting of Taiwanese Association of America (Houston Chapter), Houston, TX. February 8, 2003.
13. Plenary Speaker, "Biotechnology in the Century", the 2003 Diversity Summit and Annual Science, Engineering and Technology Seminars (SETS) "25 Year Anniversary and Beyond: Technology in the New Millennium" sponsored by Association of Chinese American Professionals (ACAP), Houston, TX, July 19, 2003.
14. Participation in the Breast Cancer Research Foundation Annual Luncheon & Symposium, NYC, NY, October 7-8, 2003.
15. Invited Speaker "Biotechnology in this century" at the Northwest Rotary Club, Taipei, Taiwan, November 12, 2003.

16. Opening remarks for the Texas Local Chapter of SCBA symposium, Houston, TX, April 17, 2004.
17. Participation in the Biennial Member meeting, Academic Sinica, Taipei, Taiwan, July 4-8, 2004.
18. Invited Speaker, Subject: Cancer for Biotech workshop for high school students and teachers in Taiwan (over 3,000 participants), Taipei, Taiwan, November 7, 2004.
19. Participation in the GI InterSPORE Pancreatic Meeting, Houston, TX, February 2-3, 2005.
20. Participation in the UT Science Symposium “Molecular Medicine: Translating Discoveries into Health”, Houston, TX, February 21-22, 2005.
21. Participation in the Symposium honoring Benoit de Crombrughe, Houston, TX, February 26, 2005.
22. Participation in AACR annual meeting, Anaheim, CA, April 16-20, 2005.
23. Participation in 5th Program Steering Committee Meeting for the U54 PRCC/MDACC Partnership for Excellence in Cancer Research, San Juan, Puerto Rico, May 17-19, 2005.
24. Participation in 13<sup>th</sup> SPORE Investigator’s Workshop, Washington DC, July 9-12, 2005.
25. Participation in the Breast Cancer Research Foundation Annual Luncheon & Symposium, NYC, NY, October 17-18, 2005.
26. Participation in the 3<sup>rd</sup> Breast SPORE Roundtable Meeting, "Overview of MDACC SPORE in Breast Cancer" and “Targeting Breast Cancer-Specific Gene Therapy” Nashville, TN, November 10-12, 2005.
27. Participation in Advisory Committee Meetings of Bio Taiwan, Industrial Technology & Strategy Review Board of Executive Yuan of Taiwan, April 7-9, and Oct 28-30, 2006.
28. Participation in the 2<sup>nd</sup> Annual MDACC Sister Institution Conference, Houston, TX, June 7 - 9, 2006.
29. Participation in the Poland Biotech Showcase, Co-hosts: Drs. James Willerson and Juan Sanchez, University of Texas, Houston, TX, June 15, 2006.
30. Participation in Dr. Kenneth Wu’s Inauguration Ceremony, National Health Research Institutes, Zhunan, Taiwan, July 1, 2006.
31. Participation in the Biennial Member meeting, Academic Sinica, Taipei, Taiwan, July 4-8, 2006.
32. Participation in the 14<sup>th</sup> SPORE Investigator’s Workshop, Baltimore, MD, July 16-19, 2006.

33. Participation in the Mid-Term Plenary Session and Validation Meeting, Michael Kadoorie Cancer Genetics Research Programme, Hong Kong, September 13 -15, 2006.
34. Participation in the INNOVATIONS IN HEALTH SCIENCE EDUCATION ANNUAL CONFERENCE, The University of Texas Academy of Health Science Education, Austin, TX, October 5-6, 2006.
35. Participation in the Breast Cancer Research Foundation Annual Luncheon & Symposium, NYC, NY, October 16-17, 2006.
36. Faculty Club, SCBA TX Chapter, "A Novel Pathway Linking Cancer, Obesity and Diabetes; and Development of Targeted Cancer Gene Therapy", Houston, TX, December 14, 2007.
37. Participation in Closing Plenary Session of Kadoorie Charitable Foundation, Hong Kong, China, March 16-18, 2008.
38. Achievement Award Acceptance Speech, "To believe or not to believe: Trafficking of Membrane Tyrosine Kinase Receptors to the nucleus-mechanism, function and clinical implication", 2008 SCBA TX Chapter Symposium, Houston, TX, April 19, 2008.
141. Participation in the Breast Cancer Research Foundation Annual Luncheon & Symposium, NYC, NY, October 28-29, 2008.
142. Participant, Symposium on Advancement of Biomedical Sciences: In Honor of Cheng-Wen Wu and His 70<sup>th</sup> Birthday, Academia Sinia, Taipei, Taiwan, June 14, 2009.